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Abstract
Postoperative pancreatic fistula (POPF) is the main cause of morbidity after distal 
pancreatectomy (DP). Its incidence remains high at 10–50 % and may lead to other, severe 
complications. Mortality after distal pancreatectomy is still low. Several surgical techiques, 
pharmacological methods and evaluation of risk factors have been studied in the past, but 
the incidence of POPF remains high. 
The aim of this thesis was to find surgical and pharmacological ways to reduce the risk 
of fistula. A further aim was to examine the effect of centralization on complications and 
fistula rate in distal pancreatectomies.
The Finnish binding anastomosis technique, where the pancreatic stump is inserted 
into the jejunal end, sutured with peripancreatic stitches and tightened by a purse-string 
suture has yielded promising results in pancreaticoduodenectomies. Study I reported the 
use of this technique on distal pancreatectomies in a randomized trial. This trial compared 
binding anastomosis to the traditional handsewn closure technique. The study showed that 
the binding anastomosis technique is not suitable for distal pancreatectomies, nor does it 
reduce the fistula rate.
Study II was a randomized placebo-controlled trial investigating the effect of 
hydrocortisone on overall complications and clinically significant POPF after open distal 
pancreatectomy. The Tampere Pancreas Group has previously shown that hydrocortisone 
lowers the rate of overall complications after pancreaticoduodenectomy. It was hypothesized 
that as an anti-inflammatory drug hydrocortisone could reduce the risk of complications 
by reducing the postoperative inflammation of the pancreatic remnant. Study II showed 
that perioperative hydrocortisone, continued for two postoperative days, may help to 
reduce overall complications after open distal pancreatectomy. The incidence of clinically 
significant POPF was significantly lowered with hydrocortisone treatment, 5.9% vs. 42.9%. 
No adverse effects were seen.
Centralization of pancreatic surgery has proceeded in Finland and its benefits have 
recently been shown in pancreaticoduodenectomies. Study III analysed the effect of 
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hospital and operation volume on major postoperative complications and POPF after 
distal pancreatectomy during the period 2012–2014. This study showed that the rates of 
POPF and major postoperative complications were similar in high and low-volume centres. 
However, management of complications differed and reoperations were performed ten 
times more often in low-volume centres. 
In conclusion, this thesis shows that the incidence of POPF after distal pancreatectomy 
is still high and that reducing it is challenging. Many surgical techniques have failed 
to reduce the rate of POPF, as did binding anastomosis. However, by administering 
perioperative hydrocortisone the incidence of complications and postoperative pancreatic 
fistula after open distal pancreatectomy were reduced.  Hospital volume had no effect on 
postoperative complications or fistulas, but for optimal treatment of complications the 
centralizing of distal pancreatectomies is also crucial. Reoperations were needed ten times 
more often in low-volume centres. In light of the results of this thesis the use of perioperative 
hydrocortisone treatment and centralizing operations to high-volume centres to reduce the 
rate of postoperative pancreatic fistula after open distal pancreatectomies and to improve 
their treatment is to be recommended.
vTiivistelmä
Haimafisteli eli haimanesteen vuoto haiman katkaisupinnasta on yleisin komplikaatio 
haiman hännän poistoleikkauksen jälkeen. Haimafistelin ilmaantuvuus on korkea 
10–50  % ja se voi johtaa muihin, vakaviinkin komplikaatioihin. Kuolleisuus haiman 
hännän poistoleikkauksen jälkeen on kuitenkin matala. Haimafistelin ehkäisemiseksi on 
yritetty kehittää uusia leikkaustekniikoita lähinnä haiman katkaisumenetelmän suhteen 
ja haimanesteen vuotoa on yritetty vähentää erilaisilla lääkeaineilla. Fisteliin johtavia 
riskitekijöitä on tutkittu laajasti, mutta ongelmaan ei ole löytynyt ratkaisua ja fistelin 
ilmaantuvuus on säilynyt korkeana.
Tämän väitöskirjan tavoitteena oli etsiä keinoja haiman hännän (ja rungon) 
poistoleikkauksen jälkeisten fisteleiden vähentämiseksi leikkausmenetelmällä ja 
lääkeaineella. Lisäksi tavoitteena oli selvittää haiman hännän poistoleikkausten 
keskittämisen vaikutusta leikkauksen jälkeisiin komplikaatioihin ja fisteleihin.
Upotussauma, jossa haiman katkaisupinta upotetaan ohutsuolen sisään, toimii haiman 
pään poistoleikkauksessa. Ensimmäisessä osatyössä haiman katkaisupinta upotettiin 
ohutsuolen sisään vastaavalla upotusmenetelmällä haiman hännän poistoleikkauksessa 
satunnaistetussa tutkimuksessa. Tutkimuksessa verrattiin upotusmenetelmää perinteiseen 
katkaisupinnan sulkuun. Tulokset osoittivat, että upotustekniikka ei sovellu haiman 
hännän poistoleikkauksiin, eikä se vähentänyt myöskään fistelien määrää.
Toinen osatyö oli satunnaistettu lume-kontrolloitu kaksoissokkotutkimus, jossa 
selvitettiin leikkauksenaikaisen hydrokortisonihoidon vaikutusta haiman hännän 
poistoleikkauksen jälkeisiin komplikaatioihin ja fisteleiden ilmaantuvuuteen. Haiman 
pään poistoleikkauspotilailla hydrokortisonin on aiemmin osoitettu vähentävän 
merkittäviä komplikaatioita. Toisen osatyön oletuksena oli, että hydrokortisoni voisi 
anti-inflammatorisena lääkeaineena vähentää komplikaatioita vähentämällä leikkauksen 
jälkeistä tulehdusreaktiota haimassa. Hydrokortisonilla oli suotuisa vaikutus leikkauksen 
jälkeisiin kokonaiskomplikaatioihin. Kliinisesti merkittävien fisteleiden ilmaantuvuuteen 
hydrokortisonihoito vaikutti alentavasti, 5,9 % vs. 42,9 %. Haittavaikutuksia ei ilmaantunut.
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Suomessa haimakirurgian keskittäminen on edennyt vähitellen ja sen edut on 
osoitettu haiman pään poistoleikkauksessa. Kolmannessa osatyössä selvitettiin 
sairaalan leikkausmäärien vaikutusta haiman hännän poistoleikkauksen jälkeisiin 
kokonaiskomplikaatioihin sekä fisteleihin Suomessa vuosina 2012–2014. Tämä tutkimus 
osoitti, että keskittäminen on järkevää myös haiman hännän poistoleikkausten suhteen. 
Korkeat leikkausmäärät eivät vaikuttaneet kokonaiskomplikaatioiden tai fisteleiden 
ilmaantuvuuteen, mutta komplikaatioiden hoidossa oli selkeä ero. Matalan leikkausmäärän 
yksiköissä tehtiin komplikaatioiden vuoksi kymmenen kertaa enemmän uusintaleikkauksia 
kuin korkean leikkausmäärän yksiköissä.
Yhteenvetona voidaan todeta, että haimafistelin ilmaantuvuus on korkea ja 
siihen vaikuttaminen on haastavaa. Toistaiseksi minkään kirurgisen katkaisupinnan 
sulkumenetelmän ei ole todettu vähentävän fisteleitä. Haiman upottaminen ohutsuoleen 
ei myöskään tuonut ratkaisua ongelmaan. Leikkauksen aikaisella hydrokortisonihoidolla 
kuitenkin saavutettiin selkeä vähenemä haimafisteleissä. Sairaalakohtaisilla 
leikkausmäärillä ei todettu vaikutusta komplikaatioiden tai fisteleiden ilmaantuvuuteen, 
mutta komplikaatioiden asiantuntevan hoidon vuoksi haiman hännän poistoleikkaustenkin 
keskittämisen todettiin olevan tärkeää. Näin vältetään tarpeettomat uusintaleikkaukset, 
joita matalan leikkausmäärien sairaaloissa tehtiin kymmenen kertaa enemmän kuin 
korkean leikkausmäärän sairaaloissa. Haiman hännän poistoleikkauksen jälkeisten 
fisteleiden vähentämiseksi ja hoidon optimoimiseksi voidaan väitöskirjatutkimuksen 
tulosten perusteella suositella hydrokortisonihoidon käyttöä ja leikkausten keskittämistä 
suuren leikkausmäärän sairaaloihin.
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1 Introduction
Distal pancreatectomy (DP) accounts for about 20% of all pancreas resections. Mortality 
has diminished close to zero mainly because of surgical techniques and improved 
perioperative care. Morbidity remains high at approximately 20–50% (Bruns et al., 2009). 
Postoperative pancreatic fistula (POPF) is the most common complication after DP, the 
incidence ranging from 15 to 50% (Knaebel et al., 2005). POPF can lead to other, severe 
complications and may prolong hospital stay and increase the costs (Reeh et al., 2011).
Fistula prevention has been a challenge in recent years. The risk factors for fistula have 
been studied extensively (Allen et al., 2014, Kleeff et al., 2007). Many different surgical 
techniques for closing the pancreas stump have been investigated and compared (Kollar 
et al., 2016). Some pharmacological methods have also been proposed. Nevertheless, the 
fistula rate has not diminished and novel techiques and treatments are needed to solve this 
problem.
In pancreaticoduodenectomy (PD) postoperative pancreatic inflammation has been 
shown to predispose to POPF (Uemura et al., 2012, Bannone et al., 2018). Hydrocortisone, 
as an anti-inflammatory drug, has reportedly reduced major complications after PD 
(Laaninen et al., 2016). Moreover, centralizing PD has led to improved quality and safety 
(Ahola et al., 2017).
This thesis focuses on improving the outcome of distal pancreatectomy by proposing 
novel ideas for reducing fistula and investigating the effect of centralization on distal 
pancreatectomy.
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2 Review of the Literature
2.1 Anatomy and physiology of the pancreas
The pancreas is a retroperitoneal organ located behind the stomach and transverse colon. 
The pancreas has five parts: the uncinate process, head, neck, body and tail. The superior 
mesenteric artery and vein go behind the neck and the tail is usually attached to the hilum 
of the spleen. The splenic vein goes underneath the pancreas and the splenic artery above it 
(Drake, T, Vogl, W. & Mitchell, A., 2005). 
The pancreas has an exocrine and endocrine function. The exocrine pancreas 
composes about 98% of the pancreas and consists of acinar and ductal cells. The acinar 
cells secrete digestive entzymes (trypsin, amylase, lipase, chymotrypsin, nucleases, elastase, 
cholesterolesterase and colipase) and the ductal cells produce electrolytes and bicarbonate, 
which neutralize gastric acid. Most enzymes are secreted in inactive form, activated in 
the duodenum due to active trypsin and enteropeptidases (Bardeesy, DePinho, 2002). 
Pancreatic juice is secreted into the main pancreatic duct (duct of Wirsung) through 
smaller ducts. The main pancreatic duct enters the duodenum through the major papilla 
of the duodenum (papilla of Vater). The pancreatic duct joins the common bile duct and 
forms the papilla of Vater before entering the duodenum. The papilla of Vater is surrounded 
by smooth muscle, making a sphincter to the papilla (sphincter of Oddi), which controls 
the secretion of pancreatic juice into the duodenum. The exocrine function is regulated by 
gastrointestinal hormones (secretin, gastrin and cholecystokinin) and the parasymphatetic 
nervous system.
The endocrine part of the pancreas consists of islets of Langerhans and constitutes only 
1–2% of the pancreas. Alpha cells secrete glucagon, beta cells produce insulin, delta cells 
somatostatin and PP cells secrete pancreatic polypeptide into the bloodstream. Insulin and 
glucacon regulate the blood glucose level, somatostatin decreases insulin, glucagon and 
pancreatic polypeptide secretion and also inhibits the exocrine function. 
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2.2 Distal pancreatectomy
2.2.1 Indications
Indications for distal pancreatectomy (DP) include malignant, premalignant or benign 
lesions in the pancreatic body or tail. Chronic inflammation or trauma may also necessitate 
DP. The abdomen is nowadays imaged more frequently and lesions are increasingly detected 
in the tail of the pancreas. 
 Malignant tumours in the tail of the pancreas usually attain a large size before causing 
any symptoms and have often reached an advanced stage by diagnosis. The most common 
symptoms are pain, weight loss and recent diabetes. However, no obstructive symptoms in 
the biliary or gastrict tract occur in tumours in the pancreatic tail. Ductal adenocarcinoma 
is found in 15% of cases in the body and tail of the pancreas. Other malignant diseases may 
also metastase to the pancreas, especially renal carcinomas.
Pancreatic cystic neoplasms (PCN) include intraductal papillary neoplasm (IPMN), 
serous cystic neoplasm (SCN) and mucinous cystic neoplasm (MCN). Three types of 
IPMNs have been identified; branch duct type, main duct type and mixed type, all being 
premalignant conditions. IPMNs are intraductal mucin-producing neoplasms and cause 
dilatation of the pancreatic duct. Frequency of malignancy is highest in main duct IPMN, 
close to 80% and significantly lower, 20%, in branch duct IPMN (Salvia et al., 2004, 
Rodriguez et al., 2007). Surgical resection is recommended for all main duct IPMNs and 
for branch duct IPMNs having worrisome features such as rapid growth, size >40 mm, 
mural nodules, symptoms, elevated serum CA19-9 tumour marker level and main duct 
dilatation >5mm. Mixed type IPMN should be managed similarly to main duct IPMN 
and the risk of malignancy is comparable to that in main duct type. Symptoms include 
pancreatitis, abdominal pain, back pain, nausea, vomiting and weight loss. Pancreatic 
insufficiency, including steatorrhoea, diabetes mellitus and jaundice may occur in later 
stages (C. Shi, Hruban, 2012). SCNs are always benign and do not require surgery unless 
the diagnosis is uncertain or significant symptoms are present (Jais et al., 2016). MCNs 
are usually found in the tail of the pancreas and appear in women. They have malignant 
potential and are usually resected. Small MCNs without worrisome features may even be 
observed. Nevertheless, accurate preoperative diagnosis is sometimes difficult to achieve 
by imaging (Nilsson et al., 2016, Keane et al., 2018). In addition, solid pseudopapillary 
neoplasm (SPN) is a rare tumour in the pancreas requiring resection (Del Chiaro, Verbeke 
et al., 2013, European Study Group on Cystic Tumours of the Pancreas, 2018).
Neuroendocrine tumours may also be found in the pancreatic tail. Non-functional and 
functional tumours have been observed. Surgery should be considered in all functional and 
also in non-functional tumours, except for the smallest perceptible (Sallinen et al., 2017). 
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2.2.2 Preoperative imaging and endoscopy
Imaging of the pancreas is crucial in evaluating pancreatic neoplasms. Ultrasound, 
multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) 
are the most used tools to achieve diagnosis. MDCT has 86% sensitivity in diagnosing 
pancreatic masses, but only 55% for tumours less than 3 cm in diameter (Sahani et al., 
2008). Most pancreatic masses are hypoattenuating and seen in the venous phase, while 
neuroendocrine tumours are often hypervascular and seen in the arterial phase. MDCT 
cannot detect small tumours, small hepatic metastases or peritoneal seeding. Magnetic 
resonance imaging (MRI), especially with magnetic resonance cholangiopancreatography, 
outperforms CT in yielding more information on the pancreatic and biliary ducts and 
evaluates the ductal communication present in branch-duct IPMN (Xu, Sethi, 2016). MRI 
can also detect smaller tumours and metastases better than CT and gives information on 
possible mural nodules on cysts, which often require surgery. Endoscopic ultrasound (EUS) 
can detect and stage small tumours (0.2 cm) and allows biopsy of lesions. Its sensitivity in 
detecting pancreatic cancer is 94–100%. The availability of EUS is limited and also entails a 
long learning curve to achieve good results (de la Santa, L G et al., 2014). EUS is useful for 
identifying worrisome features in PCN and in distinguishing features requiring surgery. 
However, EUS is recommended in addition to other imaging (European Study Group on 
Cystic Tumours of the Pancreas, 2018). 
ERCP is used in cases of biliary stricture requiring drainage and makes it possible to 
image the shape of a stricture in the biliary duct or pancreatic duct and also to take brush 
cytology or biopsies from strictures. Peroral pancreatoscopy using SpyGlass-DStm (Boston 
Scientific, Natick MA, USA) can be used to investigate IPMNs, allowing visualizing the 
pancreatic duct epithelium and direct biopsies (Nagayoshi et al., 2014, Ohtsuka et al., 2018). 
Main duct IPMN can be treated by partial pancreatectomy if no high-grade dysplasia or 
invasive carcinoma is present on the surgical margins. With pancreatoscopy, the main duct 
can be visualized pre- or perioperatively to determine the adequate transection line and 
also to visualize the possible skip lesions in remnant pancreas (Arnelo et al., 2014).
2.2.3 Surgical techniques
Distal pancreatectomy was first performed by Billroth in 1884. The pancreatic tail is removed 
left of the superior mesenteric and portal vein from subcostal or midline laparotomy or 
minimally invasively through small incisions. The pancreatic body and tail are removed 
with or without the spleen. In cases of malignancy splenectomy is performed, the short 
gastric vessels connecting the stomach and splenic hilum, splenic artery and vein are ligated 
from their origin and the pancreas is divided at the level of the portal vein. The inferior 
mesenteric vein is preserved if possible (Figure 1). For malignant tumours splenectomy 
is recommended and in the case of benign lesions the spleen can be saved if technically 
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possible (Shoup et al., 2002, Lillemoe et al., 1999). Little is known about nodal staging 
in DP, but according to a recent article, 20 or more lymph nodes should be collected in 
order to determine the nodal status. Lymph node dissection includes nodes in the splenic 
hilum, the splenic artery and on the inferior edge of the pancreas (Malleo et al., 2018). The 
pancreatic stump can be divided and closed in various ways, described later in Chapter 
2.6.1. Traditionally postoperative drains are used, but according to recent evidence their 
routine use should be abandoned (Chapter 2.6.1.6). 
Spleen preserving DP can be performed either by ligating the main vessels or by saving 
them. When ligating the veins, the risk of spleen infarction and the formation of gastric 
varices is significantly higher (Partelli et al., 2016, Butturini et al., 2011). The spleen blood 
supply is normally delivered through the short gastric vessels and the left gastroepiploic 
vessels in addition to the splenic vessels. Splenic preserving DP ligating the splenic vessels 
was first introduced by Warshaw (Warshaw, 1988). In that technique the spleen is perfused 
by the preserved short gastric vessels (Figure 2).
Figure 1. Distal pancreatectomy and splenectomy
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Spleen preserving DP with conservation of the splenic artery and vein was introduced in 
1943 and the technique was elucidated elaborated by Kimura (Kimura et al., 1996) (Figure 
3). The technique is safe and easy and can be used for benign and premalignant lesions of 
the pancreatic tail (Kimura et al., 2007). The Warshaw technique (vessel ligation) affects 
spleen perfusion more than the vessels preserving technique, but blood circulation recovers 
in the case of a normal spleen (Sato et al., 2000). Possible postoperative splenic infarction 
can generally be treated conservatively and splenectomy is seldom needed (N. Shi et al., 
2016). 
Figure 2. The Warshaw’s technique. Spleen preserving DP by ligating the splenic vessels. The 
spleen is perfused by preserved short gastric vessels
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2.2.4 Laparoscopic approach
Laparoscopic surgery has increased in recent years and has become standard for many 
operations. In laparoscopy the overall blood loss is lower, the patient recovers faster 
and hospital stay is shorter. However, laparoscopy often increases the operating time. 
Laparoscopic distal pancreatectomy (LDP) was introduced by Cuschieri in 1996 (Cuschieri, 
Jakimowicz & van Spreeuwel, 1996) and has become a common method in recent decades. 
Laparoscopy in DP has been proven to be safe and shortens the length of hospital stay 
(LOS), speeds up recovery and has become the approach of choice for lesions involving the 
pancreatic tail (Briggs et al., 2009, Butturini et al., 2011). The first RCT was conducted in 
the Netherlands, comparing time to functional recovery after minimally invasive and open 
distal pancreatectomy (LEOPARD trial). The authors reported a two-day reduction in time 
to functional recovery after minimally invasive distal pancreatectomty (MIDP) compared 
to open distal pancratectomy (ODP). Neither CR-POPF nor overall complication rate was 
reduced, but there was less DGE and better quality of life at the same cost (de Rooij et al., 
2018). 
The LEOPARD trial also showed that MIDP is at least as cost-effective as open DP in 
terms of time to functional recovery and quality-adjusted life-years. One year after surgery 
there was no difference in patients’ cosmesis and quality of life (van Hilst et al., 2019). 
Suprisingly, in the LEOPARD trial there were more cases of POPF after MIDP than after 
Figure 3. The Kimura technique. Spleen preserving DP by preserving the splenic vessels
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ODP (44% vs. 25%) at one-year follow-up. However, this trial was not powered to show 
difference in complications. The ongoing DISPACT 2 trial is intended to compare the 
complication index between ODP and MIDP, and will hopefully serve to clarify the issue 
(WHO International Clinical Trials Registry Platform).
However, MIDP may not be the optimal choice for centrally located lesions near major 
blood vessels. Laparoscopy in malignant lesions is controversial and in many institutions 
patients with malignant lesions undergo an open procedure. According to recent 
retrospective trials, early and long-term results do not differ between open and laparoscopic 
DP for pancreatic ductal adenocarcinoma (PDAC) and LDP; LDP is a safe and effective 
approach to PDAC in terms of postoperative morbidity and oncologic outcome (Sulpice et 
al., 2015, Bauman et al., 2018, Stauffer et al., 2016, Bjornsson, Sandstrom, 2014). A recent 
systematic review and meta-analysis involving over 11,000 patients reported comparable 
survival and R0 resection rate. However, because LDP was more often performed on 
smaller tumours and the lymph node invasion rate was also lower, the oncologic outcome is 
not clear (van Hilst, Korrel et al., 2018). One retrospective propensity score-matched cohort 
study was presented in January 2017 in Annals of Surgery comparing minimally invasive 
versus open distal pancreatectomy for PDAC. Oncologic safety remains unclear, because 
lymph node retrieval and the Gerotas fascia resection rate were lower in LDP, but the R0 
resection rate was higher in LDP while overall survival was similar (van Hilst et al., 2017). 
A pan-European, randomized controlled multicentre trial (DIPLOMA Trial) is currently 
enrolling patients to compare LDP with ODP for pancreatic ductal adenocarcinoma 
(PDAC) with standardized surgical technique and this trial may yield more information 
about the oncologic equivalency of ODP and LDP (van Hilst et al., 2017).
Spleen preservation with or without ligation of the splenic vessels can also be performed 
laparoscopically. Warshaw’s technique (ligation of splenic vessels) is laparoscopically faster 
and associated with reduced intraoperative blood loss (Butturini et al., 2012). After ligating 
the vessels, there is a risk of postoperative splenic infarction and the formation of perigastric 
varices due to left-sided portal hypertension. Varices are not associated with bleeding 
during long-term follow-up (Butturini et al., 2012, Miura et al., 2005). Spleen preservation 
is still worth trying, also laparoscopically with benign tumours and both techniques are 
acceptable.
2.2.5 Robotic distal pancreatectomy
Robotic distal pancreatectomy (RDP) was first performed in 2003 by Melvin (Melvin et 
al., 2003). Robotic operations allow a three-dimensional view, stabilize motion and tremor 
and have a so-called endo-wrist system to help facilitate motion. According to a recent 
meta-analysis, RDP is safe and surgically as good as LDP. It increases the rate of spleen 
preservation and reduces the risk of conversion (Guerrini et al., 2017). Some studies have 
reported longer operating time with RDP, but slightly shorter LOS and reduced blood 
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loss (Gavriilidis, Roberts & Sutcliffe, 2019). No difference in morbidity, POPF or blood 
transfusion has been reported between RDP and LDP (Daouadi et al., 2013). So far, 
no RCT has been published to confirm the findings between RDP and LDP, but RDP 
currently seems to be comparable to LDP with higher costs and better view and motion. 
2.3 Parenchyma-sparing surgery
Parenchyma-sparing surgery has been proposed for benign or low-grade malignant tumours 
in the pancreatic isthmus or body. Extended DP or extended PD would be another option 
to treat lesions in those locations. Extended operations may lead to exocrine and endocrine 
dysfunction. Postoperative diabetes rates vary from 5% to 14% in patients with normal 
pancreas after DP (Maeda, Hanazaki, 2011, De Bruijn, Kirstin M. J., van Eijck, Casper H. 
J., 2015). In chronic pancreatitis the incidence of postoperative diabetes is even higher, up 
to 40%. Central pancreatectomy (CP) and enucleation are the most common parenchyma-
sparing types of surgery. These should be considered especially for young patients to 
diminish the risk for exocrine or endocrine insufficiency. Indications for parenchyma-
sparing surgery include endocrine neoplasms, cystadenomas and solid pseudopapillary 
neoplasm (SPN). 
2.3.1 Central pancreatectomy
In CP, the pancreatic corpus with the tumour is resected and the distal stump is 
anastomosed to the jejunum or the stomach and the proximal stump is closed by sutures or 
stapler (Crippa et al., 2010). This leads to two possible sites for POPF to develop. Because 
the indication for CP is benign or premalign, the pancreas is usually “soft” with nondilated 
pancreatic duct. CP has higher morbidy rate, up to 60%, but the mortality rate is low. 
POPF occurred in 30%–60% of patients (Iacono et al., 2013, Xiao et al., 2018). Compared 
to DP, morbidity and fistula rates are significantly higher, but the incidence of exocrine or 
endocrine insufficiency is lower (Iacono et al., 2013).
2.3.2 Enucleation
In enucleation the tumour is enucleated carefully from the pancreas tissue and the small 
vessels are ligated. The pancreatic capsule is closed when possible. The diameter of the 
tumour must be <2 cm and it must be >3 mm from the main pancreatic duct. Overall 
morbidity after enucleation is high (>60%), but the rate of severe complications is low. 
The overall POPF rate is over 50%, but the CR-POPF rate is comparable to DP (Wang et 
al., 2018, Strobel et al., 2015). Usually no endocrine or exocrine dysfunction appears after 
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enucleation (Hackert et al., 2011). Enucleation is the best choice for small insulinomas, 
but preoperative imaging to determine the size and distance to the main pancreatic duct is 
crucial.
2.4 Postoperative complications after distal pancreatectomy
2.4.1 Morbidity and mortality
Distal pancreatectomy can nowadays be performed with low mortality rate thanks to 
advances in surgical techniques and perioperative care (Kleeff et al., 2007, Lillemoe et al., 
1999). Mortality ranges between 0% and 2% (Fahy et al., 2002, Nathan et al., 2009, McPhee 
et al., 2007, Sledzianowski et al., 2005) and is lower than for PD. Mortality is higher in men, 
older patients and patients operated on at the lowest-volume centres, while in high-volume 
centres it is close to 0% (McPhee et al., 2007). 
Despite low mortality, DP has a high morbidity rate, ranging from 22% to 57%, 
(Sledzianowski et al., 2005, McPhee et al., 2007, Lillemoe et al., 1999, Diener et al., 2011). 
Pancreatic fistula (defined in Chapter 2.4.2) is the main cause of postoperative morbidity 
and occurs more frequently after DP than after PD. It often leads to other complications 
like intra-abdominal abscesses, postoperative pancreatic haemorrhage, delayed gastric 
emptying, wound infection and sepsis (Knaebel et al., 2005, Kleeff et al., 2007). Perioperative 
mortality is often due to POPF (Nathan et al., 2009). The pancreatic fistula rate after DP 
is approximately 30% (Ferrone et al., 2008, Diener et al., 2011). Due to the absence of an 
extensive reconstruction as in the PD procedure, complications after DP are seldom life-
threatening but complications lengthen the hospital stay and may as much as double the 
costs (Rodriguez et al., 2006, Pratt et al., 2007). In addition, complications may require 
radiological or endoscopic intervention or even reoperation. Hospital readmissions usually 
occur in patients who develop POPF or abscesses, the most frequent complications after 
DP (Marchegiani et al., 2017).
 3RVWRSHUDWLYHSDQFUHDWLF¿VWXOD
POPF is the most common complication after DP and occurs in approximately 30% of 
patients after DP (Ferrone et al., 2008, Diener et al., 2011). Pancreatic enzymes leak from 
the cut edge and cause fluid accumulation and even severe infections, sepsis or haemorrhage. 
Various techniques for closing the pancreatic remnant have been extensively studied in 
order to decrease the fistula rate, but this problem remains unsolved (Miyasaka et al., 2017). 
It is more common in DP than in PD and the incidence varies widely depending on the 
definition used. POPF after PD is usually more severe and more life-threatening than after 
DP (McMillan et al., 2016).
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In order to objectively compare the occurrence of fistulas between different surgical 
centres, the International Study Group on Pancreatic Fistulae (ISGPF) published in 2005 
a definition for the clinical grading of POPF. POPF was defined as any measurable fluid 
output of an operatively placed drain with amylase more than three times the normal 
serum value. Grades A, B and C were defined. The definition was updated in 2016 and 
the former Grade A fistula is no longer defined as a fistula because of the lack of clinical 
impact. Instead, it has been redefined and is now known as a “biochemical leak” and the 
term fistula is only used in cases of clinical relevance. In biochemical leak the drain amylase 
level is >3 times the upper limit of normal serum amylase value. In grade B the drain is 
present and contains amylase rich fluid > three weeks after the procedure or there is a 
repositioning of the drain through percutaneous or endoscopic interventional drainage. In 
Grade B there is a change in the management of the clinical pathway and signs of infection 
are perceptible. Treatment in the ICU may be needed, but there is no organ failure. In cases 
of POPF-related haemorrhage angiographic procedures may be needed in Grade B. Grade 
C entails organ failure, reoperation or the death of a patient. Treatment in the ICU is often 
needed and LOS is greatly prolonged (Bassi et al., 2005, Bassi et al., 2017). 
This new classification improved discrimination between different POPF grades after 
DP (van Hilst, de Pastena et al., 2018). The earlier classification left more room for different 
interpretations. Some included the POPF needing interventional drainage for Grade B and 
some shifted this type of POPF to Grade C. Now it is clear; with interventional drainage 
the POPF continues to be classified as Grade B, but reoperation classifies it as Grade C, as 
does any organ failure or death (Figure 4). 
To identify patients at high risk for fistula, Fistula Risk Scores have been developed. 
Risk scores are allocated mainly for PD and have been shown to correlate with fistula 
development after PD (Callery et al., 2013). The Fistula Risk Score for PD defines four 
characteristics: soft texture of the pancreas, small diameter of the pancreatic duct, 
histopathological diagnosis and blood loss greater than 400ml, all of which warrant a score 
of 10. Patients scoring 7–10 points are at high risk for POPF. For DP, perioperative risk 
factors have been shown to have poor predictive capability and no real scoring system has 
so far been proposed (Ecker et al., 2017, McMillan, Vollmer, 2014).
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2.4.3 Postpancreatectomy haemorrhage
Postoperative pancreatic haemorrhage (PPH) is a rare and severe complication after 
pancreatic surgery. It occurs in 4–17% of patients after PD, in 2–3% after DP (Lermite 
et al., 2013, Sledzianowski et al., 2005) and is associated with a high mortality rate of 35% 
(Roulin et al., 2011). Bleeding sites after DP are the pancreatic stump, tributaries of the 
splenic artery, splenic hilus or tributaries of the splenic vein stump or resection site (Wente, 
Veit et al., 2007).
The International Study Group of Pancreatic Surgery (ISGPS) proposed a definition for 
PPH with Grades A, B and C. These are defined by four parameters: time of onset, severity, 
location and clinical impact. The onset is early (<24 h) or late (>24 h) and the location is 
intra- or extraluminal. Severity may be mild or severe and clinical impact varies. Grade A 
has no major clinical impact and does not delay the patient’s discharge from hospital. In 
Grade B the bleeding is severe and the patient may need invasive treatment (relaparotomy 
or embolization) and LOS is prolonged. Grade C is always life-threatening and the blood 
loss is severe (Wente et al., 2007).
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2.4.4 Delayed gastric emptying
Delayed gastric emptying (DGE) is the most common complication after pancreatic 
surgery, especially after pancreaticoduodenectomy (PD), but also occurs after DP (Wente, 
Bassi et al., 2007). The aetiology of DGE is uncertain, but it is often associated with other 
intra-abdominal complications (pancreatic fistula, fluid collection) or resection of the 
duodenum, which causes a decrease in plasma motilin levels (Kunstman et al., 2012). It 
has also been reported that DGE is often caused by postoperative pancreatic inflammation 
(Raty et al., 2006). It usually resolves by itself, but delays discharge from hospital, causes 
discomfort and increases costs. DGE also occurs after DP, but with lower frequency and is 
seldom reported. According to different studies, it occurs in 5–25% and is often associated 
with pancreatic fistula (Glowka et al., 2016, Seeliger et al., 2010, Kleeff et al., 2007).
The International Study Group of Pancreatic Surgery (ISGPS) also published a 
definition for DGE in 2007 defining DGE into three grades according to the duration 
of the nasogastric tube (NGT), solid food toleration, vomiting and need for prokinetics. 
Grade A does not usually change clinical management, but NGT is needed or repositioned 
between postoperative days (POD) 4 and 7 but solid foods intake resumes before POD 14. 
In Grade B the NGT is present for POD 8–14, or reinserted after POD 7. The patient can 
ingest solid food before POD 21. Grade B prolongs hospital stay and causes discomfort. 
Grade C is present when the NGT is still in place or has been repositioned after POD 14 
or if the patient cannot take solid food by 21 POD. Grade C is often associated with other 
complications and patients need nutritional supplementation (Wente et al., 2007, Park et 
al., 2009).
 &ODYLHQ'LQGRFODVVL¿FDWLRQ
Overall complications are often reported according to the Clavien-Dindo classification 
(CD), which was introduced in 1992. This classification is simple to use and enables 
international comparison of overall morbidity rates (Dindo, Demartines & Clavien, 2004). 
The therapy needed to treat the complication determines the complication grade. This 
classification is also suitable for pancreatic surgery (DeOliveira et al., 2006). Complications 
are divided into five grades. Grade III complications require invasive treatment, such as 
surgical, endoscopic or radiological interventions. The complications in Grades I and II 
require only minor deviations from the normal postoperative pathway. Grade I includes 
treatment with antiemetics, antipyretics, electrolytes or diuretics and wound infections 
opened at the bedside. Grade II patients need antibiotics, blood transfusion or parenteral 
nutrition. If the complication is life-threatening and requires ICU treatment, the grading 
is IV. Grade V means mortality.
26
2.4.6 Comprehensive complication index
In the Clavien-Dindo classification (CD), only the most severe complication is reported and 
this determines the grade. As a limitation, CD may underestimate the impact of multiple 
and less severe complications. In 2013 Slankamenac et al. introduced the comprehensive 
complication index (CCI), which classifies every postoperative complication occurring after 
an intervention. The CCI is based on the Clavien-Dindo classification; a summation of all 
complications, it reflects the overall morbidity better. The CCI is a complex formula, but 
can be calculated easily using an online CCI calculator based on CD graded complications, 
scores ranging from 0 to 100 (Slankamenac et al., 2013, Slankamenac et al., 2014, Ray et 
al., 2019).
2.5 Risk factors for complications after distal pancreatectomy
The risk factors for complications after DP can be divided into patient, surgery and hospital 
related factors (Figure 5). These risk factors have been widely studied and many methods 
have been tested to exert influence where feasible. The findings of different studies are to 
some extent contradictory, especially regarding patient related risk factors.
Patient related risk factors Surgery related risk factors Hospital related risk factors
BMI
Comorbidities
Smoking
Age
Gender
Albumin/nutrition level
Pancreatic texture
Main duct diameter
Pathology
Operative time
Blood loss
Splenectomy
Closure mechanism
Drainage
Laparoscopy
Pharmacology
Hospital volume
Patient care
Multidisciplinary team
Figure 5. Risk factors for complications after DP
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2.5.1 Patient related risk factors
2.5.1.1 Pancreatic texture
Soft (normal) pancreas has been shown to increase the risk of POPF while firm (fibrotic) 
texture lowers the POPF rate after PD and DP (Ridolfini et al., 2007, Lin et al., 2004, Fahy 
et al., 2002, Ansorge et al., 2012). A recent review and meta-analysis showed a correlation 
between soft pancreas and POPF (Peng et al., 2017). Soft pancreas is associated with a 
threefold increased risk of POPF compared to firm pancreas (Pratt, Callery & Vollmer, 
2008). Thick pancreas (diameter over 12 mm) is likewise a risk for POPF after stapler 
closure and another closing method should be used in thick pancreas (Okano et al., 2013, 
Mendoza et al., 2016, Kawai et al., 2013). Soft and normal pancreas is rich in acinar cells 
and has a narrow main pancreatic duct, while in fibrotic pancreas the main duct is dilated 
and the pancreas consists of fibrosis (Laaninen et al., 2012). A duct diameter smaller than 
3 mm is a risk factor for POPF after PD (Muscari et al., 2006). However, contradictory 
results have been reported. Martin et al. recently reported that pancreatic duct size and 
gland texture are associated with pancreatic fistula after PD but not after DP (Martin et al., 
2018). This finding may be explained by the different mechanisms of fistula formation in 
PD and DP. In DP the leak could be explained by increased pressure in the pancreatic duct 
caused by the sphincter of Oddi (Hashimoto, Traverso, 2012, Hackert et al., 2017). Main 
duct dilatation is caused by chronic pancreatitis or obstruction due to a tumour in the head 
of the pancreas. Main duct IPMN also causes widening of the main pancreatic duct. In 
DP the tumour is in the tail and does not obstruct the duct at the cut edge, so in terms of 
DP, the pancreas is usually soft and the main duct narrow (except in chronic pancreatitis), 
which is the reason for the POPF rate being higher in DP than in PD. Large volume of 
the pancreatic remnant and the transection site may also effect fistula formation; POPF 
has been shown to occur more often when the tail has been transsected (Sell et al., 2015, 
Frozanpor et al., 2010, Pannegeon et al., 2006).
The Tampere Pancreas Group has previously shown that acinar-rich cut edge (>40%) 
increases and fibrosis decreases the risk for postoperative complications after PD (Laaninen 
et al., 2012). Also, when the pancreas is fibrotic (acinar cell <40%), no complications occur 
after PD (Laaninen et al., 2016). In the case of DP, the texture of the pancreas is mainly 
normal and POPF occurs frequently.
Preoperative imaging has also been used to identify patients at risk of POPF. Frozanbor 
showed that increased pancreatic remnant volume measured on 3D CT increases the 
development of POPF (Frozanpor et al., 2010). Preoperative MRI and CT can also be used 
to measure pancreatic fat, fibrosis, thickness and cross-sectional area; cross-sectional area 
>377 mm2 significantly increases the risk for POPF (Chang et al., 2017). Thick pancreas is 
one of the risk factors for POPF formation and stapler closure in particular may predispose 
to risk of POPF (Eguchi et al., 2011).
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2.5.1.2 Body Mass Index
Obesity is associated with increased incidence of POPF after DP according to some but not 
all studies (Sledzianowski et al., 2005, Ferrone et al., 2008). High BMI has been shown to 
increase the risk for POPF and bleeding, but not to affect the short or long-term outcome 
after PD (Del Chiaro, Rangelova et al., 2013). In terms of laparoscopic distal pancreatectomy 
obesity causes longer operating time and greater blood loss, but has no significant influence 
on postoperative outcome (Sahakyan et al., 2016). High BMI correlates with other risk 
factors such as soft and fatty pancreatic parenchyma, which explains the risk (Mathur et 
al., 2007). Poor nutritional status (Sierzega et al., 2007) and hypoalbuminemia <3.5 g/dl 
have also been associated with higher POPF rate, 19.6% vs. 12.9% (Ecker et al., 2017). It is 
important to optimize the patient’s nutritional status preoperatively. 
2.5.1.3 Comorbidities and smoking
Smoking has been shown to increase the risk for POPF, and the effect of smoking on 
impaired wound healing is also well known (Krueger, Rohrich, 2001, Nathan et al., 2009). 
Preoperative diabetes may even protect against POPF according to a few studies (Nathan et 
al., 2009, Mathur et al., 2007), probably due to fibrosis of the pancreas in diabetic patients. 
2.5.1.4 Other factors (age, gender)
There are many studies about age as a risk factor for morbidity or POPF. In most studies, 
age has not been an independent risk factor but a few studies have reported a correlation. 
It has been shown that patients younger than 65 years are almost three times more likely to 
develop CR-POPF (Yoshioka et al., 2010, Ecker et al., 2017). Conversely, increased risk of 
POPF has been found in older patients (Peng et al., 2017, Kleeff et al., 2007). Male gender 
has been shown in some studies to increase the risk for complications (Ferrone et al., 2008).
2.5.2 Surgery related risk factors
2.5.2.1 Operating time and blood loss
Operating time and blood loss are independent risk factors for morbidity (especially POPF) 
after DP (Hashimoto, Traverso, 2012), which has also been shown in a meta-analysis (Peng 
et al., 2017). Blood loss >225 ml, visceral obesity and open passive drainage were recently 
shown to be independent predictive factors for CR-POPF after DP in a retrospective single-
institution analysis of 208 DP (32 CR-POPF) (Vanbrugghe et al., 2018).
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2.5.2.2 Spleen preservation
Some studies have shown that splenectomy is associated with a higher risk for POPF 
(Shoup et al., 2002, Goh et al., 2008). The reason may be the ischaemia caused to the 
pancreatic stump by splenic vessel ligation or increased operative blood loss, which may 
also affect morbidity. Kleef et al. reported a higher fistula rate in splenectomized patients, 
but in an earlier study by Lillemoe et al. no difference was seen (Kleeff et al., 2007, Lillemoe 
et al., 1999). Recent studies have also found no difference between DP with and without 
splenectomy (Peng et al., 2017, Ridolfini et al., 2007). A recent meta-analysis of seven 
studies showed that spleen preservation had no impact on CR-POPF (Tieftrunk et al., 
2018). Spleen preservation in DP for benign or low-grade malignant disease has also been 
shown to be safe and to reduce the occurrence of perioperative infection complications, 
severe complications and LOS when compared to DP with splenectomy (Pendola et al., 
2017, Shoup et al., 2002). 
2.5.3 Hospital related risk factors
2.5.3.1 Hospital volume
DP is not defined as equally high-risk surgery as PD. Mortality is close to zero even 
though morbidity rates are high. An association between high hospital volume and lower 
postoperative mortality has been shown in PD (Birkmeyer et al., 2003, Ahola et al., 2017). 
Differences in mortality between high and low-volume hospitals are not explained by fewer 
complications but by failure to rescue the patient from mortality following complications. 
Failure-to-rescue rates are significantly higher in very low-volume centres compared with 
high-volume centres (Ghaferi, Birkmeyer & Dimick, 2011). The mortality risk is also 
attributable to patient characteristics, such as age and comorbidity (LaPar et al., 2012). 
There are only a few reports making a distinction between the outcomes of pancreatic 
resections; usually the studies discuss pancreatic resections in general, or only PD. In a 
study in the United States 1998–2003, where the DP subgroup was analysed separately, 
mortality was 5.1% in LVC compared to 0.43% in HVC in DP (McPhee et al., 2007). 
2.5.3.2 Detection of complications
Distal pancreatectomy patients are at high risk for complications. DP complications are 
rarely life-threatening, but they do increase LOS and costs and also suffering to patients. 
Detection and treatment of complications after pancreatic surgery often need CT imaging 
and interventional radiology services around-the-clock. The decision on how to treat 
the complication often requires a multidisciplinary approach. A reasonable volume of 
pancreatic surgery is needed to achieve and sustain experienced perioperative management. 
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The ward staff also needs to be trained to recognize worrisome signs of complications and 
experienced surgeons need to be readily available. Most postoperative complications can 
nowadays be treated conservatively or with minimally invasive approaches instead of open 
surgery. In LVCs modern treatment may be limited.
2.6 Methods aiming to prevent complications after distal pancreatectomy
2.6.1 Surgical techniques
2.6.1.1 Conventional technique
Closure of the pancreatic stump is thought to be the most important step in DP to decrease 
the risk of POPF. Traditionally the pancreas is divided with a scalpel and the cut edge 
can be shaped in fish-mouth style in order to close the anterior and posterior capsula even 
in thicker pancreas. The pancreatic stump is closed with interrupted mattress sutures. 
Hand-sewn closure is the oldest technique and suitable for all textures. The fistula rate 
after suture closure has been reported to be unsatisfactory at approximately 30–35%, but 
the classification of fistulas in older studies is not amenable to comparison (Nathan et al., 
2009, Ferrone et al., 2008). The main pancreatic duct should be ligated separately, failure 
to ligate may double the risk of fistula development (Bilimoria et al., 2003, Yoshioka et al., 
2010, Pannegeon et al., 2006).
2.6.1.2 Stapler closure of the pancreatic stump
Stapler and suture closure are the main ways to close the pancreas remnant. Stapler closure 
was first reported in 1979 and has become a common method, mainly because of the increase 
in laparoscopic procedures. Staplers can also be used in open procedures; this is safe, easy, 
fast and ensures good haemostasis, even though thick pancreas continues to be a risk factor 
in stapler closure (Kawai et al., 2013, Okano et al., 2013). Stapler closure has been compared 
with other closure methods in many studies and POPF rates are lower with staplers, but 
not significantly in all (Probst et al., 2015, Knaebel et al., 2005, Zhang et al., 2015, Zhou et 
al., 2010, Frozanpor et al., 2010, Ban et al., 2012). Only one multicentre randomized trial 
has been reported comparing stapler closure with other methods, the DISPACT trial. This 
was a European multicentre trial with 450 patients divided into suture or stapler groups. 
No difference found in the incidence of POPF, the fistula rates in the groups being almost 
identical at 36 % vs. 37 % (Diener et al., 2011). On the other hand, stapler closure has also 
been reported to be associated with higher fistula rate (Kleeff et al., 2007).
The stapler device can be reinforced, for example, with Seamguard bioabsorbable 
membrane or mesh or the stapler line can be oversewn. Seamguard is composed of polyglycolic 
acid and trimethylene carbonate. Some studies, including one RCT, found that reinforcing 
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the staple line with some form of mesh reduced the incidence of POPF (Jimenez, Mavanur 
& Macaulay, 2007, Thaker et al., 2007, Yamamoto et al., 2009, Hamilton et al., 2012). In 
the RCT, Seamguard mesh reinforcing to the stapler line decreased CR-POPF from 24% 
to 1.9%, but BMI in the reinforced stapler group was significantly lower (Hamilton et 
al., 2012). However, contrasting results have also been reported, some with an increased 
incidence (Guzman et al., 2009, Ferrone et al., 2008, Ceppa et al., 2015). To conclude on 
the results from the meta-analyses and multicentre prospective non-randomized studies, 
no significant difference in CR-POPF was found between stapler closure with or without 
reinforcement. Both may safely be used in DP (Kawai et al., 2017, Jensen et al., 2013). A 
multicentre, randomized trial recently also showed no difference in CR-POPF between 
reinforced staplers and bare staplers, the respective fistula rates being 16.3% and 27.1% 
(Kondo et al., 2019).
Adding sutures to the stapler line does not improve the results (Zhang et al., 2015, Goh 
et al., 2008, Bilimoria et al., 2003). Tripple-row staples may be preferable to double-row 
staplers in the prevention of POPF (Sugimoto et al., 2013). Stapler closure is not superior to 
hand-sewn closure but devices may improve in the future in terms of closure mechanism, 
reinforcement techniques and suitability for use on thick pancreas. Stapler closure of a 
thick pancreas may increase the risk of POPF (Kawai et al., 2013).
2.6.1.3 Pancreatic transection devices
Many devices can be used for transection of the pancreas. These are so-called non-closure 
techniques. A retrospective study showed that bipolar scissors, which cut and coagulate 
simultaneously, decreased the risk of POPF after DP from 36% to 10% compared to 
hand-sewn suture closing (Kawai, Tani & Yamaue, 2008). Ultrasonically activated scalpel 
(Harmonic scalpel; Ethicon Endo-Surgery, Johnson & Johnson) likewise decreased 
the POPF rate from 30% to 0% (Sugo et al., 2001) and from 25.8% to 3.7% in one RCT 
comparing ultrasonic dissection (US) with conventional dissection (Suzuki et al., 1999). 
After transsecting the pancreas with US, the main pancreatic duct was ligated separately. 
US transsection and reinforced stapler (RS) was compared recently in two retrospective 
matched cohort studies. Rate of CR-POPF was 40% in the US group and 12% in the RS 
group (Pulvirenti et al., 2019). Saline-coupled radiofrequency dissector (TissueLink; Salient 
Surgical Technologies, Denver, NH, USA) was used to cut the pancreas in a retrospective 
study and achieved a 10% POPF rate vs. 36% in the traditional closure group (Blansfield et 
al., 2012). LigaSure (Covidien/Medtronic, Dublin, Ireland) sealing device has so far only 
been tested on an animal model with 0% POPF rate (Hartwig et al., 2010) but thickness 
and fibrosis of the human pancreas may enhance the result with this technique, which has 
not so far been studied in humans.
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2.6.1.4 Pancreatoenteric anastomosis
Pancreatojejunostomy (PJ) and pancreatogastrostomy have also been performed in an 
attempt to reduce the risk of POPF after DP (Okada et al., 2014, Klein et al., 2012, Kleeff 
et al., 2007). Many of these studies compare enteric anastomosis to stapler closure with no 
effect on POPF rate. A recent Japanese RCT comparing pancreaticojejunostomy and stapler 
closure likewise reported no significant difference in POPF. PJ may, however, be preferable 
to stapler closure in thick pancreas (Kawai et al., 2016). By contrast, differences in favour 
of pancreaticojejunostomy have been found, especially when comparing anastomotic 
closure to hand-sewn closure (Zhang et al., 2015, Wagner et al., 2007, Meniconi et al., 
2013, Yanagimoto et al., 2014). Zero fistula rates after pancreaticojejunostomy have been 
reported, the numbers of patients in those studies, however, were small (Meniconi et al., 
2013, Wagner et al., 2007). Pancreatigogastrostomy did not reduce CR-POPF compared 
with hand-sewn closure in a recent RCT (Uemura et al., 2017). It is to be hoped that two 
ongoing RCTs in Japan investigating anastomotic closures and POPF will clarify the 
efficacy of this method. The Finnish binding anastomosis technique, where the pancreatic 
stump is inserted into the jejunal end, sutured with peripancreatic stitches and tightened by 
a purse-string suture has yielded promising results and is routinely used in PDs performed 
in Tampere University Hospital (Nordback et al., 2008). 
2.6.1.5 Stump coverage
Covering the resection margin with autologous tissue, absorbable fibrin sealant (Tachosil®) 
or fibrin glue has been reported in some studies to lower the incidence of POPF (Hassenpflug 
et al., 2012, Walters et al., 2011, Kleeff et al., 2007, Suzuki et al., 1995). Absorbable fibrin 
sealant (Tachosil®) has been studied in several RCTs in recent years, but no significant 
reduction in POPF has been seen (Park et al., 2016, Sa Cunha et al., 2015, Montorsi et al., 
2012, Huttner et al., 2016, Gong et al., 2018). 
Fibrin glue can be added to the closure line of the pancreas and adding it to the suture 
line reportedly decreased the fistula rate from 40% in the control group to 15.4% (Suzuki 
et al., 1995). Pancreas stump coverage with falciform ligament or serosal patch from the 
jejunal loop or stomach has shown an improvement in fistula rate and also reduced LOS and 
costs (Hassenpflug et al., 2012), but the RTC (DISCOVER) by the same research group to 
investigate the use of teres ligament patch failed to show a significant decrease in clinically 
relevant fistula formation (22.4 vs. 32.9%). Ligament Teres patch still showed a significant 
decrease in readmission (13.1 vs. 31.5%) and reoperation (1.3 vs. 13%) rates (Hassenpflug et 
al., 2016). An earlier RCT adding falciform ligament patch and fibrin glue to a sutured or 
stapled line did not reduce the rate or the severity of POPF (Carter et al., 2013).
In mesh reinforcement the mesh is wrapped around the pancreatic stump after DP. 
Polyglycolic acid (PGA) mesh is composed of a bioabsorbable recombinant membrane 
made of a synthetic polymer with cellulose-like structure. In a nonrandomized retrospective 
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study it was used in DP to prevent fistula and the POPF rate was low, at 4%, compared to 
controls at 27% (Ochiai et al., 2010). In 2017 a RCT was published on PGA mesh wrapped 
over the cut edge and the rate of POPF was significantly lower in the PGA group than in 
the control group (11.4% vs. 28.3%) (Jang et al., 2017).
2.6.1.6 Postoperative drains
Postoperative drains are traditionally used in pancreatic surgery for monitoring the fluid 
postoperatively, but their advantage has recently been questioned. In the case of fistula, 
the drain creates a controlled fistula and decreases the incidence of fluid accumulation. 
Retrospective studies on both DP and PD patients have been presented. In PD, the absence 
of a drain has been shown to increase mortality (Van Buren et al., 2014) even though a 
recent RCT concluded that routine drainage after PD is unnecessary in terms of mortality, 
morbidity or reinterventions (Witzigmann et al., 2016). Another RCT reported that in 
patients at low risk for POPF (drain amylase level <5000 U/L), intra-abdominal drains can 
be safely removed on the POD 3 after standard PD or DP (Bassi et al., 2010). For DP only, 
a few non-RCT and retrospective studies have been presented reporting no difference in 
complications with or without drainage and also one RCT (Behrman et al., 2015, Paulus, 
Zarzaur & Behrman, 2012). According a recent RCT there were no differences in Grade 2 
or higher complications or in clinically relevant fistula rate with or without intraperitoneal 
drainage after DP, but the incidence of intra-abdominal fluid collections was higher in the 
no-drain group, most of whom needed no intervention (6% needed percutaneous drainage) 
(Van Buren et al., 2017). Nevertheless, prophylactic drains probably reduce the severity of 
POPF and also the reoperation rate. (Ecker et al., 2017.) On the other hand, drains may 
even prolong the fistula or contaminate sterile self-curing collections, thereby making them 
clinically relevant.
Even though routine drainage has not been shown to afford much advantage, drains 
are commonly used in clinical practice (Maggino, Malleo, Salvia et al., 2019). A recent 
observational study reported a drainage rate after DP of 84.4%, which is in line with earlier 
reports in the literature (Seykora et al., 2019, Behrman et al., 2015, El Khoury et al., 2018). 
In that study only 15.2% of drains were removed on or before the third postoperative day. 
Early drain removal was shown to have better outcomes than late removal and it moreover 
reduced the development of POPF. Drain amylase level on the first postoperative day 
(DFA1) was the best predictor of POPF. They also identified an optimal cut-off for drain 
fluid amylase value on DFA1, namely >2000 U/L (Maggino, Malleo, Bassi et al., 2019). 
DFA1 has been shown to predict POPF in other studies (Vass et al., 2018).
Type of drain used has also recently been discussed. Passive open gravity drains and 
closed-suction drains have been compared. According to a recent RCT, drain type does 
affect the POPF or complication rate in pancreatic resections (Cecka et al., 2018). A 
prospective, observational study compared these two drain types and no difference was 
found in PD or DP (Marchegiani et al., 2018). However, in a recent retrospective analysis 
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of a single institution open passive drainage was found to be an independent risk factor for 
POPF after DP in addition to visceral obesity and blood loss >225 ml (Vanbrugghe et al., 
2018).
2.6.1.7 Pancreatic stenting
Pancreatic stents can be placed pre- or peroperatively using endoscopic retrograde cholangio-
pancreaticography (ERCP) or intraoperatively during surgery by placing the stent from the 
pancreatic main duct into the duodenum before closure of the stump. The idea is to drain 
the pancreatic juice to the duodenum via the papilla of Vater and to decompress the main 
pancreatic duct. Many meta-analyses have reported good results and low POPF rates (Abe 
et al., 2008, Rieder et al., 2010, Hashimoto, Traverso, 2012, Oida et al., 2011, Fischer et al., 
2008). So far only one RCT has been published in Sweden and in that trial prophylactic 
pancreatic stenting did not reduce POPF or other complications after DP (Frozanpor et al., 
2012). There were differences in these studies, however; in the RCT the stent was placed at 
the time of pancreatic resection and in earlier studies one week before DP.
2.6.2 Pharmacological methods
Somatostatin analogues (octreotide, pasireotide) have long been used in pancreas resection 
to prevent and to treat POPF. This treatment has an inhibitory effect on the exocrine 
function of the pancreas. In a Cochrane review octreotide did not affect clinically relevant 
POPF, but studies mainly consisted of PD patients (Gurusamy et al., 2012). According to 
another meta-analysis, octreotide reduced postoperative complications, but readmission, 
LOS, mortality, reoperation and clinically relevant POPF rate remained the same (Koti et 
al., 2010). No RCT including only DP patients has been presented. Several retrospective 
analyses have been reported, some favouring the use of octreotide and some finding no 
difference (Lorenz et al., 2007, Ridolfini et al., 2007). In 2014 Allen (Allen et al., 2014) 
published an RCT where pasireotide reduced the risk of POPF in DP from 23% to 7%. 
They analysed both DP and PD and found significant differences in both groups. The 
cost analysis in that RCT also showed that POPF doubled the costs and routine use of 
pasireotide did not increase the overall costs (Ma et al., 2017). Conversely, in a recently 
published article comparing pasireotide to historical controls pasireotide did not prevent 
POPF after DP or PD, the fistula rate was 17% compared 15.5% among the historical 
controls. No difference was found in the subgroups (DP or PD), the rate being 15.2% in 
DP and 17.9% in PD (Elliott et al., 2018). This was not an RCT, but the finding renders 
the effect of pasireotides debatable. Similar findings were also reported in another recent 
article where pasireotide did not decrease CR-POPF after pancreatic surgery (PD and DP), 
nor did it reduce length of hospital stay or postoperative complications (Young et al., 2018). 
Pasireotide is an expensive drug and also causes dose-limiting nausea as a side effect, 17% 
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and 38% in the studies mentioned above. Another RCT is needed to ascertain the true 
effect of pasireotides after pancreatic resection. Tampere Pancreas Group has previously 
shown that perioperative hydrocortisone reduces the incidence of major complications 
after PD (Laaninen et al., 2016). It is cheap and has no side effects according to that study. 
Another interesting drug is botulinum toxin, which is a smooth muscle relaxant. It 
can be injected endoscopically into the Spincter of Oddi to prevent POPF by relaxing the 
muscle. Hackert et al. published a prospective clinical trial of botulinum injection six days 
before DP and it seemed to be safe and efficient. No CR-POPF was found in the botulinum 
toxin group compared to controls (33%) (Hackert et al., 2017). These results are promising 
and will be validated in a multicentre RCT in Germany.
Narcotic pain medicators may also cause dysfunction in the Sphincter of Oddi. 
Morphine, commonly used for postoperative pain, causes contraction of the Sphincter of 
Oddi. This may predispose to the development of POPF by increasing the pancreatic duct 
pressure, when the flow of pancreatic juices into the duodenum decreases and the healing 
of the stump is disrupted. Dose-dependent postoperative narcotic use has been shown to 
be associated with the development of CR-POPF after DP (Hashimoto, Traverso, 2012, 
Kowalsky et al., 2018). The use of opioids in patients after DP should be limited.
2.6.3 Patient care
Patient care during and after surgery is crucial for the morbidity rate and treatment of 
complications has attracted more attention in recent years. Postoperative care should be 
standardized and ward staff trained to detect deviations from the normal postoperative 
pathway. Routine management of postoperative pain, ICU admission criteria and routine 
use of drains and drain removal criteria should be noted. Intraoperative fluid therapy also 
needs to be observed and standardized, because it was recently been shown that liberal 
fluid balance is associated with increased rate of CD>IIIB after DP and PD (50 vs. 27.1%, 
p=0.03) (Andrianello et al., 2018). It has been shown in a retrospective analysis that the 
implementation of new departmental guidelines for distal pancreatectomy is closely 
associated with low frequency of intra-abdominal abcesses and major (Clavien-Dindo III-
IV) complications (Yui et al., 2014). In case of complications, access to and availability of 
an ICU should be fast and easy. In low-volume centres (LVC) operations are performed so 
seldom that the nurses or doctors on the ward have difficulties in establishing a routine in 
postoperative care and in detecting and managing complications.
Critical pathway protocols or fast-track protocols are good for improving quality 
and lowering costs. They provide a structured roadmap for postoperative care from the 
preoperative stage until discharge and should be in use in every high-volume centre 
(HVC) and high-quality centre. With protocols postoperative hospital stay and costs can 
be reduced, maintaining or improving outcomes without increasing readmissions in DP 
(Kennedy et al., 2009, Pecorelli et al., 2017). An enhanced recovery after surgery (ERAS) 
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programme has also been introduced in pancreatic surgery, but its benefits are not yet clear 
(Lassen et al., 2012, Kagedan et al., 2015). It seems to be safe and may reduce the incidence 
of minor complications, promote recovery and shorten LOS in high-risk pancreas surgery 
in general, even though it may not affect the rate of POPF (Ji et al., 2018, Morgan et al., 
2016). In LDP the enhanced recovery programme also improves outcomes by reducing 
LOS, saving on costs and restoring the patient’s normal gut function significantly faster 
(Richardson et al., 2015).
2.6.4 Centralization of pancreatic surgery
PD has been shown to carry lower mortality and morbidity and also better oncological 
outcome in high-volume centres (Ahola et al., 2017, Hata et al., 2016). Centralization of 
pancreatic surgery has proceeded in many countries, including Finland, in the last few 
years. So far, centralization of DPs to high-volume centres does not seem to occur and 
there are only few studies concerning only DPs in terms of postoperative complications 
and mortality and hospital volume. Most studies include all types of pancreatic resections, 
PD, DP and TP. Yet there are differences in mortality and morbidity among these different 
procedures. Postoperative mortality after DP is significantly lower than after PD and after 
TP there are no fistula related complications (McPhee et al., 2007). Few studies report 
separately on DP; no significant difference has been seen in the frequency of postoperative 
complications in DP analysed by hospital volume in the United States (Rosales-Velderrain 
et al., 2012). A difference in mortality has still been reported in DP, being 5.1% in LVCs 
and 0.43% in HVCs in the United States in the period 1998–2003 (McPhee et al., 2007).
2.6.5 Can we decrease complications after distal pancreatectomy?
Mortality after DP is low these days, due to advantages in surgical techniques and improved 
perioperative care. Yet morbidity remains high. Many of the surgical methods mentioned 
above have been tried out to improve morbidity, especially POPF rate after DP. There 
are many promising methods and encouraging results in small series, which often lack of 
significance in RCTs. So far no method has been proven to be better than others, and, due 
to inconsistent results, no consensus has been reached. More innovations are needed in this 
field. 
Our hospital has succeeded among PD patients in creating well functioning anastomosis, 
to lower the POPF rate after PD (Nordback et al., 2008). It is not known whether such 
anastomosis could also lower the fistula rate in DP patients.
The failure of numerous surgical methods to reduce the fistula rate compels us to seek 
other than surgical methods. Various drugs have been tried and pasireotide has recently 
yielded promising results (Allen et al., 2014). In a recent study on PD, perioperative 
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hydrocortisone reduced the complication rate, but its usefulness in DP is not known 
(Laaninen et al., 2016).
Morbidity and mortality have been shown to be reduced in PD after centralization 
procedures to HVCs (Hata et al., 2016). The effect of centralization on DP has not been 
established.
The question remains if it is possible to improve outcomes after DP by means of novel 
surgical or medical methods or by centralizing operations or by combination of all of these. 
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3 Aims of the Study
The aim of this thesis was to investigate the postoperative complications of distal 
pancreatectomy, various strategies to improve the outcome and to innovate new ones.  The 
specific aims were:
I To investigate whether the Finnish binding anastomosis used in PD is also suitable 
for use in DP and its effect on POPF rate.
II To investigate whether perioperative hydrocortisone treatment reduces the POPF 
rate and overall complications after open DP.
III To study the national data on DP in Finland in terms of hospital volume and 
complication rate.
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4 Patients and Methods
4.1 Study I
In Study I patients scheduled for elective DP in Tampere University Hospital 2009–2013 
were considered for recruitment. Preoperative CT scan and tumour location were used as 
the recruitment criteria. In Finnish binding pancreaticojejunal anastomosis (FBPJ) the 
transection line of the pancreas must be left of the portal vein in order to mobilize the 
pancreas 2–3 cm before inserting it into the jejunal limb. Tumours in the pancreatic body 
were eligible for randomization. FBPJ is in use in PD in Tampere University Hospital 
and has been shown to reduce the risk for POPF after PD. When the distal pancreas was 
removed, and if still eligible, the patients were randomized to either the FBPJ or the hand-
sewn group. Patients eligible for FBPJ were defined as the prospective randomised group 
(RPT arm). In addition, all other DP patients were included in the prospective follow-up 
(PFU arm). 
Out of 47 DPs, only 16 patients met the randomization criteria and were randomized 
to either the FBPJ or the conventional hand-sewn group. In two patients FBPJ was 
technically impossible and they received a hand-sewn closure. In addition, one patient had 
an inoperable disease. FBPJ anastomosis was technically possible in only five patients and 
hand-sewn closure in ten patients in the RPT arm. Hand-sewn closure was also made in 
11 patients in the non-RPT arm. A further 20 patients not included in the study in the 
prospective follow-up arm also received hand-sewn closure. Thus, a total of 41 patients had 
a hand-sewn closure (Figure 6). 
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Perioperatively all patients received prophylactic antibiotics (rocephalin 2 g ceftriaxone; 
Roche, Espoo, Finland and metronidatzole 500 mg, metronidatzole, Braun, Germany). 
Patients randomized for FBPJ received pancreaticojejunal anastomosis (Figure 7). The 
pancreatic remnant was inserted 2–3 cm inside the jejunal limb using peripancreatic sutures 
(4-0 Maxon, Covidien, USA) after which the purse-string suture (4-0 PDS, Ethicon, USA) 
was tightened and the roux-Y anastomosis completed. In the hand-sewn group the pancreas 
was divided with a scalpel, the pancreatic main duct was closed and the stump was oversewn 
with 4-0 Maxon. A non-suction drain was placed near the anastomosis in both groups.
Postoperatively, according to standard protocol, drain amylase concentrations were 
measured on the third postoperative day and daily after that if the drain was still in place. 
Postoperative complications (fistulas, bleeding, abscesses, wound infections), LOS and 
mortality were defined. POPF was defined according to the international criteria at that 
time. Primary endpoints were feasibility of FBPJ technique in DP and the effect of FBPJ 
on fistula incidence.
Figure 6. Flow chart of the study patients in Study I
Out of 47 DPs, 27 were recruited and only 16 of these met the randomization criteria. Finally, among 
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4.2 Study II
In study II, 47 patients were assessed for eligibility and 40 were randomized between 
November 2013 and January 2017 at Tampere University Hospital in Finland. Exclusion 
criteria were ongoing cortisone treatment, ceftriaxone allergy or chronic pancreatitis. 
Patients were randomized to two groups before surgery: the hydrocortisone or the placebo 
group. PD patients were also included in the study as a separate group using the same study 
protocol.
Out of 40 randomized patients, five had an advanced, inoperable disease and three 
underwent a different procedure (PD, total pancreatectomy and pseudocysto-jejunostomy) 
and were excluded from the study. Finally, 31 patients continued through the study after 
randomization; 14 were randomized to the placebo group and 17 to the hydrocortisone 
group (Figure 8).
)LJXUH )%3-DIWHUGLVWDOSDQFUHDWHFWRP\
The transsection line needs to be clearly to the left of the portal vein (a). After mobilizing the 
pancreatic stump 2–3 cm, it is inserted inside the jejunal loop with the aid of anchoring sutures (b). 
The purse-string applied in the jejunum is tightened (c) (Antila et al., 2014).
a
c
b
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All operations were open procedures with hand-sewn closure of the pancreatic stump. The 
pancreas was cut using a scalpel, the main duct was sutured separately and the cut edge 
was oversewn with interrupted 4-0 Maxon (Covidien, USA) sutures. The percentage of 
acini cells in the pancreatic transection line was analysed by the pathologist perioperatively. 
Patients received routine antibiotic prophylaxis of ceftriaxone 2 g (Rocephalin; Roche, 
Basel, Switzerland) and metronidatzole 500 mg (Metronidatzole; Braun, Melsungen, 
Germany) intravenously and either HC 100 mg or placebo intravenously depending on the 
randomisation. HC treatment continued for risk patients with 100 mg/placebo three times 
a day until the third postoperative day. Ceftriaxone 2 g i.v was also continued. 
The randomisation list was compiled by a biostatistician and randomization was 
made preoperatively. The HC solution consisted of hydrocortisone sodium succinate 
(Solu-Cortef; Pfizer Manufacturing, Puurs, Belgium) in 0.9% sodium chloride solution 
(Natriumklorid Braun, 9 mg/mL; B. Braun Melsungen, Melsungen, Germany). Infusion 
bags were filled with 100 mg hydrocortisone in 2 ml of sodium succinate added into 100 ml 
of 0.9% sodium chloride solution. The placebo solution was made up by adding 2 ml of 0.9% 
sodium chloride solution into 100 ml of 0.9% sodium chloride solution. 
PPH, DGE and POPH were defined according to international classifications (Bassi 
et al., 2005, Wente et al., 2007, Wente et al., 2007). The original ISGPF classification for 
POPF grading was used in the analysis. Grade B and C POPF were defined as clinically 
Figure 8. The Flow chart of Study II
Seventeen patients were randomized to the hydrocortisone group and fourteen to the placebo group 
(Antila et al., 2019).
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significant POPFs. Clavien-Dindo classification was used to score complications (Dindo 
et al., 2004). The primary endpoint was major complications and the secondary endpoint 
CR-POPF.
4.3 Study III
All patients who underwent DP between 2012 and 2014 were identified from the Care 
Register for Social Welfare and Heath Care and the Nordic Classification of Surgical 
Procedures using codes (ICD10 codes JLC10 and JLC11). Overall 194 patients were 
obtained. Patient data on medical history, postoperative complications, POPF, 90-day 
mortality, reoperations and hospital stay were recorded from the patient records. Data 
regarding the operation details were also studied. Emergency operations and patients with 
no records were excluded. POPFs were graded according to the new ISGPF classification 
(Bassi et al., 2017) and postoperative complications according to the Clavien-Dindo 
classification. Grades III-V were considered major complications. Operating centres were 
grouped as high-volume centres (HVC); >10 DPs, medium-volume centres (MVC); 4–9 
DPs and low-volume centres (LVC) fewer than 4 DP annually.
4.4 Statistics
For Study I, the power calculation was made by estimating that FBPJ would reduce the 
POPF rate by 50%. If the patients with hand-sewn closure had twice as many clinically 
relevant POPFs compared to FBPJ, (30% vs. 15%), we would need 26 patients in each 
group to be able to show a statistically significant difference with power π=0.80 (α 0.05). 
We estimated that about one third of the patients would not meet the recruitment 
criteria based on CT, and that about 10% of the recruited patients would not meet the 
randomization criteria according to the findings during surgery. Thus for 52 randomized 
patients we would need 58 recruited patients, and for those we would need a population of 
78 distal pancreatectomies. 
Study II was designed to include both PD and DP patients, but planned to be published 
separately (Laaninen et al., 2016). The interim analysis of PD patients showed that HC 
treatment reduced the fistula rate after PD to almost nil. For the study on DP patients for 
power calculation we used the estimate that HC would decrease the incidence of POPF to 
one seventh. We estimated that 36 consecutive patients scheduled for open distal resection 
would need to be randomised to show a statistically significant difference (alpha 0.05, 80% 
power). Finally, 40 patients were randomised to allow for 10% dropout.
In Study III, the statistical analysis was performed using IBM SPSS statistical software. 
Fisher’s exact test for cross-tabulated variables and Mann-Whitney test for quantitative 
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variables were used to calculate the significance between the two groups. P≤0.05 was 
considered statistically significant. 
4.5 Ethics
All studies were conducted in accordance with the Helsinki Declaration. The protocols for 
Studies I and II were approved by the ethics committee of Tampere University Hospital. 
Study I was registered at clinical.trials.com, NCT02113046 and Study II, NCT01460615. 
Study III was granted ethical approval by the Regional Ethics Committee of Pirkanmaa, 
Finland (ETL code R12241). The data collection for Study III was approved by the National 
Institute for Heath and Welfare in Finland.
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5 Results
5.1 Roux-Y binding pancreaticojejunal anastomosis 
and distal pancreatectomy
In Study I, out of 47 DPs, only 16 patients met the randomization criteria and were 
randomized to either FBPJ or the conventional hand-sewn group. Finally, FBPJ anastomosis 
was technically possible in only five patients and hand-sewn closure in ten patients in the 
RPT arm. In total 41 patients had a hand-sewn closure. 
Interim analysis was made when 47 consecutive patients had undergone DP and the 
study was discontinued mainly because the patients seemed not to be eligible for FBPJ 
anastomosis. 
The main endpoints were feasibility of FBPJ in DP and POPF rate. Only 13/47 (27%) 
patients were eligible for FBPJ and in addition the POPF rate was high in these FBPJ 
patients. Of the randomized patients 60% in the FBPJ group and 12.5% in the hand-sewn 
group developed POPF. Thirty-day mortality was zero and no reoperations were needed in 
either group. Patient demographics and postoperative complications are shown in Table 1. 
The incidence of POPF in the different groups is shown in Table 2. Final histopathogical 
diagnoses did not differ between groups.
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Table 1. Patient demographics and postoperative complications in Study 1 (Antila et al., 2014)
Characteristics FBPJ Hand-sewn rand Hand-sewn all
N 5 8 41
Age 67 (55–74) 60 66 (26–85)
Gender M/F  1/4 0,33 15/26
BMI (mean) 28,2 27,2 26
Smoking 1 (20%) 0 7 (17%)
Alcohol abuse 0 1 (12.5%) 5 (12.1%)
DM 0 2 (25%) 5 (12.1%)
Cardiac disease 0 1 (12.5%) 3 (7.3%)
Hypertension 2 (40%) 2 (25%) 20 (48.7%)
Wound infection 0 0 4 (9.7%)
PPH 0 0 0
Abscess 3 (60%) 0 9 (21.9%)
Pancreatitis 0 1 (12.5%) 2 (4.9%)
Trypsinogen posit 1 (20%) 1 (12.5%) 10 (24.3%)
Length of stay (d) 10 (7–15) 7 (6–9) 7 (6–32)
Readmission 1 (20%) 1 (12.5%) 4 (10%)
Operating time (mins) 170 (136–300) 162 (115–200) 170 (90–305)
Blood loss (ml) 750 (300–2350) 750 (300–1300) 750 (100–3600)
Mortality 0 0 0
Table 2. Incidence of POPF in the different groups in Study I
FBPJ n=5, randomised Hand-sewn n=8, 
randomised
All hand-sewn n=41, 
non-randomsed
3DQFUHDWLF¿VWXOD
Grade A
Grade B
Grade C
0
60% (3)
0
0
13% (1)
0
0
37% (15)
0
5.2 Prevention of complications through hydrocortisone
In Study II, pre- and perioperative characteristics were otherwise identical in the HC 
and placebo groups, but patients’ ages in the HC group were significantly higher (Table 
3). The final histopathological diagnoses did not differ between groups; 10 IPMN, 
5 adenocarcinomas, 4 NET, 3 MCN, 3 SCN, 1 metastasis from renal cancer, 1 solid 
pseudopapillary neoplasm, 1 pseudocyst, 1 lymph node, accessory spleen and 1 mesothelial 
cyst (Table 4). 
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Table 3. Pre- and perioperative characteristics in hydrocortisone and placebo group patients in 
Study II (Antila et al., 2019)
Hydrocortisone (n=17) Placebo (n=14) p value
Age yrs, median (range) 73 (41–82) 61 (39–76) 0.045
Male 7 (41%) 4 (29%) 0.707
BMI, kg/m2 27 (22–35) 29 (21–39) 0.164
COPD 1 (6%) 2 (14%) 0.576
Diabetes 7 (41%) 5 (36%) 1
ASA class
I–II
III
6 (35%)
11 (65%)
7 (50%)
7 (50%)
0.481
Operating time min, median (range) 158 (103–391) 159 
(108–224)
0.942
Blood loss mL, median (range) 550 (120–2300) 700 
(50–1400)
0.975
Main pancreatic duct diameter
< 3 mm
PP
16 (94%)
1 (6%)
13 (93%)
1 (75)
1
Splenectomy 12 (70,6%) 6 (42.9%) 0.157
Acini>40% in the transsection line 17 (100%) 14 (100%) 1
Soft pancreas texture 17 (100%) 14 (100%) 1
Table 4. Final histopathological diagnosis in the groups in Study II (Antila et al., 2019)
Hydrocortisone Placebo P value
Histopathological diagnosis
Pancreatic ductal adenocarcinoma
NET
Cystic tumour
Other
4 (23%)
2 (12%)
9 (53%)
2 (12%)
1 (7%)
2 (13%)
8 (57%)
3 (21%)
0.578
The primary endpoint was major complications graded by Clavien-Dindo scoring (Clavien-
Dindo III–V). No significant differences between the HC and placebo groups were found 
5.9% (1/17) and 21.4% (3/14) respectively (p=0.304). Hospital stay and readmission rate 
were similar and 90-day mortality was zero in both groups.
The rate of Grade B or C POPF was significantly reduced by HC treatment compared 
to the placebo group (5.9% vs. 42.9%, p=0.028). In the HC group there was only one Grade 
C fistula. This patient was treated with both percutaneous and endoscopic drainage. In the 
placebo group, patients 42.9% (6/14) developed clinically significant fistula. These included 
four Grade B fistulas and two Grade C fistulas. One Grade C fistula resulted in the 
patient’s death on day 96 post-operatively. This patient was treated with both percutaneous 
and endoscopic drainage and relaparotomy. Bowel necrosis was seen at laparotomy, caused 
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by prolonged infection inducing reduced blood circulation in the atherosclerotic vessels. 
Postoperative complications are shown in Table 5.
The incidence of biochemical leak (former POPF Grade A) was six in the HC group and 
one in the placebo group (ns). These fistulas did not affect the patients’ clinical pathways. 
Table 5. Postoperative complications in the groups in Study II (Antila et al., 2019)
 Hydrocortisone (n=17) Placebo (n=14) P value
3DQFUHDWLF¿VWXOD
Grade B
Grade C
Overall (B+C)
0
1 (5.9%)
1 (5.9%)
4 (28.6)
2 (14.2%)
6 (42.9%)
1.00
0.028
Delayed gastric emptying 1 (5.9%) 0 1.00
,QWUDDEGRPLQDOÀXLGFROOHFWLRQ 2 (11.8%) 3 (21%) 0.636
Wound infection 1 (5.9%) 3 (21%) 0.304
Intra-abdominal haemorrhage 0 0
Pneumonia 1 (5.9%) 2 (14.3%) 0.576
Spleen necrosis 1 (5.9%) 1 (7.1%) 1.00
Lymphatic leak 2 (11.8%) 1 (7.1%) 1.00
&7YHUL¿HGSDQFUHDWLWLV 1 (5.9%) 1 (7.1%) 1.00
8ULQHWU\SVLQRJHQSRVLWLYHGD\V 4 (23.5%) 5 (35.7%) 0.693
Pulmonary embolism 1 (5.9%) 0 1.00
Clavien-Dindo
I
II
III
IV
V
&OLQLFDOO\VLJQL¿FDQW,,,±9
4 (23.5%)
6 (35.3%)
1 (5.9%)
0
0
1 (5.9%)
4 (28.6%)
5 (35.7%)
2 (14.3%)
0
1 (7.1%)
3 (21.4%) 0.304
Reoperation 0 1 (7.1%) 0.452
Total hospital stay (days, range) 8 (2-23) 7 (6-38) 0.625
Readmission 3 (17.6%) 3 (21.4%) 1.00
90-day mortality 0 0  
5.3 National data on pancreatic distal resections in Finland 2012–2014
A total of 194 DPs were performed nationwide in Finland during the period 2012–2014 in 
18 different hospitals. These included 2 HVCs, 6 MCVs and 10 LVCs. Eighty-one patients 
were operated on in HVCs (42%), 84 in MVCs (43%) and 29 in LVCs (15%). Patient 
demographics or perioperative data were similar between the hospital volume groups 
(Table 6). The final histopathological diagnoses are shown in Table 7.
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Table 6. Pre- and perioperative characteristics in the groups in Study III (Antila et al., 2019)
High-Volume 
centre n=81
Medium-volume 
centre n=84
Low-volume 
centre n=29
Age , median, years (range) 62 (0.3–80) 65 (21–80) 67 (41–85)
Sex ratio (F/M) 45/36 60/24 17/12
BMI 26,1 (16–40) 23.6 (19–40) 28.4 (23–36)
Diabetes 20 (24.7%) 10 (14.1%) 8 (29.6%)
Laparoscopic procedure 23 (28.4%) 23 (27.4%) 1 (3.4%) p=0.008
Combined resection of other 
organs
9 (11.1%) 17 (20.2%) 4 (13.8%)
Hand-sewn closure of the 
pancreatic 
25 (30.9%) 20 (23.8%) 11 (37.9%)
Stapler closure of pancreatic 
stump
54 (66.7%) 64 (76.2%) 16 (55.2%)
Splenectomy 42 (51.9%) 58 (69.0%) 16 (55.2%)
Blood loss (ml) 850 (150–5300) 590 (0–16000) 500 (300–2500)
Operating time (min) 167 (115–317) 200 (114–377) 180 (120–258)
Number of hospitals 2 6 10  
Table 7. Final histopathological diagnoses in all patients in Study III (Antila et al., 2019)
 All patients n=194
Adenocarcinoma 40 (20%)
Neuroendocrine carcinoma 7 (4%)
Intraductal papillary mucinous carcinoma 2 (1%)
Gastrointestinal stromal carcinoma 1 (1%)
Renal metastasis 6 (3%)
Colon carcinoma 1 (1%)
Neuroendocrine tumour 43 (33%)
Mucinous cystic neoplasm 23 (12%)
Intraductal papillary mucinous neoplasm 17 (9%)
Serous cystic neoplasm 20 (10%)
Solid pseudopapillary neoplasm 3 (2%)
Chronic pancreatitis 7 (4%)
Pseudocyst 7 (4%)
Gastrointestinal stromal tumour 1 (1%)
Cyst 5 (3%)
Fibrosis 1 (1%)
Spleen accessorius 7(4%)
Haemangioma 1(1%)
Nesidioblastosis 1(1%)
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The rate of clinically relevant POPF did not differ between the volume groups. In all 
patients the POPF (B/C) rate was 17.2%. In HVCs CR-POPF occurred in 21%, in MVCs 
in 10.7% and in LVCs in 17.2%. However, Grade C POPF was found more often in LVCs, 
the rate being 1.2% in HVCs, 0% in MCVs and 6.9% in LVCs, p=0.030. There were no 
differences in the incidence of intra-abdominal fluid collection postoperatively. 
Clavien-Dindo Grade III–V complications likewise showed no differences; 16.0% of 
HVC patients, 18.1% of MVC patients, 20.7% of LVC patients. Furthermore, we found no 
difference in LOS or readmission rates between the different volume groups. Ninety-day 
mortality was zero in all groups. Reoperations were performed significantly more often in 
LVCs, on 10.3% of patients (3/29), and in HVCs and MVCs on 1.2% (1/81) and 1.1% (1/84) 
respectively, p=0.025. Postoperative complications in the groups are shown in Table 8.
In all open procedures the clinically relevant fistula rate was 17.2% and in the laparoscopic 
procedures 12.8% (ns). More laparoscopic procedures were performed in HVCs and MVCs 
than in LVCs (28%, 26% and 3% respectively, p=0.008). Stapler closure and hand-sewn 
closure had similar fistula rates, 17% and 17.0%. In all malignant cases the fistula rate was 
14.2%. 
Table 8. Postoperative complications in the groups in Study III (Antila et al., 2019)
% (n) High-volume 
centre n=81
Medium-volume 
centre n=84
Low-volume 
centre n=29
Pancreatic Fistula
Grade B
Grade C
Grade B/C
19.8% (16)
1.2% (1)
21.0% (17)
10.7% (9)
0.0% (0)
10.7% (9)
10.3% (3)
6.9% (2)
17.2% (5)
P=0.030
PPH 4.9% (4) 4.8% (4) 6.9% (2)
DGE 3.7% (3) 10.7% (9) 20.7% (6) P=0.018
Intra-abdominal collection 28.4% (23) 25.0% (21) 20.7% (6)
Interventional drain 13.6% (11) 11.9% (10) 10.3% (3)
Pancreatic stent 2.5% (2) 2.4% (2) 6.9% (2)
&7YHUL¿HGSDQFUHDWLWLV 3.7% (3) 2.4% (2) 0.0% (0)
Lympha leak 1.2% (1) 1.2% (1) 0.0% (0)
Wound infection 9.9% (8) 3.6% (3) 10.3% (3)
Pneumonia 12.3% (10) 6.0% (5) 10.3% (3)
Pulmonary embolism 3.7% (3) 0.0% (0) 5.0% (1)
Clavien-Dindo III–V 16.0% (13) 18.1% (15) 20.7% (6)
Reoperation 1.2% (1) 1.2% (1) 10.3% (3) p=0.025
Total hospital stay, median (range) 7 (3–25) 8 (3-30) 8 (5–40)
Readmission 16.3% (13) 13.1% (11) 24.1% (7)
90-day mortality 0.0% (0) 2.4% (2) 0.0% (0)  
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6 Discussion
Pancreatic surgery has been prone to complications, pancreatic fistula being the most 
feared. In distal pancreatectomy much effort has been made to reduce the rate of pancreatic 
fistula in terms of different closure mechanisms or medical therapy. This thesis focuses 
on the feasibility of a new anastomosis techique in DP and the effect of perioperative 
hydrocortisone treatment on postoperative complications. In addition, the benefits of 
centralization of DPs are demonstated.
Technically distal pancreatectomy differs from PD in lack of reconstructive anastomosis. 
However, in distal pancreatectomy the pancreatic cut line can also be anastomosized to 
the jejunum. Tampere binding anastomosis is now a routine procedure in PD in Tampere, 
Finland and provides low fistula rates in PD. It was therefore hoped also to achieve some 
improvement in the fistula rate after DP. Unfortunately, Tampere binding anastomosis was 
not suitable for DP, and this was the major finding in Study I. It was suitable for only a 
small number of patients and, according to our small study, it does not seem to reduce 
the POPF rate. Tampere binding anastomosis requires mobilization of the pancreatic 
stump by 2–3 cm, in order to insert it inside the jejunal loop and this is how it differs from 
other anastomosis used in DP and reported in the literature. Earlier retrospective non-
randomized studies on PJ of the pancreatic stump showed no POPF (Kleeff et al., 2007, 
Wagner et al., 2007, Meniconi et al., 2013), but a Japanese RCT reported no reduction in 
POPF between stapler and PJ groups (Kawai et al., 2016). PJ end-to-side anastomosis was 
made in duct-to-mucosa fashion in RCT and in earlier retrospective studies PJ was made in 
a capsule-to-seromuscular fashion after ligating the main pancreatic duct. In our study the 
anastomosis differs markedly from both techniques mentioned and the techniques in these 
different studies cannot really be compared. Pancreaticogastrostomy did not reduce the 
CR-POPF either in recent RTC, making pancreatic anastomosis not beneficial (Uemura 
et al., 2017). Tampere binding anastomosis works in PD, where the pancreatic juice goes 
downstream, but the mechanism for fistulae after DP is apparently different and low 
pressure in the duodenum is probably needed to allow the healing of either PJ anastomosis 
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or the cut edge. Also, opening the GI tract while performing anastomosis may turn fluid 
collections contaminated with GI tract microbes. Furthermore, in the case of a fistula, the 
intestine also leaks and makes the fistula more severe 
In Study II, among patients receiving hydrocortisone, the incidence of clinically 
significant POPF (Grades B and C), was 5.9%. In the HC group there was only one Grade 
C fistula among 17 patients (5.9%). The POPF rate with HC is comparable to that with 
another recently studied drug, pasireotide, which reduced the incidence of clinically 
relevant pancreatic fistula to as low as 7% after DP (Allen et al., 2014). The Tampere Pancreas 
Group has recently demonstrated that perioperative hydrocortisone treatment reduces CR-
POPF after PD (11% vs. 27%) (Laaninen et al., 2016). With pasireotide, the CR-POPF rate 
was 10% in PD patients (Allen et al., 2014). This makes the effect of hydrocortisone and 
pasireotide similar among pancreatic resections, PD and DP. Two retrospective studies on 
the effect of pasireotide have been published since Allen’s study, with no effect on fistula 
rate after DP and PD (Elliott et al., 2018, Young et al., 2018). To the best of my knowledge, 
so far no other studies on hydrocortisone for prevention of fistula after pancreatic surgery 
have been published. 
In Study II, the incidence of biochemical leak (formerly Grade A POPF) was similar 
between the groups, but HC clearly reduced the risk of clinically relevant fistula (Grade 
B+C) (5.9% vs. 42.9%). It is debatable HC treatment has any effect on initial fistula 
formation or inflammation, but it seems obvious that the biochemical leak does not 
advance to a clinically relevant state (B and C) due to the HC treatment. HC treatment 
may decrease the inflammation process on the pancreatic stump and still allow the juice to 
run downstream into the duodenum, as hoped. In any case Grade A fistulas do not alter 
the clinical pathway and are nowadays defined as biochemical leak rather than true POPF. 
With HC treatment, the CD III–V rate was 5.9% in DP, compared to 21% in the placebo 
group. Thus HC treatment seems also to have a lowering effect on major complications even 
though difference did not reach statistical significance in Study II. The small number of 
patients in each group may explain why no significant difference was seen. In the study on 
PD, hydrocortisone significantly reduced the major complications (CD III–V) compared 
to the placebo group, 18 % vs. 41% (Laaninen et al., 2016). HC therefore seems also to 
reduce major complications after open pancreatic surgery in general. 
Furthermore, pasireotide causes significant dose-limited nausea as a side effect (17% in 
the study by Allen and 38% in the recent study by Elliott) and significant cardiac disease 
excludes patients from taking it in the first place (Allen et al., 2014, Elliott et al., 2018). 
During HC treatment there were no adverse effects or dropouts due side effects. Another 
advantage of hydrocortisone over pasireotide is the price; HC is cheap, whereas pasireotide 
is expensive, 
Hydrocortisone is an old drug with anti-inflammatory effects. Our hypothesis is that 
POPF and other complications occur after postoperative pancreatic inflammation. By 
intervening in the inflammation cascade with HC after DP or PD, some effect on POPF 
53
or other complications could be anticipated. Postoperative pancreatitis has recently been 
shown to be associated with increased incidence of POPF (Bannone et al., 2018). The exact 
mechanism of cortisone is not fully understood; it may be both local and systematic. Tampere 
Pancreas Group currently aims to identify the mechanisms by which hydrocortisone works 
on acinar and stellate cells in our pancreas laboratory with several ongoing studies. 
Study III reported nationwide results from DPs performed in Finland in the period 
2012–2014. PDs have been transferred to higher-volume centres in recent years and this 
centralization has reduced postoperative mortality and morbidity and also improved 
long-term survival after pancreatoduodenectomy (PD) (Ahola et al., 2017, Gooiker et 
al., 2011). In the case of distal pancratectomy, the rate of POPF and the Clavien-Dindo 
III–V complication were similar in high and low-volume centres, but the management 
of complications detected differed between centres with different surgical volumes. 
Reoperations were performed ten times more often in the low-volume centres in Finland. 
Proper management of complications often requires a multidisciplinary approach, which 
is often unavailable in LVC units. Reasonable volumes are needed to achieve and sustain 
experienced perioperative management. In Finland, with a population 5.4 million, 18 
different hospitals were performing DP in 2012–2014. There were hospitals in which 
DP was performed very rarely and which lacked experienced postoperative observation. 
By checking the reoperations performed in LVCs we could speculate that they were all 
unnecessary and could have been avoided by the use of conservative or minimally invasive 
approaches. In low-volume centres CT-imaging facilities and options for modern treatment 
may be limited. The reoperation rate in most studies is around 0–5% in LDP and ODP 
(Marchegiani et al., 2017). The study showed that only the reoperation rates of HVCs are 
comparable with international results. Thus Finland can only come up to the international 
standard by centralizing operations to high volume centres.
Perioperative care in general needs improvement and it is essential for patients to 
regain full functional capacity. ERAS is a standardized and multidisciplinary model of 
perioperative treatment and can also be applied to pancreatic surgery (Pecorelli et al., 
2017). In order to introduce the ERAS model, the hospital needs a reasonable number of 
patients, which also favours centralizing DP to HVCs. In Finland, according to the current 
statement by the medical authorities, all surgery for pancreatic cancer should be centralized 
to the country’s five university hospitals.
Study III also showed underutilization of laparoscopic approach in Finland in DP. 
LDP was performed on 24% of the whole study group, most often in HVCs (28%) and 
MVCs (26%) and on only 3% in LVCs. MIDP should be increased in Finland to improve 
outcomes. Laparoscopic DP is associated with significantly less overall morbidity than 
open technique (Venkat et al., 2012). Laparoscopy shortens postoperative recovery by 
accelerating the normal gut functions (Mehrabi et al., 2015). So far there is only one RCT 
on MIDP vs. ODP showing that MIDP reduces time to functional recovery compared to 
ODP. The overall complication rate was similar in spite of less delayed gastric emptying and 
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better quality of life with MIDP (de Rooij et al., 2018). For cancer, oncologic equivalency 
has not been shown in any RCT and many European pancreatic surgeons still consider 
ODP a better choice for the treatment of cancer (de Rooij et al., 2016). ERAS is safe to 
implement in LDP and saves costs (Richardson et al., 2015). Open surgery is recommended 
for malignancies. In Study III, in 21% of DP: s the histopathological diagnosis was 
adenocarsinoma. In addition, some other diagnosis groups included patients with suspicion 
of malignancy. This means that approximately 70% of all DPs could have been performed 
laparoscopically. Since only 24% of DPs in 2012–2014 were performed laparoscopically, 
there is much room for improvement in this regard – even in high-volume centres.
A weakness of the randomized Studies I and II is definitely the small number of 
patients. It was challenging in Study I to find patients suitable for anastomosis, which was 
the reason for its early discontinuation. The only conclusion which can really be drawn 
from that Study is that binding anastomosis is not suitable for DP, mainly due to the 
location of the transection site. Transsection in DP is mainly done at the portal vein level, 
which makes binding anastomosis technically unfeasible. In Study II, the small study 
group and the open surgical technique are limitations. When the study was planned, LDP 
was not routine in our institution as it is now, and later we wanted to keep the study group 
homogenous. Nevertheless, the use of HC can be recommended in both ODP and LDP. In 
the nationwide Study III, CR-POPF incidence among all patients was very good, 16%, but 
the study population was heterogeneous with respect to the fistula reducing methods used. 
Pasireotide, HC, staplers and pancreaticojejunal anastomosis were used among patients, 
which also reflects clinical practice worldwide.
Many researchers in recent years have tried to solve the POPF problem after DP by 
innovating new surgical methods, but without success. All the different methods seem 
equally bad at improving the POPF rate and the stump could probably be closed in various 
ways with the same outcome. The risk factors for POPF are obesity, soft pancreas or gender 
and these cannot be affected. Their role in fistula formation has also been contested in 
many studies. The mechanism for POPF formation may be totally different in DP than 
in PD. Since studies of different closure mechanisms of the pancreatic stump have not 
given the answer, recent studies have focused on decreasing the pressure at the Sphincter of 
Oddi. The leak may be a result of obstruction by the Sphincter of Oddi, which increases the 
intraductal pressure in the main pancreatic duct and leads to leak. Early drain removal or no 
drain at all may be a way to decrease fistula related problems and this merits consideration. 
Fistulas still occur, but by early drain removal we might leave them in biochemical leak 
state. Long retention of the drain probably just turns them into clinically relevant ones. 
This and many other perioperative care measures are subject to variation even within 
hospitals due to a lack of perioperative protocols. In addition to standardized perioperative 
care, by increasing the use of laparoscopy we might help patients recover better than by 
developing new closure methods. From a pharmacological perspective, hydrocortisone 
seems promising in decreasing the POPF rate and morbidity in pancreatic surgery. It is 
55
speculated that the pancreatic juice may flow better into the duodenum because the 
inflammation in the pancreas decreases.
In conclusion, by centralizing surgery to high-volume centres, by increasing the use 
of laparoscopy in distal pancreatectomies and by using standardized, multidisciplinary 
perioperative protocols, we could probably improve patient recovery and morbidity after 
DP, even without being able to lower the actual POPF rate. We should concentrate more 
on dealing with the fistulas rather than identifying and preventing them. Nevertheless, 
innovations, especially for decreasing intraductal pressure, are still needed and some 
promising methods are already emerging. In pancreatic surgery, what matters is the whole 
organization, the way of detecting and healing unavoidable complications, rather than the 
individual surgeon’s skills or a single surgical method or medical therapy. 
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7 Conclusions
The conclusions of this thesis are:
I Tampere binding pancreaticojejunal anastomosis is not suitable for most cases of 
distal pancreatectomy, nor does it seem to decrease POPF.
II Hydrocortisone treatment reduces the incidence of clinically significant fistula 
after open distal pancreatectomy. HC may also have a favourable effect on overall 
complications after open DP.
III According to a nationwide register, POPF and overall complication rates were similar 
in different volume hospitals in Finland during the period 2012–1014. However, the 
management of complications may favour the centralization of pancreatic resections 
to HVCs, which was seen in the high reoperation rate in LVCs.
57
8 Acknowledgements
This study was carried out at the Department of Gastroenterology and Alimentary Tract 
Surgery, Tampere University Hospital, and at the School of Medicine, University of 
Tampere. This study was financialy supported by the Competitive State Research Funding 
of Pirkanmaa Hospital District and the Sigrid Juselius Foundation.
I warmly thank Head of Department of Surgery, Professor Teuvo Tammela and Head 
of Division, Docent Mikael Leppilahti for enabling and encouraging active research in the 
Department of Surgery.
I owe my deepest and warmest thanks to my supervisors, Associate Professor, Chief 
of Alimentary Tract Surgery Johanna Laukkarinen and Docent, Medical Director Juhani 
Sand. I thank Juhani for encouraging and constructive feedback at every step throughout 
the process. And Johanna, words are not enough to thank you for all the support during 
this work. Your skills, determination, support and endless optimism have played a 
significant role in finishing this book. We have come a long way in clinical work and also in 
research together, both of which have a lot of setbacks and successes. Your contribution to 
my reseach and clinical carrier as well has been invaluable. 
I thank Docent Isto Nordback for taking part in my work, especially in the beginning 
and for creating the Tampere Pancreas Group, a great support for researchers. Your 
insightful, intelligent and innovative comments have made a profound impression. Even 
though your time with us is nowadays limited, the research group is still going strong. 
I am very grateful to the official reviewers of this thesis, Professor Caj Haglund and 
Docent Arto Kokkola, for the time-consuming work in giving me the valuable criticism 
and comments to improve the manuscript. 
I wish to thank Reea Ahola, MD, PhD for your help and advice in the register study. I 
thank Mika Helminen for helping me with the statistics and Virginia Mattila for her fast 
expertise in revising the English language. Special thanks go to Antti Siiki, MD, PhD, not 
only for your contribution to the hydrocortisone study and surgical illustrations in the 
book, but also for being my closest colleague at work and for sharing the everyday working 
58
life and workload with me. We have experienced many ups and downs together in the field 
of pancreatic surgery, which has made us a good team during these years. It is an honour 
to work with you! I also thank all the Tampere Pancreas Group members and especially 
research nurse Satu Järvinen for chasing all the papers in the register study.
My thanks go to all my colleagues, with whom I have worked with during my career 
in the past and nowadays. Colleagues in Department Gas2 deserve special thanks, Tuula 
Tyrväinen, MD and Yrjö Vaalavuo, MD. No one has been spared from hearing about this 
project and its failures. Special thanks go to my friend and colleague Kirsi Lehto, MD, PhD 
for being my ”väitöskaaso” and for listening to and dispelling my uncertainty about almost 
everything during this project. 
I thank my dear friends from my Turku years, The Mikkos and The Vahvero; Johanna 
Hynninen, MD, PhD, Maarit Vahvelainen MD and Tanja Kaita, MD. Many good 
memories and fun times with you in the past and hopefully more to come. I also thank 
my friends from my Tampere years, my neighbours, The Muotiala Stars; Marika Savenius, 
Katri Udelius and Reetta Muhonen, PhD. Good talks and ladies evenings with you all, far 
away from medical science, have really done me a lot of good. 
My warmest gratitude goes to my mother, Lea, for having faith in me in every situation. 
She is an independent, competent and strong woman and has set me a good example of 
never giving up. Her endless support, understanding and belief in me has given me strength 
in my life. Through her example, I believe it is possible to survive almost anything and I 
dedicate this book to her.
Finally, I thank Jari for coping with me and sharing life with me. My deepest thanks go 
to my children, Leevi, Saana and Aapo. You make my life so full that I did not need to be 
reminded of life outside of research, but vice versa. You are most important to me in life and 
your wellbeing will always be my first priority. 
Tampere, on 2 October 2019
Anne Antila
59
9 References
”WHO International Clinical Trials Registry Platform. Distal pancreatectomy – A randomized 
controlled trial to compare open versus laparoscopic resection (DISPACT 2-TRIAL).” , , 
no. accessed 20 April 2018.
Abe, N., Sugiyama, M., Suzuki, Y., Yamaguchi, T., Mori, T. & Atomi, Y. 2008, ”Preoperative 
endoscopic pancreatic stenting: a novel prophylactic measure against pancreatic fistula 
after distal pancreatectomy”, Journal of hepato-biliary-pancreatic surgery, vol. 15, no. 4, pp. 
373–376.
Ahola, R., Siiki, A., Vasama, K., Vornanen, M., Sand, J. & Laukkarinen, J. 2017, ”Effect of 
centralization on long-term survival after resection of pancreatic ductal adenocarcinoma”, 
The British journal of surgery, vol. 104, no. 11, pp. 1532–1538.
Allen, P.J., Gonen, M., Brennan, M.F., Bucknor, A.A., Robinson, L.M., Pappas, M.M., Carlucci, 
K.E., D’Angelica, M.I., DeMatteo, R.P., Kingham, T.P., Fong, Y. & Jarnagin, W.R. 2014, 
”Pasireotide for postoperative pancreatic fistula”, The New England journal of medicine, vol. 
370, no. 21, pp. 2014–2022.
Andrianello, S., Marchegiani, G., Bannone, E., Masini, G., Malleo, G., Montemezzi, G.L., Polati, 
E., Bassi, C. & Salvia, R. 2018, ”Clinical Implications of Intraoperative Fluid Therapy in 
Pancreatic Surgery”, Journal of gastrointestinal surgery : official journal of the Society for 
Surgery of the Alimentary Tract, .
Ansorge, C., Strommer, L., Andren-Sandberg, A., Lundell, L., Herrington, M.K. & Segersvard, R. 
2012, ”Structured intraoperative assessment of pancreatic gland characteristics in predicting 
complications after pancreaticoduodenectomy”, The British journal of surgery, vol. 99, no. 8, 
pp. 1076–1082.
Arnelo, U., Siiki, A., Swahn, F., Segersvard, R., Enochsson, L., del Chiaro, M., Lundell, L., Verbeke, 
C.S. & Lohr, J.M. 2014, ”Single-operator pancreatoscopy is helpful in the evaluation of 
suspected intraductal papillary mucinous neoplasms (IPMN)”, Pancreatology : official 
journal of the International Association of Pancreatology (IAP) ...[et al.], vol. 14, no. 6, pp. 
510–514.
Ban, D., Shimada, K., Konishi, M., Saiura, A., Hashimoto, M. & Uesaka, K. 2012, ”Stapler and 
nonstapler closure of the pancreatic remnant after distal pancreatectomy: multicenter 
retrospective analysis of 388 patients”, World journal of surgery, vol. 36, no. 8, pp. 1866–1873.
60
Bannone, E., Andrianello, S., Marchegiani, G., Masini, G., Malleo, G., Bassi, C. & Salvia, R. 2018, 
”Postoperative Acute Pancreatitis Following Pancreaticoduodenectomy: A Determinant of 
Fistula Potentially Driven by the Intraoperative Fluid Management”, Annals of Surgery, vol. 
268, no. 5, pp. 815–822.
Bardeesy, N. & DePinho, R.A. 2002, ”Pancreatic cancer biology and genetics”, Nature reviews.
Cancer, vol. 2, no. 12, pp. 897–909.
Bassi, C., Dervenis, C., Butturini, G., Fingerhut, A., Yeo, C., Izbicki, J., Neoptolemos, J., Sarr, M., 
Traverso, W., Buchler, M. & International Study Group on Pancreatic Fistula Definition 
2005, ”Postoperative pancreatic fistula: an international study group (ISGPF) definition”, 
Surgery, vol. 138, no. 1, pp. 8–13.
Bassi, C., Molinari, E., Malleo, G., Crippa, S., Butturini, G., Salvia, R., Talamini, G. & Pederzoli, 
P. 2010, ”Early versus late drain removal after standard pancreatic resections: results of a 
prospective randomized trial”, Annals of Surgery, vol. 252, no. 2, pp. 207–214.
Bassi, C., Marchegiani, G., Dervenis, C., Sarr, M., Abu Hilal, M., Adham, M., Allen, P., Andersson, 
R., Asbun, H.J., Besselink, M.G., Conlon, K., Del Chiaro, M., Falconi, M., Fernandez-
Cruz, L., Fernandez-Del Castillo, C., Fingerhut, A., Friess, H., Gouma, D.J., Hackert, 
T., Izbicki, J., Lillemoe, K.D., Neoptolemos, J.P., Olah, A., Schulick, R., Shrikhande, S.V., 
Takada, T., Takaori, K., Traverso, W., Vollmer, C.R., Wolfgang, C.L., Yeo, C.J., Salvia, R., 
Buchler, M. & International Study Group on Pancreatic Surgery, (ISGPS) 2017, ”The 2016 
update of the International Study Group (ISGPS) definition and grading of postoperative 
pancreatic fistula: 11 Years After”, Surgery, vol. 161, no. 3, pp. 584–591.
Bauman, M.D., Becerra, D.G., Kilbane, E.M., Zyromski, N.J., Schmidt, C.M., Pitt, H.A., Nakeeb, 
A., House, M.G. & Ceppa, E.P. 2018, ”Laparoscopic distal pancreatectomy for pancreatic 
cancer is safe and effective”, Surgical endoscopy, vol. 32, no. 1, pp. 53–61.
Behrman, S.W., Zarzaur, B.L., Parmar, A., Riall, T.S., Hall, B.L. & Pitt, H.A. 2015, ”Routine 
drainage of the operative bed following elective distal pancreatectomy does not reduce 
the occurrence of complications”, Journal of gastrointestinal surgery : official journal of the 
Society for Surgery of the Alimentary Tract, vol. 19, no. 1, pp. 7–9; discussion 79.
Bilimoria, M.M., Cormier, J.N., Mun, Y., Lee, J.E., Evans, D.B. & Pisters, P.W. 2003, ”Pancreatic 
leak after left pancreatectomy is reduced following main pancreatic duct ligation”, The 
British journal of surgery, vol. 90, no. 2, pp. 190–196.
Birkmeyer, J.D., Stukel, T.A., Siewers, A.E., Goodney, P.P., Wennberg, D.E. & Lucas, F.L. 2003, 
”Surgeon volume and operative mortality in the United States”, The New England journal of 
medicine, vol. 349, no. 22, pp. 2117–2127.
Bjornsson, B. & Sandstrom, P. 2014, ”Laparoscopic distal pancreatectomy for adenocarcinoma of 
the pancreas”, World journal of gastroenterology, vol. 20, no. 37, pp. 13402–13411.
Blansfield, J.A., Rapp, M.M., Chokshi, R.J., Woll, N.L., Hunsinger, M.A., Sheldon, D.G. & 
Shabahang, M.M. 2012, ”Novel method of stump closure for distal pancreatectomy with a 
75% reduction in pancreatic fistula rate”, Journal of gastrointestinal surgery : official journal 
of the Society for Surgery of the Alimentary Tract, vol. 16, no. 3, pp. 524–528.
Briggs, C.D., Mann, C.D., Irving, G.R., Neal, C.P., Peterson, M., Cameron, I.C. & Berry, D.P. 2009, 
”Systematic review of minimally invasive pancreatic resection”, Journal of gastrointestinal 
surgery : official journal of the Society for Surgery of the Alimentary Tract, vol. 13, no. 6, pp. 
1129–1137.
61
Bruns, H., Rahbari, N.N., Loffler, T., Diener, M.K., Seiler, C.M., Glanemann, M., Butturini, G., 
Schuhmacher, C., Rossion, I., Buchler, M.W., Junghans, T. & DISPACT Trial group 2009, 
”Perioperative management in distal pancreatectomy: results of a survey in 23 European 
participating centres of the DISPACT trial and a review of literature”, Trials, vol. 10, pp. 
5–58.
Butturini, G., Inama, M., Malleo, G., Manfredi, R., Melotti, G.L., Piccoli, M., Perandini, S., 
Pederzoli, P. & Bassi, C. 2012, ”Perioperative and long-term results of laparoscopic 
spleen-preserving distal pancreatectomy with or without splenic vessels conservation: a 
retrospective analysis”, Journal of surgical oncology, vol. 105, no. 4, pp. 387–392.
Butturini, G., Partelli, S., Crippa, S., Malleo, G., Rossini, R., Casetti, L., Melotti, G.L., Piccoli, M., 
Pederzoli, P. & Bassi, C. 2011, ”Perioperative and long-term results after left pancreatectomy: 
a single-institution, non-randomized, comparative study between open and laparoscopic 
approach”, Surgical endoscopy, vol. 25, no. 9, pp. 2871–2878.
Callery, M.P., Pratt, W.B., Kent, T.S., Chaikof, E.L. & Vollmer, C.M. 2013, ”A prospectively validated 
clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy”, 
Journal of the American College of Surgeons, vol. 216, no. 1, pp. 1–14.
Carter, T.I., Fong, Z.V., Hyslop, T., Lavu, H., Tan, W.P., Hardacre, J., Sauter, P.K., Kennedy, E.P., 
Yeo, C.J. & Rosato, E.L. 2013, ”A dual-institution randomized controlled trial of remnant 
closure after distal pancreatectomy: does the addition of a falciform patch and fibrin glue 
improve outcomes?”, Journal of gastrointestinal surgery : official journal of the Society for 
Surgery of the Alimentary Tract, vol. 17, no. 1, pp. 102–109.
Cecka, F., Jon, B., Skalicky, P., Cermakova, E., Neoral, C. & Lovecek, M. 2018, ”Results of a 
randomized controlled trial comparing closed-suction drains versus passive gravity drains 
after pancreatic resection”, Surgery, .
Ceppa, E.P., McCurdy, R.M., Becerra, D.C., Kilbane, E.M., Zyromski, N.J., Nakeeb, A., Schmidt, 
C.M., Lillemoe, K.D., Pitt, H.A. & House, M.G. 2015, ”Does Pancreatic Stump Closure 
Method Influence Distal Pancreatectomy Outcomes?”, Journal of gastrointestinal surgery : 
official journal of the Society for Surgery of the Alimentary Tract, vol. 19, no. 8, pp. 1449–1456.
Chang, Y.R., Kang, J.S., Jang, J.Y., Jung, W.H., Kang, M.J., Lee, K.B. & Kim, S.W. 2017, ”Prediction 
of Pancreatic Fistula After Distal Pancreatectomy Based on Cross-Sectional Images”, World 
journal of surgery, vol. 41, no. 6, pp. 1610–1617.
Crippa, S., Boninsegna, L., Partelli, S. & Falconi, M. 2010, ”Parenchyma-sparing resections for 
pancreatic neoplasms”, Journal of Hepato-Biliary-Pancreatic Sciences, vol. 17, no. 6, pp. 782–
787.
Cuschieri, A., Jakimowicz, J.J. & van Spreeuwel, J. 1996, ”Laparoscopic distal 70% pancreatectomy 
and splenectomy for chronic pancreatitis”, Annals of Surgery, vol. 223, no. 3, pp. 280–285.
Daouadi, M., Zureikat, A.H., Zenati, M.S., Choudry, H., Tsung, A., Bartlett, D.L., Hughes, 
S.J., Lee, K.K., Moser, A.J. & Zeh, H.J. 2013, ”Robot-assisted minimally invasive distal 
pancreatectomy is superior to the laparoscopic technique”, Annals of Surgery, vol. 257, no. 
1, pp. 128–132.
De Bruijn, Kirstin M. J. & van Eijck, Casper H. J. 2015, ”New-onset diabetes after distal 
pancreatectomy: a systematic review”, Annals of Surgery, vol. 261, no. 5, pp. 854–861.
de la Santa, L G, Retortillo, J.A., Miguel, A.C. & Klein, L.M. 2014, ”Radiology of pancreatic 
neoplasms: An update”, World journal of gastrointestinal oncology, vol. 6, no. 9, pp. 330–343.
62
de Rooij, T., van Hilst, J., van Santvoort, H., Boerma, D., van den Boezem, P., Daams, F., van 
Dam, R., Dejong, C., van Duyn, E., Dijkgraaf, M., van Eijck, C., Festen, S., Gerhards, M., 
Groot Koerkamp, B., de Hingh, I., Kazemier, G., Klaase, J., de Kleine, R., van Laarhoven, 
C., Luyer, M., Patijn, G., Steenvoorde, P., Suker, M., Abu Hilal, M., Busch, O., Besselink, 
M. & Dutch Pancreatic Cancer Group 2018, ”Minimally Invasive Versus Open Distal 
Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled 
Trial”, Annals of Surgery, .
de Rooij, T., Besselink, M.G., Shamali, A., Butturini, G., Busch, O.R., Edwin, B., Troisi, R., 
Fernández-Cruz, L., Dagher, I., Bassi, C. & Abu Hilal, M. 2016, ”Pan-European survey 
on the implementation of minimally invasive pancreatic surgery with emphasis on cancer”, 
HPB : The Official Journal of the International Hepato Pancreato Biliary Association, vol. 18, 
no. 2, pp. 170–176.
Del Chiaro, M., Rangelova, E., Ansorge, C., Blomberg, J. & Segersvard, R. 2013, ”Impact of 
body mass index for patients undergoing pancreaticoduodenectomy”, World journal of 
gastrointestinal pathophysiology, vol. 4, no. 2, pp. 37–42.
Del Chiaro, M., Verbeke, C., Salvia, R., Kloppel, G., Werner, J., McKay, C., Friess, H., Manfredi, 
R., Van Cutsem, E., Lohr, M., Segersvard, R. & European Study Group on Cystic Tumours 
of the Pancreas 2013, ”European experts consensus statement on cystic tumours of the 
pancreas”, Digestive and liver disease : official journal of the Italian Society of Gastroenterology 
and the Italian Association for the Study of the Liver, vol. 45, no. 9, pp. 703–711.
DeOliveira, M.L., Winter, J.M., Schafer, M., Cunningham, S.C., Cameron, J.L., Yeo, C.J. & 
Clavien, P.A. 2006, ”Assessment of complications after pancreatic surgery: A novel grading 
system applied to 633 patients undergoing pancreaticoduodenectomy”, Annals of Surgery, 
vol. 244, no. 6, pp. 93–9.
Diener, M.K., Seiler, C.M., Rossion, I., Kleeff, J., Glanemann, M., Butturini, G., Tomazic, A., 
Bruns, C.J., Busch, O.R., Farkas, S., Belyaev, O., Neoptolemos, J.P., Halloran, C., Keck, 
T., Niedergethmann, M., Gellert, K., Witzigmann, H., Kollmar, O., Langer, P., Steger, 
U., Neudecker, J., Berrevoet, F., Ganzera, S., Heiss, M.M., Luntz, S.P., Bruckner, T., 
Kieser, M. & Buchler, M.W. 2011, ”Efficacy of stapler versus hand-sewn closure after distal 
pancreatectomy (DISPACT): a randomised, controlled multicentre trial”, Lancet (London, 
England), vol. 377, no. 9776, pp. 1514–1522.
Dindo, D., Demartines, N. & Clavien, P.A. 2004, ”Classification of surgical complications: a new 
proposal with evaluation in a cohort of 6336 patients and results of a survey”, Annals of 
Surgery, vol. 240, no. 2, pp. 205–213.
Drake, T, Vogl, W. & Mitchell, A. 2005, Abdominal viscera. Gray’s anatomy for students, 1st ed 
edn, Elsevier.
Ecker, B.L., McMillan, M.T., Allegrini, V., Bassi, C., Beane, J.D., Beckman, R.M., Behrman, S.W., 
Dickson, E.J., Callery, M.P., Christein, J.D., Drebin, J.A., Hollis, R.H., House, M.G., 
Jamieson, N.B., Javed, A.A., Kent, T.S., Kluger, M.D., Kowalsky, S.J., Maggino, L., Malleo, 
G., Valero, V., Velu, L.K.P., Watkins, A.A., Wolfgang, C.L., Zureikat, A.H. & Vollmer, 
C.M. 2017, ”Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal 
Pancreatectomy: Analysis of 2026 Resections From the International, Multi-institutional 
Distal Pancreatectomy Study Group”, Annals of Surgery, .
63
Eguchi, H., Nagano, H., Tanemura, M., Takeda, Y., Marubashi, S., Kobayashi, S., Wada, H., 
Umeshita, K., Mori, M. & Doki, Y. 2011, ”A thick pancreas is a risk factor for pancreatic 
fistula after a distal pancreatectomy: selection of the closure technique according to the 
thickness”, Digestive surgery, vol. 28, no. 1, pp. 50–56.
El Khoury, R., Kabir, C., Maker, V.K., Banulescu, M., Wasserman, M. & Maker, A.V. 2018, ”Do 
Drains Contribute to Pancreatic Fistulae? Analysis of over 5000 Pancreatectomy Patients”, 
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary 
Tract, vol. 22, no. 6, pp. 1007–1015.
Elliott, I.A., Dann, A.M., Ghukasyan, R., Damato, L., Girgis, M.D., King, J.C., Hines, O.J., Reber, 
H.A. & Donahue, T.R. 2018, ”Pasireotide does not prevent postoperative pancreatic fistula: 
a prospective study”, HPB : the official journal of the International Hepato Pancreato Biliary 
Association, .
European Study Group on Cystic Tumours of the Pancreas 2018, ”European evidence-based 
guidelines on pancreatic cystic neoplasms”, Gut, vol. 67, no. 5, pp. 789–804.
Fahy, B.N., Frey, C.F., Ho, H.S., Beckett, L. & Bold, R.J. 2002, ”Morbidity, mortality, and technical 
factors of distal pancreatectomy”, American Journal of Surgery, vol. 183, no. 3, pp. 237–241.
Ferrone, C.R., Warshaw, A.L., Rattner, D.W., Berger, D., Zheng, H., Rawal, B., Rodriguez, R., 
Thayer, S.P. & Fernandez-del Castillo, C. 2008, ”Pancreatic fistula rates after 462 distal 
pancreatectomies: staplers do not decrease fistula rates”, Journal of gastrointestinal surgery 
: official journal of the Society for Surgery of the Alimentary Tract, vol. 12, no. 10, pp. 169–8.
Fischer, C.P., Bass, B., Fahy, B. & Aloia, T. 2008, ”Transampullary pancreatic duct stenting 
decreases pancreatic fistula rate following left pancreatectomy”, Hepato-gastroenterology, 
vol. 55, no. 81, pp. 244–248.
Frozanpor, F., Albiin, N., Linder, S., Segersvard, R., Lundell, L. & Arnelo, U. 2010, ”Impact of 
pancreatic gland volume on fistula formation after pancreatic tail resection”, JOP : Journal 
of the pancreas, vol. 11, no. 5, pp. 439–443.
Frozanpor, F., Lundell, L., Segersvard, R. & Arnelo, U. 2012, ”The effect of prophylactic 
transpapillary pancreatic stent insertion on clinically significant leak rate following distal 
pancreatectomy: results of a prospective controlled clinical trial”, Annals of Surgery, vol. 255, 
no. 6, pp. 1032–1036.
Gavriilidis, P., Roberts, K.J. & Sutcliffe, R.P. 2019, ”Comparison of robotic vs laparoscopic vs open 
distal pancreatectomy. A systematic review and network meta-analysis”, HPB : the official 
journal of the International Hepato Pancreato Biliary Association, .
Ghaferi, A.A., Birkmeyer, J.D. & Dimick, J.B. 2011, ”Hospital volume and failure to rescue with 
high-risk surgery”, Medical care, vol. 49, no. 12, pp. 1076–1081.
Glowka, T.R., von Websky, M., Pantelis, D., Manekeller, S., Standop, J., Kalff, J.C. & Schafer, 
N. 2016, ”Risk factors for delayed gastric emptying following distal pancreatectomy”, 
Langenbeck’s archives of surgery, vol. 401, no. 2, pp. 161–167.
Goh, B.K., Tan, Y.M., Chung, Y.F., Cheow, P.C., Ong, H.S., Chan, W.H., Chow, P.K., Soo, K.C., 
Wong, W.K. & Ooi, L.L. 2008, ”Critical appraisal of 232 consecutive distal pancreatectomies 
with emphasis on risk factors, outcome, and management of the postoperative pancreatic 
fistula: a 21-year experience at a single institution”, Archives of surgery (Chicago, Ill.: 1960), 
vol. 143, no. 10, pp. 956–965.
64
Gong, J., He, S., Cheng, Y., Cheng, N., Gong, J. & Zeng, Z. 2018, ”Fibrin sealants for the prevention 
of postoperative pancreatic fistula following pancreatic surgery”, The Cochrane database of 
systematic reviews, vol. 6, pp. CD009621.
Gooiker, G.A., van Gijn, W., Wouters, M.W., Post, P.N., van de Velde, C J, Tollenaar, R.A. & 
Signalling Committee Cancer of the Dutch Cancer Society 2011, ”Systematic review and 
meta-analysis of the volume-outcome relationship in pancreatic surgery”, The British journal 
of surgery, vol. 98, no. 4, pp. 485–494.
Guerrini, G.P., Lauretta, A., Belluco, C., Olivieri, M., Forlin, M., Basso, S., Breda, B., Bertola, G. 
& Di Benedetto, F. 2017, ”Robotic versus laparoscopic distal pancreatectomy: an up-to-date 
meta-analysis”, BMC surgery, vol. 17, no. 1, pp. 10–3.
Gurusamy, K.S., Koti, R., Fusai, G. & Davidson, B.R. 2012, ”Somatostatin analogues for pancreatic 
surgery”, The Cochrane database of systematic reviews, vol. (6):CD008370. doi, no. 6, pp. 
CD008370.
Guzman, E.A., Nelson, R.A., Kim, J., Pigazzi, A., Trisal, V., Paz, B. & Di Ellenhorn, J. 2009, 
”Increased incidence of pancreatic fistulas after the introduction of a bioabsorbable staple 
line reinforcement in distal pancreatic resections”, The American Surgeon, vol. 75, no. 10, 
pp. 954–957.
Hackert, T., Klaiber, U., Hinz, U., Kehayova, T., Probst, P., Knebel, P., Diener, M.K., Schneider, 
L., Strobel, O., Michalski, C.W., Ulrich, A., Sauer, P. & Buchler, M.W. 2017, ”Sphincter of 
Oddi botulinum toxin injection to prevent pancreatic fistula after distal pancreatectomy”, 
Surgery, vol. 161, no. 5, pp. 1444–1450.
Hackert, T., Hinz, U., Fritz, S., Strobel, O., Schneider, L., Hartwig, W., Büchler, M.W. & Werner, 
J. 2011, ”Enucleation in pancreatic surgery: indications, technique, and outcome compared 
to standard pancreatic resections”, Langenbeck’s Archives of Surgery, vol. 396, no. 8, pp. 
1197–1203.
Hamilton, N.A., Porembka, M.R., Johnston, F.M., Gao, F., Strasberg, S.M., Linehan, D.C. & 
Hawkins, W.G. 2012, ”Mesh reinforcement of pancreatic transection decreases incidence 
of pancreatic occlusion failure for left pancreatectomy: a single-blinded, randomized 
controlled trial”, Annals of Surgery, vol. 255, no. 6, pp. 1037–1042.
Hartwig, W., Duckheim, M., Strobel, O., Dovzhanskiy, D., Bergmann, F., Hackert, T., Buchler, 
M.W. & Werner, J. 2010, ”LigaSure for pancreatic sealing during distal pancreatectomy”, 
World journal of surgery, vol. 34, no. 5, pp. 1066–1070.
Hashimoto, Y. & Traverso, L.W. 2012, ”After distal pancreatectomy pancreatic leakage from the 
stump of the pancreas may be due to drain failure or pancreatic ductal back pressure”, 
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary 
Tract, vol. 16, no. 5, pp. 993–1003.
Hassenpflug, M., Hartwig, W., Strobel, O., Hinz, U., Hackert, T., Fritz, S., Buchler, M.W. & 
Werner, J. 2012, ”Decrease in clinically relevant pancreatic fistula by coverage of the 
pancreatic remnant after distal pancreatectomy”, Surgery, vol. 152, no. 3 Suppl 1, pp. 164.
Hassenpflug, M., Hinz, U., Strobel, O., Volpert, J., Knebel, P., Diener, M.K., Doerr-Harim, C., 
Werner, J., Hackert, T. & Buchler, M.W. 2016, ”Teres Ligament Patch Reduces Relevant 
Morbidity After Distal Pancreatectomy (the DISCOVER Randomized Controlled Trial)”, 
Annals of Surgery, vol. 264, no. 5, pp. 723–730.
65
Hata, T., Motoi, F., Ishida, M., Naitoh, T., Katayose, Y., Egawa, S. & Unno, M. 2016, ”Effect of 
Hospital Volume on Surgical Outcomes After Pancreaticoduodenectomy: A Systematic 
Review and Meta-analysis”, Annals of Surgery, vol. 263, no. 4, pp. 664–672.
Huttner, F.J., Mihaljevic, A.L., Hackert, T., Ulrich, A., Buchler, M.W. & Diener, M.K. 2016, 
”Effectiveness of Tachosil((R)) in the prevention of postoperative pancreatic fistula after 
distal pancreatectomy: a systematic review and meta-analysis”, Langenbeck’s archives of 
surgery, vol. 401, no. 2, pp. 151–159.
Iacono, C., Verlato, G., Ruzzenente, A., Campagnaro, T., Bacchelli, C., Valdegamberi, A., Bortolasi, 
L. & Guglielmi, A. 2013, ”Systematic review of central pancreatectomy and meta-analysis 
of central versus distal pancreatectomy”, The British Journal of Surgery, vol. 100, no. 7, pp. 
873–885.
Jais, B., Rebours, V., Malleo, G., Salvia, R., Fontana, M., Maggino, L., Bassi, C., Manfredi, R., 
Moran, R., Lennon, A.M., Zaheer, A., Wolfgang, C., Hruban, R., Marchegiani, G., 
Fernandez Del Castillo, C., Brugge, W., Ha, Y., Kim, M.H., Oh, D., Hirai, I., Kimura, W., 
Jang, J.Y., Kim, S.W., Jung, W., Kang, H., Song, S.Y., Kang, C.M., Lee, W.J., Crippa, S., 
Falconi, M., Gomatos, I., Neoptolemos, J., Milanetto, A.C., Sperti, C., Ricci, C., Casadei, 
R., Bissolati, M., Balzano, G., Frigerio, I., Girelli, R., Delhaye, M., Bernier, B., Wang, 
H., Jang, K.T., Song, D.H., Huggett, M.T., Oppong, K.W., Pererva, L., Kopchak, K.V., 
Del Chiaro, M., Segersvard, R., Lee, L.S., Conwell, D., Osvaldt, A., Campos, V., Aguero 
Garcete, G., Napoleon, B., Matsumoto, I., Shinzeki, M., Bolado, F., Fernandez, J.M., Keane, 
M.G., Pereira, S.P., Acuna, I.A., Vaquero, E.C., Angiolini, M.R., Zerbi, A., Tang, J., Leong, 
R.W., Faccinetto, A., Morana, G., Petrone, M.C., Arcidiacono, P.G., Moon, J.H., Choi, 
H.J., Gill, R.S., Pavey, D., Ouaissi, M., Sastre, B., Spandre, M., De Angelis, C.G., Rios-
Vives, M.A., Concepcion-Martin, M., Ikeura, T., Okazaki, K., Frulloni, L., Messina, O. 
& Levy, P. 2016, ”Serous cystic neoplasm of the pancreas: a multinational study of 2622 
patients under the auspices of the International Association of Pancreatology and European 
Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas)”, Gut, vol. 65, 
no. 2, pp. 305–312.
Jang, J.Y., Shin, Y.C., Han, Y., Park, J.S., Han, H.S., Hwang, H.K., Yoon, D.S., Kim, J.K., Yoon, 
Y.S., Hwang, D.W., Kang, C.M., Lee, W.J., Heo, J.S., Kang, M.J., Chang, Y.R., Chang, J., 
Jung, W. & Kim, S.W. 2017, ”Effect of Polyglycolic Acid Mesh for Prevention of Pancreatic 
Fistula Following Distal Pancreatectomy: A Randomized Clinical Trial”, JAMA surgery, 
vol. 152, no. 2, pp. 150–155.
Jensen, E.H., Portschy, P.R., Chowaniec, J. & Teng, M. 2013, ”Meta-analysis of bioabsorbable 
staple line reinforcement and risk of fistula following pancreatic resection”, Journal of 
gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, vol. 
17, no. 2, pp. 267–272.
Ji, H.B., Zhu, W.T., Wei, Q., Wang, X.X., Wang, H.B. & Chen, Q.P. 2018, ”Impact of enhanced 
recovery after surgery programs on pancreatic surgery: A meta-analysis”, World journal of 
gastroenterology, vol. 24, no. 15, pp. 1666–1678.
Jimenez, R.E., Mavanur, A. & Macaulay, W.P. 2007, ”Staple line reinforcement reduces postoperative 
pancreatic stump leak after distal pancreatectomy”, Journal of gastrointestinal surgery : 
official journal of the Society for Surgery of the Alimentary Tract, vol. 11, no. 3, pp. 345–349.
66
Kagedan, D.J., Ahmed, M., Devitt, K.S. & Wei, A.C. 2015, ”Enhanced recovery after pancreatic 
surgery: a systematic review of the evidence”, HPB : the official journal of the International 
Hepato Pancreato Biliary Association, vol. 17, no. 1, pp. 11–16.
Kawai, M., Hirono, S., Okada, K.I., Satoi, S., Yanagimoto, H., Kon, M., Murakami, Y., Kondo, 
N., Sho, M., Akahori, T., Toyama, H., Fukumoto, T., Fujii, T., Matsumoto, I., Eguchi, H., 
Ikoma, H., Takeda, Y., Fujimoto, J. & Yamaue, H. 2017, ”Reinforced staplers for distal 
pancreatectomy”, Langenbeck’s archives of surgery, vol. 402, no. 8, pp. 1197–1204.
Kawai, M., Hirono, S., Okada, K., Sho, M., Nakajima, Y., Eguchi, H., Nagano, H., Ikoma, H., 
Morimura, R., Takeda, Y., Nakahira, S., Suzumura, K., Fujimoto, J. & Yamaue, H. 2016, 
”Randomized Controlled Trial of Pancreaticojejunostomy versus Stapler Closure of the 
Pancreatic Stump During Distal Pancreatectomy to Reduce Pancreatic Fistula”, Annals of 
Surgery, vol. 264, no. 1, pp. 180–187.
Kawai, M., Tani, M., Okada, K., Hirono, S., Miyazawa, M., Shimizu, A., Kitahata, Y. & Yamaue, 
H. 2013, ”Stump closure of a thick pancreas using stapler closure increases pancreatic fistula 
after distal pancreatectomy”, American Journal of Surgery, vol. 206, no. 3, pp. 352–359.
Kawai, M., Tani, M. & Yamaue, H. 2008, ”Transection using bipolar scissors reduces pancreatic 
fistula after distal pancreatectomy”, Journal of hepato-biliary-pancreatic surgery, vol. 15, no. 
4, pp. 366–372.
Keane, M.G., Shamali, A., Nilsson, L.N., Antila, A., Millastre Bocos, J., Marijinissen Van Zanten, 
M., Verdejo Gil, C., Maisonneuve, P., Vaalavuo, Y., Hoskins, T., Robinson, S., Ceyhan, G.O., 
Abu Hilal, M., Pereira, S.P., Laukkarinen, J. & Del Chiaro, M. 2018, ”Risk of malignancy 
in resected pancreatic mucinous cystic neoplasms”, The British journal of surgery, vol. 105, 
no. 4, pp. 439–446.
Kennedy, E.P., Grenda, T.R., Sauter, P.K., Rosato, E.L., Chojnacki, K.A., Rosato, F.E., Profeta, 
B.C., Doria, C., Berger, A.C. & Yeo, C.J. 2009, ”Implementation of a critical pathway for 
distal pancreatectomy at an academic institution”, Journal of gastrointestinal surgery : official 
journal of the Society for Surgery of the Alimentary Tract, vol. 13, no. 5, pp. 938–944.
Kimura, W., Inoue, T., Futakawa, N., Shinkai, H., Han, I. & Muto, T. 1996, ”Spleen-preserving 
distal pancreatectomy with conservation of the splenic artery and vein”, Surgery, vol. 120, 
no. 5, pp. 885–890.
Kimura, W., Moriya, T., Ma, J., Kamio, Y., Watanabe, T., Yano, M., Fujimoto, H., Tezuka, K., 
Hirai, I. & Fuse, A. 2007, ”Spleen-preserving distal pancreatectomy with conservation of 
the splenic artery and vein”, World journal of gastroenterology, vol. 13, no. 10, pp. 1493–1499.
Kleeff, J., Diener, M.K., Z’graggen, K., Hinz, U., Wagner, M., Bachmann, J., Zehetner, J., Muller, 
M.W., Friess, H. & Buchler, M.W. 2007, ”Distal pancreatectomy: risk factors for surgical 
failure in 302 consecutive cases”, Annals of Surgery, vol. 245, no. 4, pp. 573–582.
Klein, F., Glanemann, M., Faber, W., Gul, S., Neuhaus, P. & Bahra, M. 2012, ”Pancreatoenteral 
anastomosis or direct closure of the pancreatic remnant after a distal pancreatectomy: a 
single-centre experience”, HPB : the official journal of the International Hepato Pancreato 
Biliary Association, vol. 14, no. 12, pp. 798–804.
Knaebel, H.P., Diener, M.K., Wente, M.N., Buchler, M.W. & Seiler, C.M. 2005, ”Systematic 
review and meta-analysis of technique for closure of the pancreatic remnant after distal 
pancreatectomy”, The British journal of surgery, vol. 92, no. 5, pp. 539–546.
67
Kollar, D., Huszar, T., Poharnok, Z., Cselovszky, E. & Olah, A. 2016, ”A Review of Techniques for 
Closure of the Pancreatic Remnant following Distal Pancreatectomy”, Digestive surgery, vol. 
33, no. 4, pp. 320–328.
Kondo, N., Uemura, K., Nakagawa, N., Okada, K., Kuroda, S., Sudo, T., Hadano, N., Matstukawa, 
H., Satoh, D., Sasaki, M., Abe, T., Fukuda, S., Oshita, A., Nakashima, A., Hashimoto, Y., 
Ohdan, H., Murakami, Y. & Hiroshima Surgical Study Group of Clinical Oncology 2019, 
”A Multicenter, Randomized, Controlled Trial Comparing Reinforced Staplers with Bare 
Staplers During Distal Pancreatectomy (HiSCO-07 Trial)”, Annals of surgical oncology, vol. 
26, no. 5, pp. 1519–1527.
Koti, R.S., Gurusamy, K.S., Fusai, G. & Davidson, B.R. 2010, ”Meta-analysis of randomized 
controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a 
Cochrane review”, HPB : the official journal of the International Hepato Pancreato Biliary 
Association, vol. 12, no. 3, pp. 155–165.
Kowalsky, S.J., Zenati, M.S., Dhir, M., Schaefer, E.G., Dopsovic, A., Lee, K.K., Hogg, M.E., Zeh, 
H.J., Vollmer, C.M. & Zureikat, A.H. 2018, ”Postoperative narcotic use is associated with 
development of clinically relevant pancreatic fistulas after distal pancreatectomy”, Surgery, 
vol. 163, no. 4, pp. 747–752.
Krueger, J.K. & Rohrich, R.J. 2001, ”Clearing the smoke: the scientific rationale for tobacco 
abstention with plastic surgery”, Plastic and Reconstructive Surgery, vol. 108, no. 4, pp. 106–
7.
Kunstman, J.W., Fonseca, A.L., Ciarleglio, M.M., Cong, X., Hochberg, A. & Salem, R.R. 2012, 
”Comprehensive analysis of variables affecting delayed gastric emptying following 
pancreaticoduodenectomy”, Journal of gastrointestinal surgery : official journal of the Society 
for Surgery of the Alimentary Tract, vol. 16, no. 7, pp. 1354–1361.
Laaninen, M., Blauer, M., Vasama, K., Jin, H., Raty, S., Sand, J., Nordback, I. & Laukkarinen, J. 
2012, ”The risk for immediate postoperative complications after pancreaticoduodenectomy 
is increased by high frequency of acinar cells and decreased by prevalent fibrosis of the cut 
edge of pancreas”, Pancreas, vol. 41, no. 6, pp. 957–961.
Laaninen, M., Sand, J., Nordback, I., Vasama, K. & Laukkarinen, J. 2016, ”Perioperative 
Hydrocortisone Reduces Major Complications After Pancreaticoduodenectomy: A 
Randomized Controlled Trial.”, Annals of Surgery, vol. 264, no. 5, pp. 696–702.
LaPar, D.J., Kron, I.L., Jones, D.R., Stukenborg, G.J. & Kozower, B.D. 2012, ”Hospital procedure 
volume should not be used as a measure of surgical quality”, Annals of Surgery, vol. 256, no. 
4, pp. 606–615.
Lassen, K., Coolsen, M.M., Slim, K., Carli, F., de Aguilar-Nascimento, J.E., Schafer, M., Parks, 
R.W., Fearon, K.C., Lobo, D.N., Demartines, N., Braga, M., Ljungqvist, O., Dejong, C.H., 
ERAS(R) Society, European Society for Clinical Nutrition and Metabolism & International 
Association for Surgical Metabolism and Nutrition 2012, ”Guidelines for perioperative 
care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS(R)) Society 
recommendations”, Clinical nutrition (Edinburgh, Scotland), vol. 31, no. 6, pp. 817–830.
Lermite, E., Sommacale, D., Piardi, T., Arnaud, J.P., Sauvanet, A., Dejong, C.H. & Pessaux, P. 2013, 
”Complications after pancreatic resection: diagnosis, prevention and management”, Clinics 
and research in hepatology and gastroenterology, vol. 37, no. 3, pp. 230–239.
68
Lillemoe, K.D., Kaushal, S., Cameron, J.L., Sohn, T.A., Pitt, H.A. & Yeo, C.J. 1999, ”Distal 
pancreatectomy: indications and outcomes in 235 patients”, Annals of Surgery, vol. 229, no. 
5, pp. 69–700.
Lin, J.W., Cameron, J.L., Yeo, C.J., Riall, T.S. & Lillemoe, K.D. 2004, ”Risk factors and outcomes 
in postpancreaticoduodenectomy pancreaticocutaneous fistula”, Journal of gastrointestinal 
surgery : official journal of the Society for Surgery of the Alimentary Tract, vol. 8, no. 8, pp. 
951–959.
Lorenz, U., Maier, M., Steger, U., Topfer, C., Thiede, A. & Timm, S. 2007, ”Analysis of closure of 
the pancreatic remnant after distal pancreatic resection”, HPB : the official journal of the 
International Hepato Pancreato Biliary Association, vol. 9, no. 4, pp. 302–307.
Ma, L.W., Dominguez-Rosado, I., Gennarelli, R.L., Bach, P.B., Gonen, M., D’Angelica, M.I., 
DeMatteo, R.P., Kingham, T.P., Brennan, M.F., Jarnagin, W.R. & Allen, P.J. 2017, ”The 
Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a 
Prospective Randomized Trial”, Annals of Surgery, vol. 265, no. 1, pp. 11–16.
Maeda, H. & Hanazaki, K. 2011, ”Pancreatogenic diabetes after pancreatic resection”, Pancreatology: 
official journal of the International Association of Pancreatology (IAP) ... [et al.], vol. 11, no. 
2, pp. 268–276.
Maggino, L., Malleo, G., Bassi, C., Allegrini, V., Beane, J.D., Beckman, R.M., Chen, B., Dickson, 
E.J., Drebin, J.A., Ecker, B.L., Fraker, D.L., House, M.G., Jamieson, N.B., Javed, A.A., 
Kowalsky, S.J., Lee, M.K., McMillan, M.T., Roses, R.E., Salvia, R., Valero, V., Velu, 
L.K.P., Wolfgang, C.L., Zureikat, A.H. & Vollmer, C.M. 2019, ”Identification of an 
Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically 
Relevant Fistula After Distal Pancreatectomy: A Multi-institutional Analysis and External 
Validation”, Annals of Surgery, vol. 269, no. 2, pp. 337–343.
Maggino, L., Malleo, G., Salvia, R., Bassi, C. & Vollmer, C.M. 2019, ”Defining the practice of distal 
pancreatectomy around the world”, HPB : the official journal of the International Hepato 
Pancreato Biliary Association, .
Malleo, G., Maggino, L., Ferrone, C.R., Marchegiani, G., Mino-Kenudson, M., Capelli, P., Rusev, 
B., Lillemoe, K.D., Bassi, C., Fernandez-Del Castillo, C. & Salvia, R. 2018, ”Number of 
Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/
Tail Ductal Adenocarcinoma”, Annals of Surgery, .
Marchegiani, G., Andrianello, S., Pieretti-Vanmarcke, R., Malleo, G., Marchese, T., Panzeri, F., 
Fernandez-Del Castillo, C., Lillemoe, K.D., Bassi, C., Salvia, R. & Ferrone, C.R. 2017, 
”Hospital readmission after distal pancreatectomy is predicted by specific intra- and post-
operative factors”, American Journal of Surgery, .
Marchegiani, G., Perri, G., Pulvirenti, A., Sereni, E., Azzini, A.M., Malleo, G., Salvia, R. & Bassi, 
C. 2018, ”Non-inferiority of open passive drains compared with closed suction drains in 
pancreatic surgery outcomes: A prospective observational study”, Surgery, vol. 164, no. 3, 
pp. 443–449.
Martin, A.N., Narayanan, S., Turrentine, F.E., Bauer, T.W., Adams, R.B. & Zaydfudim, V.M. 
2018, ”Pancreatic duct size and gland texture are associated with pancreatic fistula after 
pancreaticoduodenectomy but not after distal pancreatectomy”, PloS one, vol. 13, no. 9, pp. 
e0203841.
69
Mathur, A., Pitt, H.A., Marine, M., Saxena, R., Schmidt, C.M., Howard, T.J., Nakeeb, A., 
Zyromski, N.J. & Lillemoe, K.D. 2007, ”Fatty pancreas: a factor in postoperative pancreatic 
fistula”, Annals of Surgery, vol. 246, no. 6, pp. 1058–1064.
McMillan, M.T., Christein, J.D., Callery, M.P., Behrman, S.W., Drebin, J.A., Hollis, R.H., Kent, 
T.S., Miller, B.C., Sprys, M.H., Watkins, A.A., Strasberg, S.M. & Vollmer, C.M. 2016, 
”Comparing the burden of pancreatic fistulas after pancreatoduodenectomy and distal 
pancreatectomy”, Surgery, vol. 159, no. 4, pp. 1013–1022.
McMillan, M.T. & Vollmer, C.M. 2014, ”Predictive factors for pancreatic fistula following 
pancreatectomy”, Langenbeck’s archives of surgery, vol. 399, no. 7, pp. 811–824.
McPhee, J.T., Hill, J.S., Whalen, G.F., Zayaruzny, M., Litwin, D.E., Sullivan, M.E., Anderson, F.A. 
& Tseng, J.F. 2007, ”Perioperative mortality for pancreatectomy: a national perspective”, 
Annals of Surgery, vol. 246, no. 2, pp. 246–253.
Mehrabi, A., Hafezi, M., Arvin, J., Esmaeilzadeh, M., Garoussi, C., Emami, G., Kossler-Ebs, J., 
Muller-Stich, B.P., Buchler, M.W., Hackert, T. & Diener, M.K. 2015, ”A systematic review 
and meta-analysis of laparoscopic versus open distal pancreatectomy for benign and 
malignant lesions of the pancreas: it’s time to randomize”, Surgery, vol. 157, no. 1, pp. 45–55.
Melvin, W.S., Needleman, B.J., Krause, K.R. & Ellison, E.C. 2003, ”Robotic resection of pancreatic 
neuroendocrine tumor”, Journal of laparoendoscopic & advanced surgical techniques.Part A, 
vol. 13, no. 1, pp. 33–36.
Mendoza, A.S., Han, H.S., Ahn, S., Yoon, Y.S., Cho, J.Y. & Choi, Y. 2016, ”Predictive factors 
associated with postoperative pancreatic fistula after laparoscopic distal pancreatectomy: a 
10-year single-institution experience”, Surgical endoscopy, vol. 30, no. 2, pp. 649–656.
Meniconi, R.L., Caronna, R., Borreca, D., Schiratti, M. & Chirletti, P. 2013, ”Pancreato-jejunostomy 
versus hand-sewn closure of the pancreatic stump to prevent pancreatic fistula after distal 
pancreatectomy: a retrospective analysis”, BMC surgery, vol. 13, pp. 2–23.
Miura, F., Takada, T., Asano, T., Kenmochi, T., Ochiai, T., Amano, H. & Yoshida, M. 2005, 
”Hemodynamic changes of splenogastric circulation after spleen-preserving pancreatectomy 
with excision of splenic artery and vein”, Surgery, vol. 138, no. 3, pp. 518–522.
Miyasaka, Y., Mori, Y., Nakata, K., Ohtsuka, T. & Nakamura, M. 2017, ”Attempts to prevent 
postoperative pancreatic fistula after distal pancreatectomy”, Surgery today, vol. 47, no. 4, 
pp. 416–424.
Montorsi, M., Zerbi, A., Bassi, C., Capussotti, L., Coppola, R., Sacchi, M. & Italian Tachosil 
Study Group 2012, ”Efficacy of an absorbable fibrin sealant patch (TachoSil) after distal 
pancreatectomy: a multicenter, randomized, controlled trial”, Annals of Surgery, vol. 256, 
no. 5, pp. 85–60.
Morgan, K.A., Lancaster, W.P., Walters, M.L., Owczarski, S.M., Clark, C.A., McSwain, J.R. & 
Adams, D.B. 2016, ”Enhanced Recovery After Surgery Protocols Are Valuable in Pancreas 
Surgery Patients”, Journal of the American College of Surgeons, vol. 222, no. 4, pp. 658–664.
Muscari, F., Suc, B., Kirzin, S., Hay, J.M., Fourtanier, G., Fingerhut, A., Sastre, B., Chipponi, J., 
Fagniez, P.L., Radovanovic, A. & French Associations for Surgical Research 2006, ”Risk 
factors for mortality and intra-abdominal complications after pancreatoduodenectomy: 
multivariate analysis in 300 patients”, Surgery, vol. 139, no. 5, pp. 591–598.
70
Nagayoshi, Y., Aso, T., Ohtsuka, T., Kono, H., Ideno, N., Igarashi, H., Takahata, S., Oda, Y., Ito, T. 
& Tanaka, M. 2014, ”Peroral pancreatoscopy using the SpyGlass system for the assessment 
of intraductal papillary mucinous neoplasm of the pancreas”, Journal of hepato-biliary-
pancreatic sciences, vol. 21, no. 6, pp. 410–417.
Nathan, H., Cameron, J.L., Goodwin, C.R., Seth, A.K., Edil, B.H., Wolfgang, C.L., Pawlik, 
T.M., Schulick, R.D. & Choti, M.A. 2009, ”Risk factors for pancreatic leak after distal 
pancreatectomy”, Annals of Surgery, vol. 250, no. 2, pp. 277–281.
Nilsson, L.N., Keane, M.G., Shamali, A., Millastre Bocos, J., Marijinissen van Zanten, M., Antila, 
A., Verdejo Gil, C., Del Chiaro, M. & Laukkarinen, J. 2016, ”Nature and management 
of pancreatic mucinous cystic neoplasm (MCN): A systematic review of the literature”, 
Pancreatology : official journal of the International Association of Pancreatology (IAP) ...[et 
al.], vol. 16, no. 6, pp. 1028–1036.
Nordback, I., Lamsa, T., Laukkarinen, J., Leppiniemi, J., Kellomaki, M. & Sand, J. 2008, 
”Pancreatico-jejunostomy with a biodegradable pancreatic stent and without stitches 
through the pancreas”, Hepato-gastroenterology, vol. 55, no. 82-83, pp. 319–322.
Ochiai, T., Sonoyama, T., Soga, K., Inoue, K., Ikoma, H., Shiozaki, A., Kuriu, Y., Kubota, T., 
Nakanishi, M., Kikuchi, S., Ichikawa, D., Fujiwara, H., Sakakura, C., Okamoto, K., Kokuba, 
Y. & Otsuji, E. 2010, ”Application of polyethylene glycolic acid felt with fibrin sealant to 
prevent postoperative pancreatic fistula in pancreatic surgery”, Journal of gastrointestinal 
surgery : official journal of the Society for Surgery of the Alimentary Tract, vol. 14, no. 5, pp. 
884–890.
Ohtsuka, T., Gotoh, Y., Nakashima, Y., Okayama, Y., Nakamura, S., Morita, M., Aly, M.Y.F., 
Velasquez, V V D M, Mori, Y., Sadakari, Y., Nakata, K., Miyasaka, Y., Ishigami, K., Fujimori, 
N., Mochidome, N., Oda, Y., Shimizu, S. & Nakamura, M. 2018, ”Role of SpyGlass-DS(tm) 
in the preoperative assessment of pancreatic intraductal papillary mucinous neoplasm 
involving the main pancreatic duct”, Pancreatology : official journal of the International 
Association of Pancreatology (IAP) ...[et al.], .
Oida, T., Mimatsu, K., Kanou, H., Kawasaki, A., Fukino, N., Kida, K., Kuboi, Y. & Amano, S. 
2011, ”A new surgical technique of transduodenal pancreatic juice drainage prevents 
pancreatic fistula following distal pancreatectomy”, Hepato-gastroenterology, vol. 58, no. 
109, pp. 1398–1402.
Okada, K., Kawai, M., Tani, M., Hirono, S., Miyazawa, M., Shimizu, A., Kitahata, Y. & Yamaue, 
H. 2014, ”Isolated Roux-en-Y anastomosis of the pancreatic stump in a duct-to-mucosa 
fashion in patients with distal pancreatectomy with en-bloc celiac axis resection”, Journal of 
hepato-biliary-pancreatic sciences, vol. 21, no. 3, pp. 193–198.
Okano, K., Oshima, M., Kakinoki, K., Yamamoto, N., Akamoto, S., Yachida, S., Hagiike, M., 
Kamada, H., Masaki, T. & Suzuki, Y. 2013, ”Pancreatic thickness as a predictive factor 
for postoperative pancreatic fistula after distal pancreatectomy using an endopath stapler”, 
Surgery today, vol. 43, no. 2, pp. 141–147.
Pannegeon, V., Pessaux, P., Sauvanet, A., Vullierme, M.P., Kianmanesh, R. & Belghiti, J. 2006, 
”Pancreatic fistula after distal pancreatectomy: predictive risk factors and value of 
conservative treatment”, Archives of surgery (Chicago, Ill.: 1960), vol. 141, no. 11, pp. 107–6; 
discussion 1076.
71
Park, J.S., Hwang, H.K., Kim, J.K., Cho, S.I., Yoon, D.S., Lee, W.J. & Chi, H.S. 2009, ”Clinical 
validation and risk factors for delayed gastric emptying based on the International Study 
Group of Pancreatic Surgery (ISGPS) Classification”, Surgery, vol. 146, no. 5, pp. 882–887.
Park, J.S., Lee, D.H., Jang, J.Y., Han, Y., Yoon, D.S., Kim, J.K., Han, H.S., Yoon, Y., Hwang, D., 
Kang, C.M., Hwang, H.K., Lee, W.J., Heo, J., Chang, Y.R., Kang, M.J., Shin, Y.C., Chang, 
J., Kim, H., Jung, W. & Kim, S.W. 2016, ”Use of TachoSil((R)) patches to prevent pancreatic 
leaks after distal pancreatectomy: a prospective, multicenter, randomized controlled study”, 
Journal of hepato-biliary-pancreatic sciences, vol. 23, no. 2, pp. 110–117.
Partelli, S., Cirocchi, R., Randolph, J., Parisi, A., Coratti, A. & Falconi, M. 2016, ”A systematic 
review and meta-analysis of spleen-preserving distal pancreatectomy with preservation or 
ligation of the splenic artery and vein”, The surgeon : journal of the Royal Colleges of Surgeons 
of Edinburgh and Ireland, vol. 14, no. 2, pp. 109–118.
Paulus, E.M., Zarzaur, B.L. & Behrman, S.W. 2012, ”Routine peritoneal drainage of the surgical 
bed after elective distal pancreatectomy: is it necessary?”, American Journal of Surgery, vol. 
204, no. 4, pp. 422–427.
Pecorelli, N., Capretti, G., Balzano, G., Castoldi, R., Maspero, M., Beretta, L. & Braga, M. 2017, 
”Enhanced recovery pathway in patients undergoing distal pancreatectomy: a case-matched 
study”, HPB : the official journal of the International Hepato Pancreato Biliary Association, 
vol. 19, no. 3, pp. 270–278.
Pendola, F., Gadde, R., Ripat, C., Sharma, R., Picado, O., Lobo, L., Sleeman, D., Livingstone, 
A.S., Merchant, N. & Yakoub, D. 2017, ”Distal pancreatectomy for benign and low grade 
malignant tumors: Short-term postoperative outcomes of spleen preservation-A systematic 
review and update meta-analysis”, Journal of surgical oncology, vol. 115, no. 2, pp. 137–143.
Peng, Y.P., Zhu, X.L., Yin, L.D., Zhu, Y., Wei, J.S., Wu, J.L. & Miao, Y. 2017, ”Risk factors of 
postoperative pancreatic fistula in patients after distal pancreatectomy: a systematic review 
and meta-analysis”, Scientific reports, vol. 7, no. 1, pp. 18–8.
Pratt, W.B., Callery, M.P. & Vollmer, C.M. 2008, ”Risk prediction for development of pancreatic 
fistula using the ISGPF classification scheme”, World journal of surgery, vol. 32, no. 3, pp. 
419–428.
Pratt, W.B., Maithel, S.K., Vanounou, T., Huang, Z.S., Callery, M.P. & Vollmer, C.M. 2007, 
”Clinical and economic validation of the International Study Group of Pancreatic Fistula 
(ISGPF) classification scheme”, Annals of Surgery, vol. 245, no. 3, pp. 443–451.
Probst, P., Huttner, F.J., Klaiber, U., Knebel, P., Ulrich, A., Buchler, M.W. & Diener, M.K. 2015, 
”Stapler versus scalpel resection followed by hand-sewn closure of the pancreatic remnant 
for distal pancreatectomy”, The Cochrane database of systematic reviews, vol. (11):CD008688. 
doi, no. 11, pp. CD008688.
Pulvirenti, A., Landoni, L., Borin, A., De Pastena, M., Fontana, M., Pea, A., Esposito, A., Casetti, L., 
Tuveri, M., Paiella, S., Marchegiani, G., Malleo, G., Salvia, R. & Bassi, C. 2019, ”Reinforced 
stapler versus ultrasonic dissector for pancreatic transection and stump closure for distal 
pancreatectomy: A propensity matched analysis”, Surgery, .
Raty, S., Sand, J., Lantto, E. & Nordback, I. 2006, ”Postoperative acute pancreatitis as a major 
determinant of postoperative delayed gastric emptying after pancreaticoduodenectomy”, 
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary 
Tract, vol. 10, no. 8, pp. 1131–1139.
72
Ray, S., Mehta, N.N., Mangla, V., Lalwani, S., Mehrotra, S., Chugh, P., Yadav, A. & Nundy, S. 2019, 
”A Comparison Between the Comprehensive Complication Index and the Clavien-Dindo 
Grading as a Measure of Postoperative Outcome in Patients Undergoing Gastrointestinal 
Surgery-A Prospective Study”, The Journal of surgical research, vol. 244, pp. 417–424.
Reeh, M., Nentwich, M.F., Bogoevski, D., Koenig, A.M., Gebauer, F., Tachezy, M., Izbicki, J.R. 
& Bockhorn, M. 2011, ”High surgical morbidity following distal pancreatectomy: still an 
unsolved problem”, World journal of surgery, vol. 35, no. 5, pp. 1110–1117.
Richardson, J., Di Fabio, F., Clarke, H., Bajalan, M., Davids, J. & Abu Hilal, M. 2015, 
”Implementation of enhanced recovery programme for laparoscopic distal pancreatectomy: 
feasibility, safety and cost analysis”, Pancreatology : official journal of the International 
Association of Pancreatology (IAP) ...[et al.], vol. 15, no. 2, pp. 185–190.
Ridolfini, M.P., Alfieri, S., Gourgiotis, S., Di Miceli, D., Rotondi, F., Quero, G., Manghi, R. 
& Doglietto, G.B. 2007, ”Risk factors associated with pancreatic fistula after distal 
pancreatectomy, which technique of pancreatic stump closure is more beneficial?”, World 
journal of gastroenterology, vol. 13, no. 38, pp. 5096–5100.
Rieder, B., Krampulz, D., Adolf, J. & Pfeiffer, A. 2010, ”Endoscopic pancreatic sphincterotomy 
and stenting for preoperative prophylaxis of pancreatic fistula after distal pancreatectomy”, 
Gastrointestinal endoscopy, vol. 72, no. 3, pp. 536–542.
Rodriguez, J.R., Germes, S.S., Pandharipande, P.V., Gazelle, G.S., Thayer, S.P., Warshaw, A.L. 
& Fernandez-del Castillo, C. 2006, ”Implications and cost of pancreatic leak following 
distal pancreatic resection”, Archives of surgery (Chicago, Ill.: 1960), vol. 141, no. 4, pp. 36–5; 
discussion 366.
Rodriguez, J.R., Salvia, R., Crippa, S., Warshaw, A.L., Bassi, C., Falconi, M., Thayer, S.P., Lauwers, 
G.Y., Capelli, P., Mino-Kenudson, M., Razo, O., McGrath, D., Pederzoli, P. & Fernandez-
Del Castillo, C. 2007, ”Branch-duct intraductal papillary mucinous neoplasms: observations 
in 145 patients who underwent resection”, Gastroenterology, vol. 133, no. 1, pp. 7–10.
Rosales-Velderrain, A., Bowers, S.P., Goldberg, R.F., Clarke, T.M., Buchanan, M.A., Stauffer, J.A. 
& Asbun, H.J. 2012, ”National trends in resection of the distal pancreas”, World journal of 
gastroenterology, vol. 18, no. 32, pp. 4342–4349.
Roulin, D., Cerantola, Y., Demartines, N. & Schafer, M. 2011, ”Systematic review of delayed 
postoperative hemorrhage after pancreatic resection”, Journal of gastrointestinal surgery : 
official journal of the Society for Surgery of the Alimentary Tract, vol. 15, no. 6, pp. 1055–1062.
Sa Cunha, A., Carrere, N., Meunier, B., Fabre, J.M., Sauvanet, A., Pessaux, P., Ortega-Deballon, P., 
Fingerhut, A., Lacaine, F. & French Federation de Recherche EN Chirurgie (FRENCH) 
2015, ”Stump closure reinforcement with absorbable fibrin collagen sealant sponge 
(TachoSil) does not prevent pancreatic fistula after distal pancreatectomy: the FIABLE 
multicenter controlled randomized study”, American Journal of Surgery, vol. 210, no. 4, pp. 
739–748.
Sahakyan, M.A., Rosok, B.I., Kazaryan, A.M., Barkhatov, L., Lai, X., Kleive, D., Ignjatovic, D., 
Labori, K.J. & Edwin, B. 2016, ”Impact of obesity on surgical outcomes of laparoscopic 
distal pancreatectomy: A Norwegian single-center study”, Surgery, vol. 160, no. 5, pp. 1271–
1278.
Sahani, D.V., Shah, Z.K., Catalano, O.A., Boland, G.W. & Brugge, W.R. 2008, ”Radiology of 
pancreatic adenocarcinoma: current status of imaging”, Journal of gastroenterology and 
hepatology, vol. 23, no. 1, pp. 23–33.
73
Sallinen, V., Le Large, T.Y., Galeev, S., Kovalenko, Z., Tieftrunk, E., Araujo, R., Ceyhan, G.O. & 
Gaujoux, S. 2017, ”Surveillance strategy for small asymptomatic non-functional pancreatic 
neuroendocrine tumors - a systematic review and meta-analysis”, HPB : the official journal of 
the International Hepato Pancreato Biliary Association, vol. 19, no. 4, pp. 310–320.
Salvia, R., Fernandez-del Castillo, C., Bassi, C., Thayer, S.P., Falconi, M., Mantovani, W., Pederzoli, 
P. & Warshaw, A.L. 2004, ”Main-duct intraductal papillary mucinous neoplasms of the 
pancreas: clinical predictors of malignancy and long-term survival following resection”, 
Annals of Surgery, vol. 239, no. 5, pp. 67–7.
Sato, Y., Shimoda, S., Takeda, N., Tanaka, N. & Hatakeyama, K. 2000, ”Evaluation of splenic 
circulation after spleen-preserving distal pancreatectomy by dividing the splenic artery and 
vein”, Digestive surgery, vol. 17, no. 5, pp. 519–522.
Seeliger, H., Christians, S., Angele, M.K., Kleespies, A., Eichhorn, M.E., Ischenko, I., Boeck, S., 
Heinemann, V., Jauch, K.W. & Bruns, C.J. 2010, ”Risk factors for surgical complications in 
distal pancreatectomy”, American Journal of Surgery, vol. 200, no. 3, pp. 311–317.
Sell, N.M., Pucci, M.J., Gabale, S., Leiby, B.E., Rosato, E.L., Winter, J.M., Yeo, C.J. & Lavu, H. 
2015, ”The influence of transection site on the development of pancreatic fistula in patients 
undergoing distal pancreatectomy: A review of 294 consecutive cases”, Surgery, vol. 157, no. 
6, pp. 1080–1087.
Seykora, T.F., Liu, J.B., Maggino, L., Pitt, H.A. & Vollmer, C.M. 2019, ”Drain Management 
Following Distal Pancreatectomy: Characterization of Contemporary Practice and Impact 
of Early Removal”, Annals of Surgery, .
Shi, C. & Hruban, R.H. 2012, ”Intraductal papillary mucinous neoplasm”, Human pathology, vol. 
43, no. 1, pp. 1–16.
Shi, N., Liu, S.L., Li, Y.T., You, L., Dai, M.H. & Zhao, Y.P. 2016, ”Splenic Preservation Versus 
Splenectomy During Distal Pancreatectomy: A Systematic Review and Meta-analysis”, 
Annals of surgical oncology, vol. 23, no. 2, pp. 365–374.
Shoup, M., Brennan, M.F., McWhite, K., Leung, D.H., Klimstra, D. & Conlon, K.C. 2002, ”The 
value of splenic preservation with distal pancreatectomy”, Archives of surgery (Chicago, Ill.: 
1960), vol. 137, no. 2, pp. 164–168.
Sierzega, M., Niekowal, B., Kulig, J. & Popiela, T. 2007, ”Nutritional status affects the rate of 
pancreatic fistula after distal pancreatectomy: a multivariate analysis of 132 patients”, 
Journal of the American College of Surgeons, vol. 205, no. 1, pp. 52–59.
Slankamenac, K., Graf, R., Barkun, J., Puhan, M.A. & Clavien, P.A. 2013, ”The comprehensive 
complication index: a novel continuous scale to measure surgical morbidity”, Annals of 
Surgery, vol. 258, no. 1, pp. 1–7.
Slankamenac, K., Nederlof, N., Pessaux, P., de Jonge, J., Wijnhoven, B.P., Breitenstein, S., Oberkofler, 
C.E., Graf, R., Puhan, M.A. & Clavien, P.A. 2014, ”The comprehensive complication index: 
a novel and more sensitive endpoint for assessing outcome and reducing sample size in 
randomized controlled trials”, Annals of Surgery, vol. 260, no. 5, pp. 75–3.
Sledzianowski, J.F., Duffas, J.P., Muscari, F., Suc, B. & Fourtanier, F. 2005, ”Risk factors for 
mortality and intra-abdominal morbidity after distal pancreatectomy”, Surgery, vol. 137, no. 
2, pp. 180–185.
74
Stauffer, J.A., Coppola, A., Mody, K. & Asbun, H.J. 2016, ”Laparoscopic Versus Open Distal 
Pancreatectomy for Pancreatic Adenocarcinoma”, World journal of surgery, vol. 40, no. 6, 
pp. 1477–1484.
Strobel, O., Cherrez, A., Hinz, U., Mayer, P., Kaiser, J., Fritz, S., Schneider, L., Klauss, M., Büchler, 
M.W. & Hackert, T. 2015, ”Risk of pancreatic fistula after enucleation of pancreatic 
tumours”, The British Journal of Surgery, vol. 102, no. 10, pp. 1258–1266.
Sugimoto, M., Gotohda, N., Kato, Y., Takahashi, S., Kinoshita, T., Shibasaki, H., Nomura, S., 
Konishi, M. & Kaneko, H. 2013, ”Risk factor analysis and prevention of postoperative 
pancreatic fistula after distal pancreatectomy with stapler use”, Journal of hepato-biliary-
pancreatic sciences, vol. 20, no. 5, pp. 538–544.
Sugo, H., Mikami, Y., Matsumoto, F., Tsumura, H., Watanabe, Y. & Futagawa, S. 2001, ”Comparison 
of ultrasonically activated scalpel versus conventional division for the pancreas in distal 
pancreatectomy”, Journal of hepato-biliary-pancreatic surgery, vol. 8, no. 4, pp. 349–352.
Sulpice, L., Farges, O., Goutte, N., Bendersky, N., Dokmak, S., Sauvanet, A., Delpero, J.R. & 
ACHBT French Pancreatectomy Study Group 2015, ”Laparoscopic Distal Pancreatectomy 
for Pancreatic Ductal Adenocarcinoma: Time for a Randomized Controlled Trial? Results 
of an All-inclusive National Observational Study”, Annals of Surgery, vol. 262, no. 5, pp. 
86–4.
Suzuki, Y., Fujino, Y., Tanioka, Y., Hori, Y., Ueda, T., Takeyama, Y., Tominaga, M., Ku, Y., 
Yamamoto, Y.M. & Kuroda, Y. 1999, ”Randomized clinical trial of ultrasonic dissector 
or conventional division in distal pancreatectomy for non-fibrotic pancreas”, The British 
journal of surgery, vol. 86, no. 5, pp. 608–611.
Suzuki, Y., Kuroda, Y., Morita, A., Fujino, Y., Tanioka, Y., Kawamura, T. & Saitoh, Y. 1995, ”Fibrin 
glue sealing for the prevention of pancreatic fistulas following distal pancreatectomy”, 
Archives of surgery (Chicago, Ill.: 1960), vol. 130, no. 9, pp. 952–955.
Thaker, R.I., Matthews, B.D., Linehan, D.C., Strasberg, S.M., Eagon, J.C. & Hawkins, W.G. 2007, 
”Absorbable mesh reinforcement of a stapled pancreatic transection line reduces the leak 
rate with distal pancreatectomy”, Journal of gastrointestinal surgery : official journal of the 
Society for Surgery of the Alimentary Tract, vol. 11, no. 1, pp. 59–65.
Tieftrunk, E., Demir, I.E., Schorn, S., Sargut, M., Scheufele, F., Calavrezos, L., Schirren, R., Friess, 
H. & Ceyhan, G.O. 2018, ”Pancreatic stump closure techniques and pancreatic fistula 
formation after distal pancreatectomy: Meta-analysis and single-center experience”, PloS 
One, vol. 13, no. 6, pp. e0197553.
Uemura, K., Murakami, Y., Sudo, T., Hashimoto, Y., Nakashima, A., Yamaoka, E. & Sueda, T. 
2012, ”Elevation of urine trypsinogen 2 is an independent risk factor for pancreatic fistula 
after pancreaticoduodenectomy”, Pancreas, vol. 41, no. 6, pp. 876–881.
Uemura, K., Satoi, S., Motoi, F., Kwon, M., Unno, M. & Murakami, Y. 2017, ”Randomized 
clinical trial of duct-to-mucosa pancreaticogastrostomy versus handsewn closure after distal 
pancreatectomy”, The British journal of surgery, vol. 104, no. 5, pp. 536–543.
75
Van Buren, G., Bloomston, M., Hughes, S.J., Winter, J., Behrman, S.W., Zyromski, N.J., Vollmer, 
C., Velanovich, V., Riall, T., Muscarella, P., Trevino, J., Nakeeb, A., Schmidt, C.M., 
Behrns, K., Ellison, E.C., Barakat, O., Perry, K.A., Drebin, J., House, M., Abdel-Misih, 
S., Silberfein, E.J., Goldin, S., Brown, K., Mohammed, S., Hodges, S.E., McElhany, A., 
Issazadeh, M., Jo, E., Mo, Q. & Fisher, W.E. 2014, ”A randomized prospective multicenter 
trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage”, 
Annals of Surgery, vol. 259, no. 4, pp. 605–612.
Van Buren, G., Bloomston, M., Schmidt, C.R., Behrman, S.W., Zyromski, N.J., Ball, C.G., Morgan, 
K.A., Hughes, S.J., Karanicolas, P.J., Allendorf, J.D., Vollmer, C.M., Ly, Q., Brown, K.M., 
Velanovich, V., Winter, J.M., McElhany, A.L., Muscarella, P., Schmidt, C.M., House, 
M.G., Dixon, E., Dillhoff, M.E., Trevino, J.G., Hallet, J., Coburn, N.S.G., Nakeeb, A., 
Behrns, K.E., Sasson, A.R., Ceppa, E.P., Abdel-Misih, S.R.Z., Riall, T.S., Silberfein, E.J., 
Ellison, E.C., Adams, D.B., Hsu, C., Tran Cao, H.S., Mohammed, S., Villafane-Ferriol, 
N., Barakat, O., Massarweh, N.N., Chai, C., Mendez-Reyes, J.E., Fang, A., Jo, E., Mo, Q. & 
Fisher, W.E. 2017, ”A Prospective Randomized Multicenter Trial of Distal Pancreatectomy 
With and Without Routine Intraperitoneal Drainage”, Annals of Surgery, vol. 266, no. 3, 
pp. 421–431.
van Hilst, J., de Pastena, M., de Rooij, T., Alseidi, A., Busch, O.R., van Dieren, S., van Eijck, C.H., 
Giovinazzo, F., Groot Koerkamp, B., Marchegiani, G., Marshall, G.R., Abu Hilal, M., Bassi, 
C. & Besselink, M.G. 2018, ”Clinical impact of the updated international postoperative 
pancreatic fistula definition in distal pancreatectomy”, HPB : the official journal of the 
International Hepato Pancreato Biliary Association, .
van Hilst, J., de Rooij, T., Klompmaker, S., Rawashdeh, M., Aleotti, F., Al-Sarireh, B., Alseidi, A., 
Ateeb, Z., Balzano, G., Berrevoet, F., Bjornsson, B., Boggi, U., Busch, O.R., Butturini, G., 
Casadei, R., Del Chiaro, M., Chikhladze, S., Cipriani, F., van Dam, R., Damoli, I., van 
Dieren, S., Dokmak, S., Edwin, B., van Eijck, C., Fabre, J.M., Falconi, M., Farges, O., 
Fernandez-Cruz, L., Forgione, A., Frigerio, I., Fuks, D., Gavazzi, F., Gayet, B., Giardino, 
A., Bas Groot, K., Hackert, T., Hassenpflug, M., Kabir, I., Keck, T., Khatkov, I., Kusar, 
M., Lombardo, C., Marchegiani, G., Marshall, R., Menon, K.V., Montorsi, M., Orville, 
M., de Pastena, M., Pietrabissa, A., Poves, I., Primrose, J., Pugliese, R., Ricci, C., Roberts, 
K., Rosok, B., Sahakyan, M.A., Sanchez-Cabus, S., Sandstrom, P., Scovel, L., Solaini, L., 
Soonawalla, Z., Souche, F.R., Sutcliffe, R.P., Tiberio, G.A., Tomazic, A., Troisi, R., Wellner, 
U., White, S., Wittel, U.A., Zerbi, A., Bassi, C., Besselink, M.G., Abu Hilal, M. & European 
Consortium on Minimally Invasive Pancreatic Surgery, (E-MIPS) 2017, ”Minimally 
Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A 
Pan-European Propensity Score Matched Study”, Annals of Surgery, .
van Hilst, J., Korrel, M., de Rooij, T., Lof, S., Busch, O.R., Groot Koerkamp, B., Kooby, D.A., van 
Dieren, S., Abu Hilal, M., Besselink, M.G. & DIPLOMA study group 2018, ”Oncologic 
outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal 
adenocarcinoma: A systematic review and meta-analysis”, European journal of surgical 
oncology : the journal of the European Society of Surgical Oncology and the British Association 
of Surgical Oncology, .
76
van Hilst, J., Strating, E.A., de Rooij, T., Daams, F., Festen, S., Groot Koerkamp, B., Klaase, 
J.M., Luyer, M., Dijkgraaf, M.G., Besselink, M.G. & Dutch Pancreatic Cancer Group 
and LEOPARD trial collaborators 2019, ”Costs and quality of life in a randomized trial 
comparing minimally invasive and open distal pancreatectomy (LEOPARD trial)”, The 
British journal of surgery, .
Vanbrugghe, C., Ronot, M., Cauchy, F., Hobeika, C., Dokmak, S., Aussilhou, B., Ragot, E., 
Gaujoux, S., Soubrane, O., Levy, P. & Sauvanet, A. 2018, ”Visceral Obesity and Open Passive 
Drainage Increase the Risk of Pancreatic Fistula Following Distal Pancreatectomy”, Journal 
of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, .
Vass, D.G., Hodson, J., Isaac, J., Marudanayagam, R., Mirza, D.F., Muiesan, P., Roberts, K. & 
Sutcliffe, R.P. 2018, ”Utility of drain fluid amylase measurement on the first postoperative 
day after distal pancreatectomy”, HPB : the official journal of the International Hepato 
Pancreato Biliary Association, vol. 20, no. 9, pp. 803–808.
Venkat, R., Edil, B.H., Schulick, R.D., Lidor, A.O., Makary, M.A. & Wolfgang, C.L. 2012, 
”Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity 
compared to the open technique: a systematic review and meta-analysis”, Annals of Surgery, 
vol. 255, no. 6, pp. 1048–1059.
Wagner, M., Gloor, B., Ambuhl, M., Worni, M., Lutz, J.A., Angst, E. & Candinas, D. 2007, ”Roux-
en-Y drainage of the pancreatic stump decreases pancreatic fistula after distal pancreatic 
resection”, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the 
Alimentary Tract, vol. 11, no. 3, pp. 303–308.
Walters, D.M., Stokes, J.B., Adams, R.B. & Bauer, T.W. 2011, ”Use of a falciform ligament pedicle 
flap to decrease pancreatic fistula after distal pancreatectomy”, Pancreas, vol. 40, no. 4, pp. 
595–599.
Wang, X., Tan, C., Zhang, H., Chen, Y., Yang, M., Ke, N. & Liu, X. 2018, ”Short-term outcomes 
and risk factors for pancreatic fistula after pancreatic enucleation: A single-center experience 
of 142 patients”, Journal of Surgical Oncology, vol. 117, no. 2, pp. 182–190.
Warshaw, A.L. 1988, ”Conservation of the spleen with distal pancreatectomy”, Archives of surgery 
(Chicago, Ill.: 1960), vol. 123, no. 5, pp. 550–553.
Wente, M.N., Bassi, C., Dervenis, C., Fingerhut, A., Gouma, D.J., Izbicki, J.R., Neoptolemos, J.P., 
Padbury, R.T., Sarr, M.G., Traverso, L.W., Yeo, C.J. & Buchler, M.W. 2007, ”Delayed gastric 
emptying (DGE) after pancreatic surgery: a suggested definition by the International Study 
Group of Pancreatic Surgery (ISGPS)”, Surgery, vol. 142, no. 5, pp. 761–768.
Wente, M.N., Veit, J.A., Bassi, C., Dervenis, C., Fingerhut, A., Gouma, D.J., Izbicki, J.R., 
Neoptolemos, J.P., Padbury, R.T., Sarr, M.G., Yeo, C.J. & Buchler, M.W. 2007, 
”Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic 
Surgery (ISGPS) definition”, Surgery, vol. 142, no. 1, pp. 20–25.
Witzigmann, H., Diener, M.K., Kienkotter, S., Rossion, I., Bruckner, T., Barbel, W., Pridohl, O., 
Radulova-Mauersberger, O., Lauer, H., Knebel, P., Ulrich, A., Strobel, O., Hackert, T. & 
Buchler, M.W. 2016, ”No Need for Routine Drainage After Pancreatic Head Resection: The 
Dual-Center, Randomized, Controlled PANDRA Trial (ISRCTN04937707)”, Annals of 
Surgery, vol. 264, no. 3, pp. 528–537.
Xiao, W., Zhu, J., Peng, L., Hong, L., Sun, G. & Li, Y. 2018, ”The role of central pancreatectomy in 
pancreatic surgery: a systematic review and meta-analysis”, HPB: the official journal of the 
International Hepato Pancreato Biliary Association, vol. 20, no. 10, pp. 896–904.
77
Xu, M.M. & Sethi, A. 2016, ”Imaging of the Pancreas”, Gastroenterology clinics of North America, 
vol. 45, no. 1, pp. 101–116.
Yamamoto, M., Hayashi, M.S., Nguyen, N.T., Nguyen, T.D., McCloud, S. & Imagawa, D.K. 2009, 
”Use of Seamguard to prevent pancreatic leak following distal pancreatectomy”, Archives of 
surgery (Chicago, Ill.: 1960), vol. 144, no. 10, pp. 894–899.
Yanagimoto, H., Satoi, S., Toyokawa, H., Yamamoto, T., Hirooka, S., Yamao, J., Yamaki, S., 
Ryota, H., Matsui, Y. & Kwon, A.H. 2014, ”Pancreaticogastrostomy following distal 
pancreatectomy prevents pancreatic fistula-related complications”, Journal of hepato-biliary-
pancreatic sciences, vol. 21, no. 7, pp. 473–478.
Yoshioka, R., Saiura, A., Koga, R., Seki, M., Kishi, Y., Morimura, R., Yamamoto, J. & Yamaguchi, 
T. 2010, ”Risk factors for clinical pancreatic fistula after distal pancreatectomy: analysis of 
consecutive 100 patients”, World journal of surgery, vol. 34, no. 1, pp. 121–125.
Young, S., Sung, M.L., Lee, J.A., DiFronzo, L.A. & O’Connor, V.V. 2018, ”Pasireotide is not 
effective in reducing the development of postoperative pancreatic fistula”, HPB : the official 
journal of the International Hepato Pancreato Biliary Association, .
Yui, R., Satoi, S., Toyokawa, H., Yanagimoto, H., Yamamoto, T., Hirooka, S., Yamaki, S., Ryota, H., 
Michiura, T., Inoue, K., Matsui, Y. & Kwon, A.H. 2014, ”Less morbidity after introduction 
of a new departmental policy for patients who undergo open distal pancreatectomy”, Journal 
of hepato-biliary-pancreatic sciences, vol. 21, no. 1, pp. 72–77.
Zhang, H., Zhu, F., Shen, M., Tian, R., Shi, C.J., Wang, X., Jiang, J.X., Hu, J., Wang, M. & Qin, 
R.Y. 2015, ”Systematic review and meta-analysis comparing three techniques for pancreatic 
remnant closure following distal pancreatectomy”, The British journal of surgery, vol. 102, 
no. 1, pp. 4–15.
Zhou, W., Lv, R., Wang, X., Mou, Y., Cai, X. & Herr, I. 2010, ”Stapler vs suture closure of pancreatic 
remnant after distal pancreatectomy: a meta-analysis”, American Journal of Surgery, vol. 
200, no. 4, pp. 529–536.
78
79
Original Publications
80
Clinical Study
Is Roux-Y Binding Pancreaticojejunal Anastomosis
Feasible for Patients Undergoing Left Pancreatectomy?
Results from a Prospective Randomized Trial
Anne Antila, Juhani Sand, Isto Nordback, Sari Räty, and Johanna Laukkarinen
Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Teiskontie 35, P.O. Box 2000,
33521 Tampere, Finland
Correspondence should be addressed to Johanna Laukkarinen; johanna.laukkarinen@fimnet.fi
Received 14 March 2014; Accepted 21 May 2014; Published 11 June 2014
Academic Editor: Roberto Cirocchi
Copyright © 2014 Anne Antila et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. After pancreaticoduodenectomy, the Finnish binding pancreaticojejunal anastomosis (FBPJ) seems to reduce the risk
for pancreatic fistula (POPF). Our aim was to investigate whether FBPJ is feasible and prevents the risk for POPF even after left
pancreatectomy (LP). Patients and Methods. 47 consecutive patients underwent LP. 27 patients were recruited on the basis of CT
and, of these, 16 patients were randomized on the basis of findings during surgery (transection line must be left of portal vein, as
2-3 cm pancreaticmobilization is required for FBPJ) to receive either Roux-Y FBPJ or hand-sewn closure of the pancreatic remnant.
Results. Only 34% (16/47) of the patients met the randomization criteria. Clinically significant POPF rate was higher in FBPJ group
(60%) compared to thand-sewn closure group (13%; 𝑃 < 0.05). POPF rate in FBPJ group was higher even when compared to
all patients with hand-sewn closure (60% versus 37%; 𝑃 < 0.05). Overall, FBPJ was technically feasible for only 28% of patients.
Conclusion. FBPJ cannot be recommended for the routine closure of the pancreatic remnant after LP, as it was not technically
achievable in 72% of the cases. Moreover, the technique does not seem to reduce the risk for POPF compared to the hand-sewn
closure.
1. Introduction
Left pancreatectomy (LP) is used to treat benign and malig-
nant lesions in the body and tail of the pancreas or after
abdominal trauma.The postoperativemorbidity rate remains
high, 30–50% [1, 2], and this is mainly due to pancreatic
fistula (POPF) resulting from leakage of pancreatic enzymes
from the transsection line of the pancreas. In addition to
being themost common and clinically relevant complication,
POPF is often associated with other complications such as
intra-abdominal abscess, delayed gastric emptying (DGE),
postpancreatectomy haemorrhage (PPH), wound infection,
respiratory complications, and sepsis [1]. The risk for POPF
after distal pancreatectomy remains an unsolved problem
despite efforts to improve the surgical resection and closure
techniques of the pancreatic remnant. These include hand-
sewn suture techniques, stapled closure techniques, pan-
creatic transsection using various energy devices, pancre-
aticoenteric anastomosis techniques, application of meshes,
sealing with fibrin sealants, pancreatic stent placement, and
administration on octreotide [3–9]. A recent retrospective
cost analysis showed that patients with pancreatic fistula
double the cost and dramatically increase health care resource
utilization [2, 10].
Previously we have shown that after pancreaticoduo-
denectomy the novel Finnish binding (purse-string) pancre-
aticojejunal anastomosis (FBPJ) technique reduces the risk
for POPF [11].The aimof this studywas to investigatewhether
FBPJ is a feasible technique after distal pancreatectomy and
whether it prevents the risk for POPF after distal pancreatec-
tomy.
2. Patients and Methods
A prospective, randomized trial was designed to include
patients with the type of distal pancreatic resection that is
technically possible with FBPJ (RPT arm). In addition, all
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pancreatic distal resections were included in the prospective
follow-up (PFU arm).
2.1. Surgical Technique. In FBPJ, the pancreatic remnant
was inserted 2-3 cm inside the jejunal limb with the aid of
seven peripancreatic sutures (4-0 Maxon, Covidien, USA)
after which the purse-string suture (4-0 PDS, Ethicon, USA)
was tightened and a roux-Y entero-enteroanastomosis was
performed (Figure 1). In the hand-sewn closure group, the
main pancreatic duct was closed by suturing, followed by
oversewing the pancreatic stump with 4-0 Maxon. A Penrose
drain was placed near the anastomosis in all patients. A
schematic drawing of the FBPJ is shown in Figure 1.
2.2. Recruitment Criteria for the RPTArm. FBPJ is technically
achievable only when the transection line of pancreas is
clearly to the left of the portal vein because the pancreatic
remnant needs to be mobilized 2-3 cm to be able to insert
it into the jejunal limb. All patients were studied preop-
eratively by contrast-enhanced computer tomography scan
(CT). Patients eligible for randomization according to the
location of tumour in the CT analysis were recruited for the
study.The rest of the patientswere included in the prospective
follow-up.
2.3. RandomizationCriteria for the RPTArm. After removing
the distal pancreas, the patients still considered eligible for the
FBPJ (i.e., transection line to the left of the portal vein) were
randomized to receive either FBPJ or traditional hand-sewn
closure of the pancreatic stump.
2.4. Patient Care and Follow-Up. Perioperatively all patients
received a single-dose antibiotic prophylaxis IV (ceftriaxone
2 g, Rocephalin, Roche, Finland, and metronidazole 500mg,
metronidazole, Brown, Germany) and routine antithrom-
botic (enoxaparin 40mg, Klexane, Sanofi-Aventis, France,
or tinzaparin 4500 IU, Innohep, LEO Pharma, France) pro-
phylaxis s.c. Postoperatively the patients were monitored
by the standard pancreatic resection protocol of Tampere
University Hospital. Abdominal drain output was recorded
daily and the amylase concentration was measured from it
on the third postoperative day, and thereafter if the drain still
remained in place. The drain was removed when the drain
amylase output was less than three times the serum upper
limit. The urine trypsinogen strip test was used to detect
postoperative pancreatitis and wasmeasured daily during the
first postoperative week [12]. Patient demographics (age, sex,
BMI, and comorbidities) were compared and postoperative
complications (fistulas, bleeding, abscesses, andwound infec-
tions) andmortality were defined and compared between the
groups. POPF was classified into three grades (A, B, and C)
depending on the clinical impact according to the ISGPF
classification [13].
2.5. Power Analysis. For the RPT arm, population size was
estimated on the basis of the results from our earlier study
of FBPJ after pancreaticoduodenectomy [11], where the rate
of clinically relevant (grades B-C) POPF was reduced by
50% compared to our historical controls. If the patients with
hand-sewn closure had twice as much clinically relevant
POPF compared to FBPJ (30% versus 15%), we would need
26 patients in each group to be able to show a statistically
significant difference with power 𝜋 = 0.80 (𝛼 0.05). We
estimated that about one-third of the patients would notmeet
the recruitment criteria based on CT and that about 10%
of the recruited patients would not meet the randomization
criteria according to findings during surgery. Thus for 52
randomized patients we would need 58 recruited patients,
and for those we would need a population of 78 distal
pancreatectomies. We planned to run the interim analysis
when 29 patients had been recruited and estimated that about
40 distal pancreatectomies would be needed to achieve this
recruited population.
The interim analysis was run in August, 2013. A total
of 47 consecutive patients (16M/31 F) had undergone dis-
tal pancreatectomy with the remaining pancreatic head in
Tampere University Hospital between October 2009 and July
2013. We were prepared to increase our series but this proved
unnecessary after analysing the results of these 47 patients.
The study protocol was approved by the Ethics Commit-
tee of Tampere University Hospital. The study was registered
with clinical.trials.com NCT02113046.
Statistical analysiswas performedusing Fisher’s exact test,
Mann-Whitney 𝑈-test, and logistic regression test. 𝑃 < 0.05
was considered statistically significant.
3. Results
Out of the 47 caudal resections, 27 met the recruitment
criteria, but only 16 of these met the randomization criteria
in the operation (as described in Section 2, the transsection
line or the pancreas needed to be clearly to the left of
the portal vein for the patient to be randomized). Patients
were randomized into FBPJ or hand-sewn group. Out of
the 8/16 patients randomised for FBPJ, in two patients,
FBPJ was still technically impossible to accomplish and they
received a hand-sewn closure. In addition, one had after
all an advanced disease, and distal pancreatectomy was not
performed. 8/16 were randomized for hand-sewn closure.
Thus, of the recruited patients, five received a FBPJ and ten
a hand-sewn closure in the RPT arm and 11 in the non-RPT
arm. More 20 patients received a hand-sewn closure in the
prospective follow-up arm. Thus a total of 41 patients had a
hand-sewn closure. The flow chart is shown in Figure 2.
Patients were well comparable for age, sex, and comor-
bidities. Patient demographics are shown in Table 1. Indi-
cations for surgery were malignant tumours in 28 patients,
benign tumors in 14 patients, chronic pancreatitis in 1
patient, and pancreatic pseudocyst in 3 patients. The final
histopathological diagnoses are shown in Table 2.
The main endpoints of the study were the feasibility
of FBPJ in LP patients and the POPF rate. POPF was
significantly higher in the FBPJ group, in which 3/5 patients
(60%) developed a grade B POPF compared to the hand-
sewn group, where 1/8 patients (13%) developed a grade
B fistula (𝑃 < 0.05). In the FBPJ group two patients
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Table 1: Patient demographics and postoperative complications in the groups (FBPJ: randomized binding pancreaticojejunal group, hand-
sewn rand.: randomized hand-sewn group, and hand-sewn all: all patients with hand-sewn anastomosis).
FBPJ Hand-sewn rand. Hand-sewn all
𝑛 5 8 41
Age (median and range) 67 (55–74) 60 (26–80) 66 (26–85)
Gender M/F 1/4 2/6 15/26
BMI (mean) 28.2 27.2 26
Smoking 1 (20%) 0 7 (17%)
Alcohol abuse (audit > 6) 0 1 (12.5%) 5 (12.1%)
Diabetes 0 2 (25%) 5 (12.1%)
Cardiac disease 0 1 (12.5%) 3 (7.3%)
Hypertension 2 (40%) 2 (25%) 20 (48.7)
Wound infection 0 0 4 (9.7%)
PPH 0 0 0
Abscess 3 (60%) 0 9 (21.9)
Pancreatitis (CT verified) 0 1 (12.5%) 2 (4.9%)
Trypsinogen strip test positive 1 (20%) 1 (12.5%) 10 (24.3%)
Length of stay (days) 10 (7–15) 7 (6–9) 7 (6–32)
Readmission 1 (20%) 1 (12.5%) 4 10%
Operative time (mins, median, and range) 170 (136–300) 162 (115–200) 170 (90–305)
Blood loss (mL, median, and range) 750 (300–2350) 750 (300–1300) 750 (100–3600)
Mortality 0 0 0
Table 2: Final histopathologic diagnoses (FBPJ: randomised binding pancreaticojejunal group, hand-sewn rand.: randomised hand-sewn
group, and hand-sewn all: all patients with hand-sewn anastomosis).
FBPJ Hand-sewn rand. Hand-sewn all
𝑛 5 8 41
Adenocarcinoma 2 (40%) 4 (50%) 13 (32%)
Neuroendocrine tumour 3 (60%) 2 (25%) 9 (22%)
Intraductal papillary mucinous neoplasm 4 (10%)
Pseudocyst 1 (12.5%) 3 (7%)
Mucinous cystic neoplasm 2 (5%)
Chr. pancreatitis 1 (2%)
Haemangioma 1 (12.5%)
Nesidioblastoma 1 (2%)
Kidney ca metastases 1 (2%)
Serous cystadenoma 5 (12%)
None 1 (2%)
had an operatively placed drain removed and needed an
interventional radiology placed drain due to subsequent
abscess. The third patient had a high amylase output from
the operatively placed drain, which was kept in place and
removed five weeks postoperatively. In the hand-sewn group
the patient who developed a grade B fistula was discharged
with the drain but was readmitted and the CT showed
pancreatitis and collection of fluid. The operatively placed
drain was removed after six weeks, after which no additional
drainage was needed. Fistula rates are shown in Figure 2.
The fistula rate in the FBPJ groupwas significantly higher,
not only compared to the RPT hand-sewn group (POPF gr B
60% versus 13%; 𝑃 < 0.05) but also compared to all hand-
sewn closures (POPF gr B 60% versus 37%; 𝑃 < 0.05).
In addition to the high fistula rate, only 13/47 (27%)
of patients were eligible for FBPJ according to our interim
analysis, so we decided to discontinue the study at this point.
30-day mortality was zero. There was no postoperative
haemorrhage. No reoperation was needed in either group.
Among the prospective follow-up hand-sewn patients, four
patients had a wound infection, one patient had a lymphatic
leak, and two patients had pancreatitis. Urine trypsinogen
strip test was positive on two or more days in one patient
in FBPJ (20%) and in ten patients in all hand-sewn groups
(24%; NS) suggesting postoperative pancreatitis. Blood loss
during surgery, length of hospital stay, and readmission rate
to hospital were comparable between the groups. All these
characteristics are shown in Table 1.
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(a) (b)
(c)
Figure 1: Schematic drawing of the binding (purse-string) pancreaticojejunal anastomosis (FBPJ) after left pancreatectomy.The transsection
line needs to be clearly to the left of the portal vein (a). The pancreatic remnant is mobilized 2-3 cm and it is inserted inside the jejunal loop
with the aid of anchoring sutures (b). The purse string applied in the jejunum is tightened to secure the anastomosis (c).
4. Discussion
POPF remains the most common complication after distal
pancreatectomy with an incidence between 20 and 40%
[3, 14, 15] and many surgical techniques for resection and
closure of the pancreatic remnant have been studied without
major success [3–5, 7, 9, 14, 16–19]. We have previously
shown that the novel FBPJ technique reduces the risk for
pancreatic fistula after pancreaticoduodenectomy [11], and
within this study we investigated whether the FBPJ technique
was feasible even for LP. We concluded that FBPJ cannot be
recommended for a routine for pancreatic remnant closure
after LP, as it is not technically achievable in most of the cases
and does not seem to reduce the risk for POPF compared to
the hand-sewn closure.
Stapler and suture closure are the two most common
strategies for managing the pancreatic remnant. In the
DISPACT trial [3], which included 450 patients, two groups
of patients were randomized to either stapler or hand-sewn
closure of the pancreatic remnant with no difference found
in POPF incidence. The meta-analysis likewise revealed no
significant differences between suture and stapler closure [4].
Several other methods have also been tried [16]. Recently
the use of saline-coupled radiofrequency dissector in stump
closure reduced the POPF rate, but further prospective
studies are needed [5]. Pancreaticojejunostomies (PJ) have
also been performed to reduce the fistula rate and the findings
have been encouraging [6, 8]. In 2007 Wagner et al. [6]
found a zero POPF rate Roux-en-Y end-to-side PJ after
suture closure versus 20% in suture closure only. In their
study, POPF was not classified into three grades according
to the ISGPF definition and the number of patients was only
23 versus 20 in either group. In 2013 Meniconi et al. [8]
reported a retrospective analysis where the fistula rate was
also zero in PJ and 29% in the hand-sewn group. In the PJ
group the main pancreatic duct was closed, after which the
pancreatic remnant was invaginated into a jejunal loop. This
was a nonrandomized retrospective study on a small group of
patients (24 versus 12). We have shown previously that after
pancreaticoduodenectomy the novel FBPJ technique reduces
the risk for pancreatic fistula [11].
In this study we wanted to investigate whether FBPJ can
also be used in distal pancreatectomy and whether it reduces
the risk of pancreatic fistulae. FBPJ is technically achievable
only when the transsection line of the pancreas is clearly to
the left of the portal vein because the pancreatic remnant
needs to be mobilized 2-3 cm before it can be inserted inside
the jejunal loop. This is the reason why only 27 out of
47 patients who received an LP resection were recruited.
We estimated the suitable patients based on the location
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POPF n POPF n POPF n
0 2 40.0 0 1 50.0 0 7 87.5
A 0 0.0 A 0 0.0 A 0 0.0
B 3 60.0 B 1 50.0 B 1 12.5
C 0 0.0 C 0 0.0 C 0 0.0
POPF n POPF n
0 8 80.0 0 18 58.1
A 0 0.0 A 0 0.0
B 2 20.0 B 13 41.9
C 0 0.0 C 0 0.0
POPF n
0 26 63.4
A 0 0.0
B 15 36.6
C 0 0.0
27 recruited for the study
16 randomized
5 FBPJ 2 not suitable, made hand-sewn 8 hand-sewn
8 FBPJ 1 inoperable
41 hand-sewn, in total
31 hand-sewn, nonrandomised
11 not randomised (not suitable)
20 not recruited for the study
10 hand-sewn, randomised
(%)
(%)
(%)(%)(%)
(%)
47 left pancreatectomies 2009–2013
Figure 2: Flow chart of the study patients and POPF rate in each group. Out of 47 consecutive patients, 27 were recruited and only 16 of these
met the randomization criteria. Finally, only 5 patients received a FBPJ (POPF 60%) and 8 patients a hand-sewn closure (POPF 12.5%) from
the randomized patients. The POPF rate was 36.6% in all hand-sewn closure patients.
of the tumour preoperatively with the help of contrast-
enhancedCT scan. Randomizationwas done intraoperatively
and only 16 patients out of the total 46met the randomization
criteria, and of these one had an inoperable tumour and
in two the FBPJ was impossible to perform. In most of
the distal pancreatectomies it is not technically possible to
mobilize the pancreatic remnant 2-3 cm in order to insert
it inside the jejunal loop. The FBPJ would therefore have
been technically feasible for only 28% (13/47) of patients. In
the other studies where PJ was performed with good results
[6, 8] the pancreatic remnant was invaginated instead of
being inserted inside the jejunal loop. The anastomosis was
made by capsule-to-seromuscular single layer sutures when
the pancreatic remnant did not need to be mobilized as in
our FBPJ technique. This may explain why it was possible to
perform PJ on all patients in those studies.
FBPJ did not decrease the number of pancreatic fistulae
in this small study. On the contrary, it seemed to increase the
cases of POPF. In addition, FBPJ anastomosis is feasible in
only a minority of patients, which is why we discontinued the
study after performing the interim analysis. The number of
patients who received FBPJ was small, but, as most patients
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did not seem to be eligible for this kind of anastomosis, it was
challenging to achieve a large enough patient population in
the FBPJ group to show the differences in the fistula forming.
In conclusion, the FBPJ technique, which reduces the
POPF rate after pancreaticoduodenectomy, is suitable only
for selected patients with LP and thus it cannot be rec-
ommended for routine use in the closure of the pancreatic
remnant. In addition, according to this study it does not seem
to reduce the risk of POPF.
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Background: Postoperative pancreatic ﬁstula (POPF) is the most common complication after distal
pancreatectomy (DP). In a recent RCT on pancreaticoduodenectomy (PD), perioperative hydrocortisone
(HC) treatment reduced Clavien-Dindo (C-D) III-V complications. The aim of this study was to investigate
whether perioperative HC treatment reduces the overall complications and clinically signiﬁcant POPF
after distal pancreatectomy (DP).
Methods: Fourty consecutive patients undergoing DP were randomized to receive intravenous HC
100mg/placebo every eight hours until the second postoperative day. Thirty-one patients were
completed with DP and received HC/placebo every 8 h for two days postoperatively. The primary
endpoint was overall complications (C-D III-V) and the secondary endpoint was the development of
clinically signiﬁcant POPF.
Results: Pancreatic duct diameter, operative time and blood loss were similar in the groups. Ninety-day
mortality was zero. With HC treatment the rates of C-D III-V complications tended to be lower compared
to the placebo group (5.9% vs 21.4%, p¼ 0.034). The rate of grade B/C POPF was signiﬁcantly reduced with
HC treatment compared to the placebo group (5.9% vs. 42.9%, p¼ 0.028).
Conclusion: Perioperative HC treatment may have a favourable effect on overall major complications
after open DP. HC treatment reduces the incidence of clinically signiﬁcant POPF after open DP.
© 2019 IAP and EPC. Published by Elsevier B.V. All rights reserved.
Introduction
Post-operative pancreatic ﬁstula (POPF) is the most common
complication after DP, and the incidence remains high ranging
16e50% [1,2]. POPF is often associated with other complications,
including wound infection, intra-abdominal abscess, delayed
gastric emptying (DGE), postpancreatectomy haemorrhage (PPH),
wound infection or sepsis [3,4]. Many surgical strategies have been
studied to decrease ﬁstula formation after DP [5e9] as well as
endoscopic pancreatic duct decompression [10,11] and pharma-
ceutical measures [12].
We have shown in a recent RCT that perioperative hydrocorti-
sone (HC) treatment reduces major complications (Clavien-Dindo
III-V) after pancreaticoduodenectomy (PD) in high-risk patients
with “soft”, acinar-cell rich pancreas. HC treatment also tended to
reduce the rate of clinically relevant POPF, but the difference was
not statistically signiﬁcant in this patient population alone (11% vs
27%; p¼ 0.118) [13].
The aim of this study was to investigate whether perioperative
HC treatment reduces major complications (Clavien-Dindo III-V)
and prevents the risk of POPF after open DP.
Methods
We conducted a prospective, single-centre, randomized trial at
Tampere University Hospital, Finland. The RCT was conducted ac-
cording to the Helsinki Declaration. The study protocol was
approved by the Ethics Committee of Tampere University Hospital.
The study was designed simultaneously with another study on HC
treatment in PD patients, reported recently in Annals of Surgery
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[13] and conducted partly parallel with this study. The Clinical Trial
number is NCT01460615. The study was duly monitored and
approved by the Finnish Medicines Agency (FIMEA).
Patients
Eligibility criteria included consecutive adult patients scheduled
for elective, open DP for a disease of the pancreatic body or tail.
Patients with ongoing cortisone treatment, ceftriaxone allergy or
chronic pancreatitis were excluded. It was intented to include only
patients with soft high-isk pancreas in the study. The patients gave
their written and oral informed consent before randomization.
Randomization
The randomization list was made at the beginning of the study
by a biostatistician. After providing written informed consent, pa-
tients were randomized before surgery to either the HC or the
placebo group. The research nurse delivered the externally similar
HC/placebo bags to the surgical ward on the morning of the pro-
cedure according to the randomization number. The HC solution
contained hydrocortisone sodium succinate (Solu-Cortef; Pﬁzer
Manufacturing, Puurs, Belgium) in 0.9% sodium chloride solution
(Natriumklorid Braun, 9mg/mL; B. Braun Melsungen, Melsungen,
Germany) Infusion bags were ﬁlled with 100mg hydrocortisone in
2ml of sodium succinate added into 100ml of 0.9% sodium chloride
solution. The placebo solution was made up by adding 2ml of 0.9%
sodium chloride solution into 100ml of 0.9% sodium chloride
solution.
Intervention
All operations were open procedures with a standard technique
performed by experienced surgeons. No laparoscopic procedures
were included in the study to standardize the operation. No
octreotide or pasireotide were used. Pancreatic parenchyma was
divided with a scalpel. Bleeding was controlled with Prolene 5e0
(Ethicon, USA) suturing. During the operation the percentage of
acini cells in the pancreatic transection line was analysed by the
pathologist [14]. Pancreas texture type was also estimated to be
either soft or hard. Pancreatic duct diameter was measured by
probing. All patients underwent standard hand-sewn closure of the
stump. The main pancreatic duct was closed separately by suturing,
followed by oversewing of the pancreatic stump with interrupted
4-0 Maxon (Covidien, USA) sutures. A Penrose drain was placed
beside the stump.
At the induction of anaesthesia, all patients received a routine
antibiotic prophylaxis of ceftriaxone 2 g (Rocephalin; Roche, Basel,
Switzerland) and metronidatzole 500mg (Metronidatzole; Brown,
Melsungen, Germany) intravenously and either HC 100mg or pla-
cebo intravenously depending on the randomization. Patients
needing other resections than DP were excluded from the study.
The patients who continued in the study received HC 100 mg/
placebo every eight hours until the second postoperative day (total
of 9 doses). Ceftriaxone 2 g i.v. was also continued until the second
postoperative day.
Postoperatively the patients were followed-up according to the
standard pancreatic resection protocol of Tampere University
Hospital. Abdominal drain output was measured and recorded
daily. Amylase concentration was measured on the third post-
operative day from the drain and repeatedly thereafter if the drain
was still in place. The drain was removed when the amylase levels
were less than three times the serum upper limit and the ﬂuid was
clear. Patients’ age, sex, BMI and comorbidities were recorded.
Postoperative complications; ﬁstulas, bleeding, wound infections,
general infections, abscesses and 90-day mortality were recorded
prospectively and compared between the groups.
Endpoints and deﬁnitions
The primary endpoint was the development of overall compli-
cations and the secondary endpoint was the development of clin-
ically relevant POPF. The studywas conducted before the new ISGPF
classiﬁcation, and thus the original ISGPF classiﬁcationwas used for
POPF grading in the analysis. Grade B and C POPF were deﬁned as
clinically signiﬁcant POPFs [15]. The overall postoperative compli-
cations were graded by Clavien-Dindo scoring [16]. Overall
morbidity was deﬁned as Grades II-V, and major complications as
Grades III-V according to the Clavien-Dindo classiﬁcation. Post-
operative hospital stay was deﬁned as primary hospital stay after
the surgery. Overall hospital stay also included the days after
readmission. Mortality was recorded as death within 90 days of
surgery.
Statistical analysis
The study was designed simultaneously with another RCT on HC
treatment in high-risk PD patients [13]. At that time, it was esti-
mated that HC treatment on high-risk PD-patients lowered the
overall complication and ﬁstula rate after PD to one seventh, which
was used for the power calculation. Calculationsweremade prior to
the randomized trial. We estimated that 36 consecutive patients
scheduled for open distal resection would need to be randomized
to show a statistically signiﬁcant difference (alpha 0.05, 80% po-
wer). Due to the estimation of a 10% dropout, 40 patients were
randomized.
The statistical analysis was performed using SPSS statistical
software. Fisher's exact test for cross-tabulated variables and
Mann-Whitney test for quantitative variables were used to calcu-
late the signiﬁcance between the two groups.
Results
Over the study period of 27 months, 47 patients were scheduled
to undergo an open DP for benign or malignant disease. Of these,
sevenwere excluded before randomization: 4 for logistic reasons, 2
did not meet the inclusion criteria and one had a previous PD. The
remaining 40 patients were randomized preoperatively. Of these,
one was observed to be on ongoing cortisone treatment only after
inclusion for randomization, andwas excluded from the study prior
to surgery. During surgery, ﬁve patients were diagnosed with
advanced, inoperable disease and three patients went through a
different procedure (PD, total pancreatectomy and pseudocysto-
jejunostomy) and were excluded from the study. The remaining
31 patients continued through the study after randomization. Of
these, 14 were randomized to the placebo group and 17 to the hy-
drocortisone group. The ﬂowchart is shown in Fig. 1.
No signiﬁcant differences in the pre- or perioperative charac-
teristics were found between the hydrocortisone and placebo
groups, except that the median age was slightly higher in the HC
group, p¼ 0.045. Patient characteristics are shown in Table 1 and
the ﬁnal histopathological diagnoses are seen in Table 2. No dif-
ference in previous diseases or drug usage was observed and no
octreotide or pasireotide was used for the patients. The percentage
of acinar cells at the transsection line analysed intraoperatively
from the frozen section was over 40% in all patients. Pancreas
texture was also deﬁned as soft for all patients during the opera-
tion. Pancreatic duct diameters were similar between the groups,
94% in the HC group and 93% in the placebo group being <3mm.
Operative time was similar in the groups, as was blood loss. The
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surgical technique was similar for all patients, the pancreas was cut
with a scalpel and the duct was closed and the cut edge was hand
sewn. Splenectomy was performed on 70% (12/17) in the HC group
and on 42% (6/14) in the placebo group, p¼ 0.157. These parameters
are shown in Table 1.
Primary endpoint
The overall morbidity was 48.4% (15/31), deﬁned as
complications graded Grade II or higher on the Clavien-Dindo
classiﬁcation [16]. In the HC group the overall morbidity was 41%
(7/17 patients) and in the placebo group 57% (8/14). Major com-
plications (Clavien III-V) occurred in 12.9% (4/31) of all patients.
There were no statistically signiﬁcant differences between the
groups, 5.9% (1/17) and 21.4% (3/14) in the HC and placebo group
respectively (p¼ 0.304) The details of complications and their
management are presented in Table 3.
Secondary endpoint
The secondary endpoint of this study, the incidence of clinically
signiﬁcant POPF (grades B and C), was 22.6% (7/31) among all pa-
tients. In the HC group there was only one Grade C ﬁstula among 17
patients (5.9%). This patient developed sepsis, and needed both
percutaneous drainage and endoscopic retrogradic pancreaticog-
raphy (ERP) to treat the POPF. She also developed a pulmonary
embolism.
Fig. 1. CONSORT ﬂow diagram for the trial.
Table 1
Pre- and perioperative characteristics of the HC group and the placebo group.
Hydrocortisone (n¼ 17) Placebo (n¼ 14) p value
Age yrs, median (range) 73 (41e82) 61 (39e76) 0.045
Male 7 (41%) 4 (29%) 0.707
BMI, kg/m2 27 (22e35) 29 (21e39) 0.164
COPD 1 (6%) 2 (14%) 0.576
Diabetes 7 (41%) 5 (36%) 1.00
ASA class
I-II 6 (35%) 7 (50%) 0.481
III 11 (65%) 7 (50%)
Operative time min, median (range) 158 (103e391) 159 (108e224) 0.942
Operative blood loss mL, median (range) 550 (120e2300) 700 (50e1400) 0.975
Main pancreatic duct diameter
< 3mm 16 (94%) 13 (93%) 1.00
 3mm 1 (6%) 1 (7%)
Splenectomy 12 (71%) 6 (43%) 0.157
Acini >40% in the transsection line 17 (100%) 14 (100%) 1.00
Soft pancreas texture 17 (100%) 14 (100%) 1.00
Table 2
Final histopathological diagnoses in the groups.
HC Placebo P value
Histopathological diagnosis 0.578
Pancreatic ductal adenocarcinoma 4 (23%) 1 (7%)
NET 2 (12%) 2 (13%)
Cystic tumour 9 (53%) 8 (57%)
Other 2 (12%) 3 (21%)
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In total, 6/14 (42.9%) clinically signiﬁcant ﬁstulas developed in
the placebo group. Four of these were Grade B ﬁstulas. They were
treated with original, intra-operatively placed drain and medical
interventions. One Grade C ﬁstula required percutaneous drainage
followed by ERP and a pancreatic stent. Another Grade C ﬁstula
resulted in the patient's death on day 96 post-operatively. He was
readmitted for infected collection of ﬂuid and treated with a
percutaneous radiologic drain and an endoscopic stent for collec-
tion. Finally the patient developed an intestinal necrosis seen in
laparotomy due atherosclerosis and attributed to prolonged infec-
tion. With HC treatment the rate of clinically relevant POPF (5.9% vs
42.9%, p¼ 0.0281) was signiﬁcantly lower compared to that in the
placebo group. Fig. 2.
The incidence of former grade A POPF, also called a biochemical
leak, was 22.6% (7/31) among all patients: 6 in the HC group and 1
in the placebo group (ns). These ﬁstulas had no impact on the
treatment of the patient. Thus, the overall incidence of any POPF
was 45.2%: 22.5% grade A, 12.9% grade B and 9.6% grade C. The
overall incidence of any POPF was similar in the two groups, but,
interestingly, six out of the seven clinically relevant grade BeC
ﬁstulas were seen in the placebo group, whereas in the HC group
almost only grade A ﬁstulas were seen.
HC treatment was well tolerated and no adverse events
occurred. The rates of wound infections and other infections were
similar in the HC and placebo groups. Length of primary or total
hospital stay did not differ between the groups with 8 (3e23) vs. 7
(6e38) days' total stay and 7 (6e14) and 8 (3e16) days’ primary
stay.
Table 3
Postoperative complications in the groups. The overall ﬁstula rate was signiﬁcantly lower in the hydrocortisone group (6% vs 43%). Hydrocortisone also seems to have a
favourable effect on major complications (Clavien-Dindo III-V).
Hydrocortisone (n¼ 17) Placebo (n¼ 14) P value
Pancreatic ﬁstula
Overall (B þ C) 1 (6%) 6 (43%) 0.028
Grade B 0 4 (29%)
Grade C 1 (6%) 2 (14%)
Delayed gastric emptying 1 (6%) 1 (7%) 1.00
Intra-abdominal ﬂuid collection 2 (12%) 3 (21%) 0.636
Wound infection 1 (6%) 3 (21%) 0.304
Intra-abdominal haemorrhage 0 0
Pneumonia 1 (6%) 2 (14%) 0.576
Spleen necrosis 1 (6%) 1 (7%) 1.00
Lymphatic leak 2 (12%) 1 (7%) 1.00
CT veriﬁed pancreatitis 1 (6%) 1 (7%) 1.00
Urine trypsinogen positive 2 days 4 (24%) 5 (36%) 0.693
Pulmonary embolism 1 (6%) 0 1.00
Clavien-Dindo
I 4 (24%) 4 (29%)
II 6 (35%) 5 (36%)
III 1 (6%) 2 (14%)
IV 0 0
V 0 1 (7.1%)
Clinically signiﬁcant (IIIeV) 1 (6%) 3 (21%) 0.304
Reoperation 0 1 (7.1%) 0.452
Total hospital stay (days, range) 8 (2e23) 7 (6e38) 0.625
Readmission 3 (18%) 3 (21%) 1.00
90-day mortality 0 0
Fig. 2. Hydrocortisone treatment signiﬁcantly reduced the rate of clinically signiﬁcant POPF (5.9% vs 42.9%, p¼ 0.0281.
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The readmission rates were similar: 17.6% and 21.4% respectively
in the HC and placebo groups. Of these, in the HC group one patient
had a spleen necrosis diagnosed on the twelfth postoperative day
and one patient had an intra-abdominal haematoma diagnosed on
the 24th postoperative day. Both were completely healed with no
need for invasive procedures.
In both groups 90-day mortality was zero.
Discussion
Postoperative pancreatic ﬁstula remains the most common
complication after DP. In our recent randomized trial we showed
that perioperative HC treatment reduces Clavien-Dindo 3e5 com-
plications after PD, and also the clinically relevant POPF rate tended
to be lower (11% vs. 27%). The present study was run partly
concomitant with the PD RCT with the same protocol. Our main
ﬁnding was that HC treatment signiﬁcantly reduced the risk of
POPF after DP from 43% to 5.9%. A tendency for fewer overall
Clavien-Dindo III-V complications in the HC group was also seen.
Many recent RCTs have tried to lower the ﬁstula rate after DP.
The multicentre randomized DISPACT trial in 2011 found no dif-
ference between the stapler and hand-sewn group in the incidence
of pancreatic ﬁstula: 32% vs. 28% [5]. However, somemeta-analyses
have reported reduction in ﬁstula rates after stapler closure [1,17].
Resection with a stapler reinforced with absorbable materials has
been shown to reduce POPF, the B and C ﬁstula rate being 1.9%
among patients with mesh reinforcement vs. 20% of the patients
without mesh in the stapler line [6]. The Tachocil patch has been
shown in two RCTs not to lower the incidence of POPF [18]. How-
ever, adding a seromuscular patch to the staple line signiﬁcantly
decreased morbidity, but the clinically different POPF rate was
similar [19]. Teres ligament patch reduced the complications after
DP, but the clinically relevant ﬁstula rate was not reduced [20].
Pancreaticojejunal anastomosis and pancreaticogastrostomy of the
pancreatic stump have also been used without a signiﬁcant
decrease in ﬁstula rate [9,21,22]. Preoperative endoscopic pancre-
atic stenting was studied in one prospective single-institution RCT
in Sweden and did not reduce PF after DP [10]. Inducing relaxation
of the Sphincter of Oddi by endoscopic botulinum toxin injection is
promising according to one non-randomized trial having a B/C
ﬁstula rate of 0% vs. 33% and an RCT to clarify the effect is ongoing in
Germany [11].
On the pharmaceutical side, octreotide and pasireotide have
been investigated. Octreotide has showed a reduction in overall
ﬁstula rate after pancreas surgery, but no difference was found in
clinically relevant POPF [23]. Somatostatin analogue pasireotide
signiﬁcantly reduced the incidence of clinically relevant pancreatic
ﬁstula in a recent RCT to as low as 7% [12].
In this study HC treatment reduced the clinically relevant B/C
ﬁstula rate to 5.9%, which is equivalent to the low ﬁstula rates re-
ported in the studies before [5,6]. For instance, pasireotide treat-
ment reduced the B/C ﬁstula rate from 23% to 7% in patients
undergoing DP [12]. Difference was found only on clinically rele-
vant POPF, not among Grade C ﬁstulas only. The overall incidence of
clinically relevant POPF in the placebo group of this study was 42%,
within the range reported in earlier studies with open DP
[10,12,20,24]. In our series less than 10% of the patients had corpus
tail resections, without difference between the groups. This partly
explains the ﬁstula rate, as tail resections have been reported to
carry a higher incidence of POPF compared to corpus þ tail re-
sections [25].
Severe complications (Clavien-Dindo III-V) tended to occur less
often in the HC group than in the placebo group (5.9% and 21.4; ns;
p¼ 0.30 respectively). Furthermore, the rate of severe complica-
tions in the HC group (5.9%) was less than half of the rate of severe
complications reported in a recent RCT comparing PJ and stapler
closure 11.3% vs. 13.1% [21].
The prevalence of splenectomywas 71% in the HC group and 43%
in the placebo group (ns). No association to the POPF or overall
complications was seen in the splenectomized patients or in the
patients where the spleen was saved. There was one spleen ne-
crosis detected in both groups, both of these healed conservatively
and were graded as Clavien-Dindo grade II complications. The rates
of wound infections and other infections as well as the readmission
rates were similar in the HC and placebo groups. There was one
death on the 96th day in the placebo group, whichwas not included
in 90-day mortality since it did not occur during the initial
admission: The patient was readmitted and died of bowel necrosis
caused by prolonged infection and atherosclerosis.
This study was performed partly simultaneously with the RCT
on PD with the same HC/placebo protocol [13], but designed to be
presented separately, mainly because of the different POPF and
complication proﬁles of PD and DP. By separating these studies, we
give valuable information to the ﬁeld on these two different oper-
ations. If the results are combined, the overall incidence of clinically
signiﬁcant POPF is 8.9% in the HC group and 27.1% in the placebo
group (p¼ 0.032). Thus HC seems to be effective in reducing clin-
ically signiﬁcant ﬁstula overall in open pancreatic resections. As
comparing these two studies, the effect of HC treatment on ﬁstula
rate seems to be higher after DP than after PD. The mechanism of
ﬁstula formation after DP is somewhat different compared to that
after PD. Presumably after both operations, HC decreases inﬂam-
mation and oedema in the pancreatic tissue. One may speculate
that in the DP operation this effect is enough to create a lower
pressure inside the pancreatic duct, enabling a better ﬂow towards
duodenum, thus preventing the formation of a ﬁstula. In PD oper-
ation the prevention of ﬁstula may be more complex, as also a good
healing of the pancreatico-jejunal anastomosis is needed to prevent
a ﬁstula.
High frequency of acinar cells (>40%) in the cut edge of the
pancreas increases the risk of postoperative complications and is an
objectivemethod to recognize the soft, nonﬁbrotic pancreas [14]. In
our hospital acinar cells in PD and DP are nowadays counted
routinely by a pathologist perioperatively from a frozen section to
identify patients at risk of complications. In general, the majority of
DP patients are at high risk of complications and have an acinar-rich
cut edge and thus a high incidence of POPF. Unlike with the
pancreatic head tumors, distally located tumors do not occlude
pancreatic ﬂow in the remaining pancreas, and thus in the
remaining pancreas less ﬁbrosis and more acinar cells as well as a
normal pancreatic duct are present. Also on the present study all
patients had an acinar-rich high-risk soft pancreas with a non-
dilated duct, and thus the tumour pathology did not seem have
an effect on the individuals’ risk to develop a POPF.
The HC dose we used was identical to that used in the other RCT
in PD patients. Also in this study the peri-operative use of 100mg of
hydrocortisone three times a daywas conﬁrmed safe [13]. Similarly,
a study using it to prevent atrial ﬁbrillation in cardiac surgery found
it safe without any increase in adverse effects such as wound
infection or stomach ulcers [26]. HC treatment in our studywas also
well tolerated, and no adverse events occurred. With pasireotide
the most common adverse events were dose-limiting nausea (17%)
and hyperglycaemia [12].
We hypothesize that POPF and other complications occur after
postoperative pancreatic inﬂammation. Earlier we have reported
that a large proportion of acinar cells at the transection line of the
pancreas indicate a signiﬁcant risk for complications. We have also
demonstrated that the inﬂammation cascade at the transection line
of the pancreas begins early and that the peak activation of
inﬂammationmarkers (NF-kB andMCP-1) can be seenwithin 4 h of
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surgical trauma. Recently it was shown that postoperative acute
pancreatitis is associated with increased occurrence of POPF and
overall morbidity after PD [27] In this study the activation was
signiﬁcantly higher in acinar cell rich pancreata than in ﬁbrotic
pancreata [14]. These ﬁndings led us to hypothesize that post-
operative inﬂammation increases complications, and that wemight
be able to reduce the complications with corticosteroid treatment.
In our pancreas laboratory we are currently performing mecha-
nistic studies on the effect of hydrocortisone on experimental acute
pancreatitis, but at the moment it is too early to speculate with the
mechanisms.We assume that the favourable effect of HC is not only
“local”, but also systematic. Cortisone has been used in experi-
mental acute pancreatitis in animal models [28,29] and also in the
treatment of autoimmune pancreatitis [30]. Interestingly, cortico-
steroids have not been shown to reduce post-ERCP pancreatitis [31]
nor to reduce trypsinogen leak after PD [13]. However, the aetiology
of the inﬂammation process due to surgical trauma may differ from
that arising in ERCP, which should be a subject for further research.
The strength of this study was that all patients were high-risk
patients, having a soft pancreas and narrow pancreatic duct. This
was conﬁrmed by analysing the acini in the transection line,
considered more objective and not based on the surgeons’ sub-
jective estimates of gland texture. All patients had a standardized,
similar open tail resection (to standardize the pancreatic trauma).
The small number of patients in each groupwas themainweakness
of this study. Likewise the fact that we included only open pro-
cedures. At the moment we are using the HC treatment as a routine
even for laparoscopic distal resections. Thus we would recommend
the use for laparoscopic operations also, even though this has not
been shown in a study. However, larger studies are needed to
conﬁrm our ﬁndings.
HC treatment seems to be a safe, inexpensive and well-tolerated
pharmaceutical method in preventing POPF after DP. Among drugs
so far only pasireotide has been shown to have a signiﬁcant effect
on POPF after DP, a similar effect on lowering the ﬁstula and
complication rate than HC, but seems to have some adverse events.
The cost-effectiveness of pasireotide has also been studied and did
not increase the overall cost of pancreatic resection [32], but might
save costs within the health care system [33]. Nevertheless, the
costs using pasireotide are considerably higher than the cost of
inexpensive HC treatment, which necessitates further comparative
studies with cost-analysis.
For future studies it would also be important to validate the
system to conﬁrm a “soft“ high-risk pancreas. Acinar cell count is an
easy and objective intraoperative method to identify patients at
high risk for POPF [14]. This method is routinely used in our hos-
pital among PD and DP patients as is perioperative HC treatment for
patients deemed to have a high risk for complications. On the other
hand, HC treatment is discontinued after the initial dose if the
intra-operative acinar cell analysis renders the patient low-risk for
POPF.
In conclusion, perioperative HC treatment reduces the incidence
of clinically signiﬁcant ﬁstula after open distal pancreatectomy. The
frequency of POPF after HC treatment is low also when compared to
other means of POPF prevention studied earlier. Overall in open
pancreatic surgery (PD and DP), HC seems to be effective in
reducing clinically signiﬁcant ﬁstula and may have a favourable
effect also on overall complications.
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Background: Centralization of pancreatic surgery has proceeded in the last few years in many countries.
However, information on the effect of hospital volume speciﬁcally on distal pancreatic resections (DP) is
lacking.
Aim: To investigate the effect of hospital volume on postoperative complications in DP patients in
Finland.
Methods: All DP performed in Finland during the period 2012e2014 were analyzed, information having
been retrieved from the appropriate national registers. Hospital volumes, postoperative pancreatic
ﬁstulae (POPF) and overall complications were graded. High volume centre (HVC) was deﬁned as per-
forming> 10 DPs, median volume centre (MVC) 4e9 DPs and low volume centre (LVC) fewer than 4 DP
annually.
Results: A total of 194 DPs were performed at 18 different hospitals. Of these 42% (81) were performed in
HVCs (2 hospitals), 43% (84) in MVCs (6 hospitals) and the remaining 15% (29) in LVCs (10 hospitals).
Patient demographics did not differ between the hospital volume groups. The overall rate of clinically
relevant POPF, Clavien-Dindo grade 3e5 complications, and 90-day mortality showed no signiﬁcant
differences between the different hospital volumes. Grade C POPF was found more often in LVCs, being
1.2% in HVCs, 0% in MCVs and 6.9% in LVCs, p¼ 0.030. More reoperations were performed in LVCs (10.3%)
than in HVCs (1.2%) or MVCs (1.2%); p¼ 0.025.
Conclusions: Even though the rate of postoperative complications after DP is not affected by hospital
volume, reoperations were performed ten times more often in the low-volume centres. Optimal man-
agement of postoperative complications may favour centralization not only of PD, but also of DP.
© 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.
Introduction
Centralization of treatment of pancreatic surgery reduces
postoperative mortality and morbidity and also improves long-
term survival after pancreatoduodenectomy (PD) [1e4].
Compared to PD, postoperative pancreatic ﬁstulas (POPF) are even
more common e though less life-threatening - after distal
pancreatectomy (DP) and overall morbidity also remains high
[5e7]. The effect of hospital volume on complications after DP has
not been widely studied [8]. The aim of this study was to analyze
whether hospital volume affects the rate of POPF and overall
morbidity after DP according to a nationwide database.
Methods
All patients undergoing DP in the period 2012e2014 were
identiﬁed from the Finnish Operation and Treatment Register
(HILMO) using Nordic Classiﬁcation of Surgical Procedures codes
(ICD10 codes JLC10 and JLC11). All patient records were collected
and examined manually. Emergency operations and patients with
no data available were excluded.
Postoperative complications, POPF, mortality, reoperations and
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hospital stay were registered. Data on the course of the surgery was
also gathered. Complications were graded according to the Clavien-
Dindo classiﬁcation and grades 3e5 were considered major com-
plications [9]. Postoperative pancreatic ﬁstulas were graded ac-
cording to the new ISGPF classiﬁcation [10,11]. In grade B ﬁstula the
drain is left in place for over 3 weeks or repositioned through
percutaneous or endoscopic procedures. Grade C ﬁstula requires
either reoperation or leads to organ failure or death of the patient.
The ﬁnal histopathological diagnoses were also gathered.
The hospital DP volumes were calculated and the hospitals were
categorized according to operation volume. For this study, high-
volume centres (HVC) were deﬁned as those performing 10 or
more distal pancreatectomies per year Median-volume centres
(MVC) accomplished 4e9 DPs and low-volume centres (LVC) less
than 4 DPs per year.
Ethical approval for the study was granted by the Regional
Ethics Committee of Pirkanmaa, Finland (ETL code R12241).
Statistical analysis
Fisher's exact test and 2 test were used as appropriate to
calculate statistical differences. Statistical analysis was performed
with IBS SPSS statistics software. P 0.05 was considered statisti-
cally signiﬁcant.
Results
One hundred and ninety-four DPs were performed in Finland
between 2012 and 2014 in 18 different hospitals. There were two
HVCs, 6MVCs, and 10 LVCs. Of DPs 85% (165) were performed in
HVCs and MVCs (41% in HCVs and 44% in MVCs) and 15% (29) in
LVCs. In total 81 DP/3 yr were performed in HVCs, 84 in MVCs and
29 in LVCs.
Patient demographics or perioperative data did not differ be-
tween the centres (Table 1). Combined splenectomy (median 60%,
range 51e69%) and resection of other organs (16%, range 11e20%)
were performed without differences between the centres. Blood
loss (median 700ml, range 10e16000ml) and operative time
(median 187min, range 114e317min) were also similar regardless
of hospital volume. For pancreatic stump closure stapler was used
in 69% of patients, and the methods did not differ between the
groups. There were more laparoscopic procedures in HVCs and
MVCs than in LVCs (28%, 27% and 3% respectively, p¼ 0.008).
The proportion of malignant diseases was similar between the
centres. The ﬁnal histopathological diagnoses are shown in Table 2.
The overall rate for POPF (B/C) rate was 17.2% in all patients.
POPF occurred in 21% in HVCs, 10.7% in MVCs and 17.2% in LVCs.
Grade C POPF was found more often in LVCs, the rate being 1.2% in
HVCs, 0% in MCVs and 6.9% in LVCs, p¼ 0.030. The rate of intra-
abdominal collections was similar; they occurred respectively in
28%, 25%, and 20.7% in HVCs, MVCs and LVCs. Interventional drain
or pancreatic stent was used similarly in the centres to drain a
collection in the postoperative treatment of POPF. Delayed gastric
emptying (DGE) was found to be more common in LVCs (20.7%)
than in HVCs/MVCs (3.7%/10.7%; p¼ 0.018). However, no difference
was found in other complications such as postoperative pancrea-
titis, lymphatic leak, post-pancreatic hemorrhage (PPH), wound
infection, pneumonia or pulmonary embolism (Table 3).
Clavien-Dindo 3e5 complications occurred in 16.0% of HVC
patients, in MVCs in 18.1% of patients, and in LVCs in 20.7% of pa-
tients. In LVCs the rate for major complications tended to be higher,
but this was not statistically signiﬁcant (p¼ 0.81). Ninety-day
mortality was 0% in HVCs and in the LVC group and 2.4% in MVCs.
Signiﬁcantly more reoperations were performed in LVCs, on
10.3% of patients (3/29), than in HVCs and MVCs: 1.2% (1/82) and
1.2% (1/87) respectively, p¼ 0.025. Due to the small number of
reoperations, multivariate analysis was not possible. Out of the
three re-operated patients in the LVCs, the ﬁrst patient had POPF,
PPH and pneumonia and was treated in the ICU. He underwent
reoperation twice; on day 19 due to PPH and intra-abdominal
collection (splenectomy and drain repositioned) and on day 49
due to 15 cmwide peripancreatic collectionwith amylase-rich ﬂuid
(drain repositioned). The second patient underwent reoperation on
Table 1
Pre- and perioperative characteristics across the groups.
High-Volume centre n
(DP)¼ 81
Medium-volume centre
n(DP)¼ 84
Low-volume centre n
(DP)¼ 29
Overall volume n
(DP)¼ 194
Age, median, years (range) 62 (0.3e80) 65 (21e80) 67 (41e85) 64 (0,3e85)
Sex ratio (F/M) 45/36 60/24 17/12 122/72
BMI 26,1 (16e40) 23,6 (19e40) 28,4 (23e36) 26,1 (16e40)
Diabetes 20 (24,7%) 10 (14,1%) 8 (29,6%) 21,2% (38)
Laparoscopic procedure 23 (28,4%) 23 (27,4%) 1(3,4%) 47 (24,2%) p¼ 0.008
Combined resection of other
organs
9 (11,1%) 17 (20,2%) 4 (13,8%) 30 (15,5%)
Hand -sewn closure of the
pancreatic
25 (30,9%) 20 (23,8%) 11 (37,9%) 56 (28,9%)
Stapler closure of pancreatic stump 54 (66,7%) 64 (76,2%) 16 (55,2%) 134 (69,1%)
Splenectomy 42 (51,9%) 58 (69,0%) 16 (55,2%) 116 (59,8%)
Blood loss (ml) 850 (150e5300) 590 (0e16000) 500 (300e2500) 700 (0e16000)
Oper. time (min) 167 (115e317) 200 (114e377) 180 (120e258) 187 (114e377)
Number of hospitals 2 6 10 18
Table 2
Final histopathological diagnoses: all patients.
Adenocarcinoma 40 (21%)
Neuroendocrine carcinoma 7(3,6%)
Intraductal papillary mucinous carcinoma 2(1%)
Gastrointestinal stromal carcinoma 1 (0,5%)
Kidney metastasis 6 (3%)
Colon carcinoma 1 (0,5%)
Neuroendocrine tumour 43 (22,%)
Mucinous cystic nesplasm 23(11,9%)
Intraductal papillary mucinous neoplasm 17 (8,8%)
Serous cystic neoplasm 20 (10%)
Solid pseudopapillary neoplasm 3 (1,5%)
Chronic pancreatitis 7 (3,6%)
Pseudocyst 7 (3,6%)
Gastrointestinal stromal tumour 1 (0,5%)
Cyst 5 (2,6%)
Fibrosis 1 (0,5%)
Spleen accessorius 7(3,6%)
Hemangioma 1(0,5%)
Nesidioblastooma 1(0,5%)
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day 8 due to infection and inadequate blood ﬂow to the spleen seen
in ultrasound (splenectomy, drain repositioned; produced amylase-
rich ﬂuid). The third patient underwent reoperation on day 10 due
to DGE (nasogastric tube repositioned, inﬂammation detected
around pancreas with jejunal loops attached). The indications for
reoperations in the HVC group were bowel necrosis caused by
atherosclerosis and prolonged infection due to POPF, and in the
MVC group ureter injury sustained in the primary operation.
Clavien-Dindo complication, reoperation and readdmission rates
are seen in Fig. 1.
Therewere no differences in total hospital stay, readmission rate
or 90-day mortality. These parameters are shown in Table 3. There
were two deaths within 90 days postoperatively, both in the MVC
group. The ﬁrst patient died on day 3. This patient had a BMI of 40,
and had breathing problems before his death, probably because of a
pulmonary embolism. The second patient died on day 12 due to
postoperative bleeding. Hemoglobin level was 23 g/l before her
death. She also had cholangitis and a choledochal stone had been
removed in endoscopic retrograde cholangiography (ERC) 2 days
earlier.
In univariate analysis, no single factor signiﬁcantly affecting the
formation of clinically relevant POPF was found. In all open pro-
cedures the clinically relevant ﬁstula rate was 17.2% and in the
laparoscopic procedures 12.8% (ns). Combined resection of other
organs raised the ﬁstula rate up to 23.3% but without a signiﬁcant
difference between different centre volumes. In stapler closure and
in hand sewn closure groups the respective ﬁstula rates were 17%
and 17.0% (ns). Malignancy did not protect against ﬁstula formation,
the POPF rate being 14,2% in all malignant cases.
Discussion
Ample evidence supports the centralization of PDs [12e16], but
it is not known whether it would be beneﬁcial also to centralize
DPs. Our aim was to study the effect of hospital volume on the
outcome of all DP operations performed nationwide in Finland
during the period 2012e2014. We found that the frequencies of
clinically relevant POPF and Clavien-Dindo 3e5 complications were
not related to hospital volume. However, the management of
complications differed signiﬁcantly, as more reoperations were
performed in the LVCs.
The reoperation rate in LVC was 10.3% and included three pa-
tients. One might speculate that these were all unnecessary. The
ﬁrst patient with PPH, POPF and intra-abdominal collection, who
twice underwent relaparotomy, could have been managed by
interventional radiological procedures. The second patient who had
an infection and inadequate blood ﬂow to the spleen on ultrasound
could have beenmanagedwithout laparotomy if a CT scan had been
performed. The third patient who underwent a laparotomy for DGE
could have been managed by watchful waiting, medical treatment,
and repeated imaging. Most of the postoperative complications,
which in the past may have needed surgery, can today be treated
with conservative or minimally invasive approaches. In the low-
volume centres the options for modern treatment may be limited.
A laparoscopic approach was taken, most often in HVCs and
MVCs. Overall, laparoscopy seems to be underutilized in DPs in
Finland, as the overall rate is so low (24%). Laparoscopic DP is
associated with signiﬁcantly less overall morbidity than open
technique. Blood loss is smaller and the length of hospital stay is
shorter [17]. However, no signiﬁcant difference in clinically relevant
POPF was found. In the LVCs laparoscopic approach was rare which
might be explained by the low volume affecting the learning pro-
cess. Thus, centralizing the procedures to at least MVC/HVC level
might be beneﬁcial even in this respect.
The overall clinically relevant POPF rate in our study was 17.2%,
which is comparable to what has been reported elsewhere. Post-
operative complications occur even in HVCs, and also in this study
Table 3
Postoperative complications in the groups.
% (n) High-volume centre n¼ 81 Medium-volume centre n¼ 84 Low-volume centre n¼ 29
Pancreatic Fistula
Grade B 19,8% (16) 10,7% (9) 10,3% (3)
Grade C 1,2% (1) 0,0% (0) 6,9% (2) P¼ 0,030
Grade B/C 21,0% (17) 10.7% (9) 17,2% (5)
PPH 4,9% (4) 4,8% (4) 6,9% (2)
DGE 3,7% (3) 10,7% (9) 20,7% (6) P¼ 0,018
Intra-abdominal collection 28,4% (23) 25,0% (21) 20,7% (6)
Interventional drain 13,6% (11) 11,9% (10) 10,3% (3)
Pancreatic stent 2,5% (2) 2,4% (2) 6,9% (2)
CT veriﬁed pancreatitis 3,7% (3) 2,4% (2) 0,0% (0)
Lympha leak 1,2% (1) 1,2%(1) 0,0% (0)
Wound-infection 9,9% (8) 3,6% (3) 10,3% (3)
Pneumonia 12,3% (10) 6,0% (5) 10,3% (3)
Pulmonary embolism 3,7% (3) 0,0% (0) 5,0% (1)
Clavien-Dindo III-V 16,0% (13) 18,1% (15) 20,7% (6)
Reoperation 1,2% (1) 1,2% (1) 10,3% (3) p¼ 0,025
Total hospital stay, median (range) 7 (3e25) 8 (3e30) 8 (5e40)
Readmission 16,3% (13) 13,1% (11) 24,1% (7)
90-day mortality 0,0% (0) 2,4% (2) 0,0% (0)
Fig. 1. Reoperation, Clavien-Dindo 3e5 grades and readdmission rates seen in different
centres. HVC¼ high volume centre, MVC¼median volume centre, LVC¼ low volume
centre).
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no signiﬁcant difference was found either in the incidence of POPF
or in Clavien-Dindo 3e5 complications. Nor has a decrease in
overall complication rate or POPF rate after DP been reported in
HVCs vs. LVCs in the literature. However, only few studies report the
rates of complications after DP separately [8]. In our study, DGE
seemed to be more common in LVCs, but the patient records may
not have all the information reliably listed.
Several studies have reported an association between high
hospital volume and lower postoperative mortality in pancreatic
surgery [1,2]. It has been shown that higher mortality in low vol-
ume centres with high-risk surgery is associated with the hospital's
ability to rescue patients from major complications [3,18] The
mortality risk is also attributable to patient characteristics, such as
age and comorbidity [19]. In this study the deaths occurred in the
MVC group and were both sudden and not caused by a treated
complication, but one of themwas associatedwith comorbidity, i.e.,
obesity.
PD has been shown to carry lower mortality and morbidity and
also better oncological outcome in high-volume centres [1,20]. So
far, centralization of DPs in high-volume centres does not seem to
occur, although only few studies have been presented concerning
only DPs in terms of postoperative complications and hospital
volume [8]. One article which claimed that pancreatic resections
can be safely done in MVCs had only 13 DP/11 yrs with a clinically
relevant POPF rate in DP of 32% [21]. Factors favoring centralizing
DP as well as PD include the overall knowledge of pancreatic sur-
gery and its complications and postoperative care. Treatment and
caremay require imaging and interventional radiology around-the-
clock and the decision-making for treatment also needs a multi-
disciplinary approach, which is often lacking in LVC units.
Reasonable volumes are needed to achieve and maintain experi-
enced perioperative management. When analysing all patient re-
cords from each hospital manually we found no differences
between HVCs and LVCs in terms of equipment used in surgery.
Time of drain removal varies within centres according to individual
surgeon. However, we did ﬁnd that multidisciplinary teams were
used in all tertiary but only in some secondary hospitals (HVCs and
MCVs) and in neither of the LVC hospitals. In Finland, where the
population is only 5.4 million and both DP and PC volumes are
generally small, it would be wise to centralize the know-how in
fewer centres in order to achieve the best results.
Risk factors for POPF have been widely studied. A laparoscopic
approach has been shown to reduce the overall complications, but
not POPF [22]. Many closure methods for pancreatic stump have
been developed to reduce the complications, especially POPF. The
pancreas can be closed by suturing or staplers, the stump can be
covered with various patches or meshes or Tachosil [23].
Pancreatico-jejunal anastomosis and preoperative pancreatic stent
have also been used [24,25]. Neither of these has reduced the POPF
rate in RCTs. In a recent RCT a ligament Teres patch was shown to
signiﬁcantly decrease reoperation, readmission and reintervention
rates without affecting the POPF rate [26]. On the pharmaceutical
side, the use of octreotide is controversial. It has no effect on clin-
ically relevant POPF, but it may reduce overall morbidity [27].
Pasireotide has been shown to reduce POPF rate to 7% after DP, in a
recent RCT. High BMI has also been shown to increase themorbidity
rate [28,29]. The effect of hospital volume in DP only has been
poorly reported.
The strength of this study is the nationwide coverage of all DP
operations performed in a single country during the study period.
The study provides valuable information on nationwide DP vol-
umes and complications rates. This is the ﬁrst nationwide study on
DP in Europe.
The weaknesses of this study include the missing and incom-
plete data. Patient data was collected retrospectively from 18
different hospitals in Finland and analyzed manually. POPF classi-
ﬁcation was made according the data found by the authors, so the
analysis is consistent throughout the study [11]. Octreotide was not
used routinely in any of the hospitals studied, although some sur-
geons did use it occasionally. It is therefore no included in the
analysis. We could ﬁnd no accurate information on drain removal
time and were therefore unable to include this in the data. . Overall,
the information is missing randomly and should not affect the re-
sults. The hospital volume deﬁnition is somewhat arbitrary, as in
the literature deﬁnitions of volume mostly include both DP and PD.
The number of patients in this study is also rather low since DP was
performed quite rarely, which is also weakness of the study.
In conclusion, this nationwide register study shows similar POPF
and overall complication rates after DPs performed in different
volume hospitals in Finland during the period 2012e1014. How-
ever, there was a signiﬁcant difference in the management of
postoperative complications, as the reoperation rate was signiﬁ-
cantly more common in the LVCs. With experienced postoperative
management, reoperations could possibly be avoided. This may
favour the centralization of pancreatic resections to HVCs e not
only for PD, but also for DP.
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